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CHAPTER I 
 
INTRODUCTION 
 
Exposure and Toxicity 
Physicians and scientists have described the association between chemical 
exposure and toxicity in human populations for several hundred years.  The Swiss 
physician, alchemist, and philosopher, Paracelsus, stated in the 1600s that, “all things are 
poison and nothing is without poison, only the dose permits something not to be 
poisonous” (1).  Poisons of the 17th century are, in general, the toxic chemical and 
biological agents of today’s generation.  Even the enigmatic Paracelsus could not have 
imagined just how intensely the dose-response relationship of chemical agents would be 
investigated in today’s field of chemical toxicology. 
Correlations between exposure and cancer incidence were first observed in the 
18th century.  An English physician, John Hill, reported in his 1761 essay on the Cautions 
against the immoderate use of snuff an increased incidence of nasal cancer among 
individuals who partook in tobacco snuff (2).  Hill stated, “If only five in a hundred 
ruined their constitutions by it [snuff], who shall be able to say, when he enters on the 
custom, whether he shall be one of the ninety-five who escape, or of the five that perish?” 
Another English physician, Percivall Pott, reported an increase incidence of scrotal 
cancer among chimney sweeps in the late 1700s.  Young boys were typically recruited as 
chimney sweeps because their slender bodies enabled easier passage through the narrow 
chimneys.  Children engaged in this labor without clothing to prevent them from getting 
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caught-up in the chimney.  Naturally, the lack of clothing led to excessive contact with 
soot from the chimney.  Baths were not taken regularly.  Pott noted in his essay Cancer 
Scroti in 1775 that, “The disease in these people, seems to derive its origin from a 
lodgement of soot in the rugae of the scrotum” (3). 
The mechanisms by which the complex mixtures of tobacco and soot elicited their 
toxic effects were eventually elucidated by investigators in the twentieth century. 
Exogenous compounds were found to be metabolically activated to reactive electrophiles 
that were capable of reacting with proteins and nucleic acids.  Bioactivation became a 
common theme in the newly emerging field of chemical carcinogenesis (4, 5).  
Additionally, Avery’s discovery of DNA as the inheritable, genetic material (6), and the 
description of its structure by Watson and Crick greatly advanced the field of cancer 
research (7, 8). 
The polyaromatic hydrocarbon (PAH) benzo[a]pyrene (B[a]P), a component of 
soot and tobacco smoke) and other structurally related PAHs were the focus of research 
for many laboratories.  Monooxygenase systems such as the cytochrome P450 (CYP) 
enzymes were found to play a key role in the metabolism of environmental compounds 
like the PAHs.  Several metabolites of B[a]P were characterized.  Of particular interest 
were the multiple epoxidation reactions of B[a]P resulting in the product 7,8-diol-9,10-
epoxy-B[a]P, which was determined to be an ultimate carcinogen of B[a]P metabolism 
(Figure 1).  The 7,8-diol-9,10-epoxy-B[a]P proved to be a potent electrophile and was 
found to react with DNA (principally, deoxyguanosine residues (dG)) to generate DNA 
adducts (9). 
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Figure 1.  Metabolic activation of B[a]P to 7,8-diol-9,10-epoxy-B[a]P and its reaction 
with dG residues in DNA. 
 
 
The concept that strong electrophiles were capable of modifying cellular 
macromolecules was an important advancement, and strengthened the association 
between environmental exposure and the onset of toxicity in human populations.  When 
metabolic activation of exogenous chemicals led to modification of DNA, a vital link to 
cancer development was forged.  However, it became increasingly apparent that 
exogenous carcinogens were not the only chemicals capable of modifying DNA.  DNA 
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was found to undergo spontaneous depurination and deamination reactions, which 
produced abasic sites and mispairing in DNA (10).  Additionally, work from the Ames 
Laboratory demonstrated the presence of oxidized bases, and correlated their occurrence 
with age and metabolic rates (11, 12).  Later Randerath et al. demonstrated the presence 
of modifications on DNA from unknown sources (13-16).  These observations suggested 
that an uncharacterized population of chemical agents was contributing to DNA damage 
in human populations.  As a result, the field of chemical carcinogenesis shifted its focus, 
in part, to the production of reactive electrophiles and nucleophiles by cells and tissues 
within the body.  These factors were described as endogenously produced chemical and 
biological agents, and were found in abundance during the inflammatory response. 
 
Inflammation and cancer 
In 1863 Rudolf Virchow hypothesized that inflammatory cells (leukocytes) were 
responsible for cancer development due to their ability to induce the proliferation of 
neighboring cells (17, 18). To date the strongest association between inflammation and 
carcinogenesis is seen with ulcerative colitis and the onset of colon cancer (18).  In 1925 
Burril B. Crohn detailed that inflammation recurrence in ulcerative colitis impacted 
nearly the entire digestive tract from anus to ceacum, and these effects were not due to a 
microorganism.  He noted the most aggressive forms of ulcerative colitis were highly 
correlated with an outcome of malignancy (19).  Decades of research have connected 
carcinoma development in ulcerative colitis to two main factors: the age of the individual 
when ulcerative colitis begins and the length of time the disease persists (20, 21).  Other 
diseases of chronic inflammation have also revealed an increased incidence of cancer 
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development such as hepatitis C viral infection leading to hepatocellular carcinoma (22), 
and Helicobacter pylori infection leading to gastric cancer (23). 
 
Reactive oxygen species 
A uniting aspect of the chronic inflammatory response is the steady and persistent 
recruitment of activated macrophages to the site of inflammation.  The presence and 
activity of these immune cells results in a constant barrage of chemical agents designed to 
eliminate pathogens.  However, the non-specific release and reaction of these chemicals 
exposes host tissue to the same barrage of chemical damage (Figure 2).  Immune cells 
release large amounts of reactive oxygen species (ROS) in the form of superoxide anion 
(O2•-), which dismutates to form H2O2.  A more powerful oxidant, hydroxyl radical 
(•OH), can be produced in Fenton reactions from H2O2 in the presence of ferrous iron 
(Fe2+) or other transition metals. Considered the most powerful endogenously produced 
oxidant, •OH is extremely reactive and diffuses less than 5 molecular diameters before 
reacting (24). 
Nitric oxide (NO•), an important signaling molecule, is released from activated 
macrophages following production by inducible nitric oxide synthase. O2•- and NO• react 
rapidly forming peroxynitrite (ONOO-) (25), which may undergo proton-catalyzed 
homolysis to •OH and NO2• (26-28).  The reported pKa for ONOO- is 6.8, which suggests 
that at physiological pH a significant amount of ONOO- exists in the protonated state as 
peroxynitrous acid (ONOOH). ONOOH is direct oxidant and undergoes homolysis to 
•OH and NO 2• (27, 29, 30). ONOO- also reacts with CO2 to form nitrosoperoxycarbonate  
(ONO2CO2-), which is  a  reactive  nitrogen  species capable  of  additional  oxidation and  
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Figure 2.  Generation of ROS from endogenous sources. 
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nitration reactions (31, 32). In addition to an abundance of ROS released from 
macrophages, the nitrosating agent N2O3 and the chlorinating agent HOCl are also 
produced, which are both capable of modifying cellular macromolecules (30). 
The generation of ROS is not limited to the immune response. Humans are 
aerobic animals that utilize molecular oxygen and often release ROS as by products of 
cellular metabolism.  Approximately 4-5% of the oxygen metabolized during cellular 
respiration is released as ROS (principally as O2•- via NADPH oxidase) (33), and 
peroxisomal metabolism significantly contributes to the production (and scavenging) of 
H2O2 in cells (34).  ROS are also produced on membranes or within the cytosol by 
oxidative enzymes such as CYPs (35, 36), xanthine oxidase (XO) (37), and others (38). 
High levels of ROS can lead to oxidative stress, which occurs when the cell’s 
antioxidant defense is overmatched by an abundance of ROS, and results in radical 
reactions with cellular macromolecules such as DNA, lipid and protein.  Modification of 
cellular components due to ROS exposure is broadly referred to as oxidative damage.  
Oxidative damage to protein is an important and emerging area of research, but it will not 
be discussed in detail.  It should be noted, though, that protein damage produces altered 
protein structure and function, changes in cell signaling, gene transcription and may 
result in necrosis or apoptosis (39).  Reactions of radicals with polyunsaturated fatty acids 
in the lipid bilayer results in lipid peroxidation, which is the non-enzymatic degradation 
of lipids producing multiple downstream products, many of which are potent 
electrophiles.  Radical reactions with DNA can lead to strand breaks, oxidized bases and 
the production of electrophiles generated in close proximity to nucleic acids. 
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Lipid peroxidation 
All known phospholipids in cell membranes contain an unsaturated fatty acid at 
the 2-position on the glycerol portion of the phospholipid head group.  Many of these 
unsaturated lipids are polyunsaturated (linoleic acid, linolenic acid, arachidonic acid, etc.) 
(Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Common fatty acids found in biological membranes. 
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As with all free radical chain reactions, the autoxidation of polyunsaturated fatty 
acids (PUFAs) is described as a three-step process: initiation, propagation and 
termination (Figure 4).  Methylene hydrogens in between the double bonds (bis-allylic 
hydrogens) of PUFAs are the target of free-radical abstraction by ROS (initiation) 
(Figure 5).  The resulting carbon-centered radical is delocalized across adjacent double 
bonds as a pentadienyl radical that rapidly reacts with molecular oxygen to form peroxyl 
radicals.   Peroxyl radicals may then abstract a bis-allylic hydrogen from a neighboring 
PUFA to form a lipid hydroperoxide and produce another carbon-centered radical 
(propagation) (Figure 6).  In this way, it is estimated that initiation of one PUFA peroxyl 
radical may propagate as many as 10 to 200 additional free radical reactions (depending 
on the degree of unsaturation in the lipid environment).  Lipid peroxidation is terminated 
upon reaction of two radicals, forming a non-radical species (termination). 
 
 
 
 
 
 
 
 
Figure 4.  General mechanism of autoxidation. 
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Figure 5.  Initiation of lipid peroxidation occurs by radical abstraction of a bis-
allylic hydrogen from a PUFA producing a carbon-centered pentadienyl radical. 
 
 
A competing reaction for the peroxyl radical is intramolecular cyclization.  This 
can occur when the oxidized PUFA contains three or more double bonds with an inner 
peroxyl radical (a peroxyl radical positioned between double bonds).  The inner peroxyl 
radical may react with an unsaturated carbon center three atoms away producing an 
endoperoxide.  The endoperoxide radical may react with oxygen, or initiate another 
intramolecular cyclization forming a bicyclic endoperoxide (Figure 6).  Products 
resulting from lipid peroxidation are numerous, and complex in regards to 
stereochemistry, with the abundance of products proportional to the degree of 
unsaturation. 
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Figure 6.  Autoxidation of arachidonic acid.  Following initial hydrogen abstraction 
from C-7 on arachidonic acid, an inner peroxyl radical forms leading to the production of 
lipid hydroperoxides, endoperoxides, and bicyclic endoperoxides (Figure adapted from 
(40)). 
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 The initial products derived from lipid peroxidation are subject to decomposition 
reactions, which may be facilitated by the presence of metals and other one electron 
donating species. The bicyclic endoperoxide and hydroperoxide products are of particular 
importance.  Cyclic peroxides have been reported to undergo acid catalyzed ring scission 
across the endoperoxide to yield the three-carbon dialdehyde, malondialdehyde (MDA) 
(Figure 7) (41).  MDA is also produced enzymatically from the endoperoxide-
metabolizing enzyme thromboxane synthase (42, 43).  MDA is an abundant product of 
lipid peroxidation and reactive with protein and DNA nucleosides (see discussion below). 
Lipid hydroperoxides are produced from non-enzymatic lipid peroxidation 
reactions and as products of lipoxygenase and cyclooxygenase enzymes (44-47).  The 
lipid hydroperoxides 9- and 13-hydroperoxy-octadecadieneoic acid (HPODE) are 
precursors to the production of several reactive bifunctional electrophiles.  In the 
presence of Vitamin C or transition metals (Fe2+, Cu1+), 9- and 13-HPODE are 
decomposed to 4-hydroperoxy-2-nonenal, 4-oxo-2-nonenal, 4-hydroxy-2-nonenal, and 
4,5-epoxy-2-decenal, among other products (Figure 8); these compounds display varied 
reactivity with cellular macromolecules. Decomposition of other lipid hydroperoxides 
such as 5- and 15-hydroperoxyeicosatetraenoic acid (derived from arachidonic acid) also 
leads to a similar array of products (48-50).  Several mechanisms for the decomposition 
of lipid hydroperoxides have been implicated, such as homolytic cleavage, autoxidation 
and Hock cleavage (51-54).  Both 4-hydroperoxy-2-nonenal and 4-oxo-2-nonenal can be 
directly produced from lipid hydroperoxide decomposition of 13-HPODE (51-53).  4-
Oxo-2-nonenal is also a dehydration product of 4-hydroperoxy-2-nonenal (55).  4-
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Hydroxy-2-nonenal can form from the reduction of 4-oxo-2-nonenal, but is mainly 
produced from the reduction of 4-hydroperoxy-2-nonenal (51, 53). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Beta-scission of a bicyclic endoperoxide to generate MDA. 
 
 
 
 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Non-enzymatic degradation of 9- and 13-HPODE.  Production of reactive 
bifunctional electrophiles: 4-hydroperoxy-2-nonenal, 4-oxo-2-nonenal, 4-hydroxy-2-
nonenal, and 4,5-epoxy-2-decenal. 
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Two other important bifunctional electrophiles produced during lipid peroxidation 
are acrolein and crotonaldehyde.  These molecules are also environment contaminants, 
which arise during the combustion of organic material (56, 57).  Acrolein and 
crotonaldehyde are 3- and 4-carbon α,β-unsaturated aldehydes, respectively, and their 
reactivity with cellular macromolecules is similar to 4-hydroxy-2-nonenal. 
 
Deoxyribose peroxidation 
ROS can initiate free radical reactions with the deoxyribose scaffold of DNA.  
Every hydrogen on the deoxyribose ring is subject to free radical-mediated abstraction 
and subsequent diffusion-limited reactivity with molecular oxygen.  Each site of 
peroxidation leads to a separate and overlapping array of products.  Following hydrogen 
abstraction on deoxyribose by ROS, a peroxyl radical is rapidly formed leading to 
additional intra- and intermolecular reactions, producing abasic sites and strand breaks. 
DNA strand breaks and abasic sites are thought to significantly contribute to the toxicity 
and mutagenicity induced by ROS.  Several side-products derived from fragmentation of 
the deoxyribose ring are produced such as MDA, base propenal and base propenoate.  
These electrophiles, which are generated within DNA, have been characterized to react 
with nucleic acids. 
Chemistry at the 4′-position of deoxyribose has been extensively studied due to 
the availability of reagents producing radical formation at this site (bleomycin, 
calicheamicin, ONOO-, and Fe2+-EDTA) (58-61).  4´-Free radical formation produces 
either an abasic site or a strand break with a free 3′-phosphoglycolate terminus. 
Fragmentation products derived from the deoxyribose moiety following a strand break 
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depend on the free radical initiator (60), and form either base propenal or MDA and a 
free base, which appear to be derived from separate mechanisms (Figure 9) (61-63). 
 
 
 
 
 
Figure 9. 4´-Autoxidation of deoxyribose.  4´-Autoxidation of deoxyribose leads to the 
production of a free phosphoglycolate with either a base propenal or MDA and the base 
(Figure adapted from (63)). 
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Assessing exposure to oxidative damage 
Oxidative damage to membranes initiates lipid peroxidation to induce the 
formation of many highly reactive lipid electrophiles.  These molecules can react with 
cellular nucleophiles to alter native function.  Also produced from lipid peroxidation are a 
series of molecules known as the isoprostanes.  Isoprostanes are non-enzymatic lipid 
oxidation products of arachidonic acid that are isomeric to the enzymatically produced 
prostaglandins (64).  Cyclooxygenase imparts a trans orientation of the side chains on the 
bicyclic endoperoxide of the prostaglandin products.  The isoprostanes are a racemic mix 
of diastereomer, but the alkyl side chains are predominantly in the cis orientation (65).  
Isoprostanes are byproducts of lipid peroxidation and are widely considered the best in 
vivo marker of oxidative stress (66).  Increased isoprostanes levels have been correlated 
with several pathological conditions including atherosclerosis (67), Alzheimer’s disease 
(68), and ischemia-reperfusion injury (69, 70), among others (71, 72).  Additionally, they 
are strongly correlated with lipid peroxidation in animal models (73, 74).  Despite their 
strong correlations to multiple pathologies, their appearance does not necessarily reflect 
genomic exposure to oxidative damage. 
Since many endogenously produced nucleophiles and electrophiles that modify 
DNA are highly reactive, their direct detection is not feasible.  Identifying end products 
of their reactions may be a useful approach to assessing their production.  In the case of 
reactions with DNA, adducted DNA basesare often considered terminal products of 
reaction.  Therefore, monitoring the levels of endogenously formed DNA adducts has 
been proposed as a means of assessing genomic exposure to oxidative damage (75).  
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Evaluating the formation of DNA adducts and their biological processing is an essential 
prerequisite to their use as a marker of exposure to endogenous sources of DNA damage. 
 
Chemistry and Biology of MDA 
MDA is an abundant product of lipid peroxidation, and one of the first products 
hypothesized to arise from the oxidation of lipids (76-80).  MDA is a bifunctional 
electrophile with pH-dependent reactivity. At lower pH values (< 5), MDA displays 
similar reactivity to that of other bifunctional electrophiles produced from lipid 
peroxidation. At pH values above 5, MDA exists as an enolate ion and is considerably 
less reactive towards nucleophiles.  Understanding the reactivity of MDA offers insight 
into the reactivity of a broad class bifunctional electrophiles derived from lipid and DNA 
peroxidation. 
 
Cellular effects of MDA 
MDA exists as the β-hydroxyacrolein tautomer in polar solvents (81) and forms 
an enolate at physiological pH (pKa = 4.46) (82) (Figure 10).  Early studies on the 
biological consequences of MDA exposure demonstrated weak mutagenicity in bacteria 
and human cells, and MDA was found to be carcinogenic in mice (83-86). Acid 
hydrolysis of commercially available tetraalkoxypropanes was commonly performed as a 
means of producing MDA.  Subsequent investigations revealed that the earlier 
mutagenesis studies were influenced by impurities present from the preparation of MDA 
from tetraalkoxypropanes.  Marnett and Tuttle demonstrated that incomplete acid 
hydrolysis of tetraalkoxypropanes yielded side products (i.e., β-alkoxyacroleins) that 
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were 20 to 40 times more mutagenic than the conjugate base of β-hydroxyacrolein (87).  
Later, Basu and Marnett unequivocally demonstrated that pristine preparations of MDA 
were weakly mutagenic in bacteria (88), and topical exposures to mice demonstrated 
MDA was not carcinogenic (89).  However, MDA was found to be carcinogenic in rats 
and mice upon administration by oral gavage (90). 
 
 
 
 
 
 
 
Figure 10. Tautomerization of MDA to β-hydroxyacrolein and pH-dependent 
formation of the enolate ion. 
 
 
Further investigation into the mutagenicity of MDA-like molecules was 
undertaken using a structure-based approach with model electrophiles similar to β-
hydroxyacrolein.  Chemical substitutions were made at the β-position and the 
mutagenicity of each analog was evaluated with tester strains of bacteria.  It was found 
that mutagenicity was related to the strength of the leaving group at the β-position: as the 
strength of the leaving increased, so did mutagenicity (β-chloroacrolein > di-γ-
oxopropenal ether > β-(p-nitrophenoxy)-acrolein > β-benzoyloxyacrolein).  Additionally, 
as the steric bulk of the β-substitution increased, without changing the electron 
withdrawing nature of the leaving group, the mutagenicity decreased (β-methoxyacrolein 
> β-ethoxyacrolein > β-isobutoxyacrolein) (91).  It should be noted that substituting non-
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ionizeable derivatives in place of the hydroxyl on β-hydroxyacrolein resulted in greater 
mutagenicity.  Thus, it was implied that the negative charge carried by the conjugate base 
of β-hydroxyacrolein at physiological pH negatively impacted mutagenicity. 
 
Chemical reactivity of MDA and β-substituted acroleins with nucleosides 
Initial studies on the reactivity of MDA with DNA were performed by Brooks and 
Klammerth, who demonstrated that DNA treated with MDA (at pH 4.6 and not at pH 6.9) 
resulted in altered thermal decomposition profiles and resistance to deoxyribonuclease 
cleavage (92).  Additionally, Reiss et al. found DNA treated with MDA at pH 4.6 
exhibited a significant increase in fluorescence and enhanced absorbance at long 
wavelengths (~320 nm) (93).  Reiss et al. also found that when reacted with MDA, 
adenine and guanine produced fluorescent products (93).  Implicit in these results was the 
dependence of pH on reactivity, which demonstrated that β-hydroxyacrolein was much 
less reactive at pH values greater than 4.5 (82).  These studies provided multiple lines of 
evidence, which suggested MDA was very reactive with DNA at low pHs leading to the 
formation of fluorescent modifications. 
Early characterization of the reactivity of nucleosides with MDA and related 
structural analogs stemmed from work in the Leonard Laboratory.  Moschel and Leonard 
found that dG reacted under acidic conditions with α-substituted MDA analogs, and 
produced fluorescent products exhibiting pyrimidopurinone structures (94).  
Subsequently, it was found that reactions of guanosine and dG under acidic conditions 
with MDA yielded two products: a pyrimidopurinone molecule (similar to that found by 
Moschel and Leonard), with one equivalent of MDA incorporated (95-97), and an 
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oxadiazabicyclononene-derivative (a pair of enantiomers), with two equivalents of MDA 
incorporated (Figure 11).  The MDA-dG derivatives were named based on the number of 
MDA equivalents added to dG (M1dG = 1 equivalent and M2dG = two equivalents added 
to dG).  Reaction of MDA at neutral pH in the presence of a mixture of deoxynucleosides 
revealed dG was the most reactive (dG > 2′-deoxyadenosine (dA) > > 2′-deoxycytidine 
(dC)), but adducts were formed in low yields (< 1%) (98).  A thymidine adduct was not 
observed (98). 
Reaction of MDA with dA and dC was also investigated.  Single and multimeric 
additions of MDA were observed with the deoxynucleosides (99-102).  One equivalent of 
MDA added to the exocyclic amino group yielding oxopropenyl-derivatives: N6-(3-oxo-
1-propenyl)-dA (OPdA or M1dA) and N4-(3-oxo-1-propenyl)-dC (OPdC or M1dC) 
(Figure 11).  Mulitmeric adducts arose from reactions of polymers derived from MDA in 
situ and were not the product of successive additions of MDA to the oxopropenyl-
derivatives (99-101).  The multimeric adducts are unlikely to form in vivo.  Thus, the 
significance of their formation is currently unknown. 
 The reaction mechanism of β-substituted acroleins with dG was investigated 
using deuterium labeled β-(p-nitrophenoxy)-acrolein.  The reaction was found to proceed 
via 1,2-addition of the exocyclic N2-amino group to the aldehyde of the β-substituted 
acrolein, followed by cyclization on the ring nitrogen (N1).  Cyclization was preceded by 
hydrolysis of the β-substituent forming a 3-oxo-1-propenyl intermediate on the exocyclic 
N2 (103). The reaction mechanism was further explored in reactions of dG with a series 
base propenals (β-substituted acroleins derived from DNA peroxidation). Plastaras et al. 
observed that the extent of reactivity of β-substituted acroleins with dG was dependent on 
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Figure 11.  DNA adducts derived from MDA and related β-substituted acroleins. 
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the pKa of the conjugate acid for the leaving group (Figure 12) (104).  The order of 
reactivity observed in reactions of base propenals with dG was as follows: adenine 
propenal (9.8) > cytosine propenal (12.2) > thymine propenal (>13) > β-hydroxyacrolein 
(15.7) (pKa values for the leaving groups in parenthesis).  The use of the pKa for β-
hydroxyacrolein understates the reactivity of its conjugate base because β-
hydroxyacrolein exists principally as an enolate ion at neutral pH.  In the case of the 
MDA-enolate ion, the oxide is an exceptionally poor leaving group. 
 
 
 
 
Figure 12.  Reaction mechanism for the 1,2-addition of β-substituted acroleins 
(thymine propenal) with dG (Figure adapted from (104)). 
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Based on the reaction mechanism for β-hydroxyacrolein derivatives with dG, 
which followed 1,2-addition to the exocyclic N2-amino group, it was hypothesized that 
the position of the N2-atom within DNA may impact its reactivity towards model 
electrophiles (105). The N2-position of dG is located in the minor groove and is involved 
in hydrogen bonding.  Investigations into the DNA structural requirements leading to the 
formation of M1dG revealed access of electrophiles (β-hydroxyacrolein, adenine 
propenal) to the minor groove was critical for reaction.  Factors that limited access to the 
minor groove (high ionic strength, minor groove binding agents) reduced M1dG 
formation, while factors that enhanced access to the minor grove (intercalating agents, 
major groove binders) increased M1dG formation.  Furthermore, single-stranded DNA 
was found to be more reactive than double-stranded DNA, implying that access to the 
exocyclic N2-position of dG was critical for the formation of M1dG. Considering M1dG 
formation in the context of double stranded DNA, initial approach of an enolate ion may 
be affected by charge repulsion from the negatively charged phosphate backbone of 
DNA.  Thus, at physiological pH the formation of M1dG is likely to arise from neutral β-
hydroxyacrolein analogs such as base propenal. 
Two recent studies strongly support the hypothesis that base propenals are the 
principal reactants leading to M1dG formation.  Investigation by Zhou et al. demonstrated 
an increase in M1dG levels in vitro when calf thymus DNA was exposed to reagents that 
promote base propenal formation (bleomycin or ONOO-) and no change in M1dG levels 
with reagents that principally produce MDA (Fe2+-EDTA or γ-radiation) (106).  
Additionally, in bacterial cells an increase in M1dG formation was dependent on ONOO- 
exposure (produces base propenal) but not seen following exposure to γ-radiation 
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(produces MDA) (106).  Jeong and Swenberg made similar observations (107).  In their 
study with uniformly 13C-labeled DNA in the presence of H2O2 and Cu1+, all M1dG was 
derived from deoxyribose.  The same results were obtained when the above incubation 
was supplemented with non-isotopically enriched oleic acid (18:1).  Upon addition of 
non-isotopically enriched PUFAs the majority of M1dG was derived from deoxyribose 
rather than lipid (107). 
 
Stability of M1dG: hydrolytic ring-opening and reaction with nucleophiles 
Investigations on the aqueous stability of M1dG revealed that the adduct was 
subject to hydrolytic ring opening in basic solutions resulting in the formation of 3-oxo-
1-propenyl-moiety on the exocyclic N2-position of dG (OPdG) (108). This structure was 
analogous to the OPdA and OPdC structures previously characterized as major reaction 
products of MDA with dA and dC, respectively.  Further investigation into the 
mechanism of ring opening for M1dG revealed that hydroxide ion added directly to C8 of 
the exocyclic ring producing a transient carbinolamine, which rapidly ring-opened by 
breaking the C8-N9 bond (109) (Figure 13).  A resulting negative charge remains on the 
purine nitrogen (N1) in the ring-opened state, which has a calculated pKa of 6.9 (110).  
The negative charge on OPdG impacts further reactions with nucleophiles (see below).  
Ring opening of M1dG is reversible, and OPdG is subject to a general-acid-catalyzed 
ring-closure.  This reaction is biphasic with a fast protonation step (protonation of N1) 
and a slower dehydration step (110). 
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Figure 13. Hydrolytic ring opening of M1dG to OPdG and general-acid-catalyzed 
ring-closure of OPdG to M1dG. 
 
The mechanism of M1dG ring-opening is not limited to reactions with hydroxide.  
Other nucleophiles have been characterized to react with M1dG such as amines, 
hydroxylamines, and hydrazines (111-113).  These reactions principally occur by direct 
addition to C8, but nucleophiles also may react with the free aldehyde of OPdG (112, 
113) demonstrating that other oxopropenyl derivatives (OPdA, OPdC, base propenal, 
etc.) are subject to derivatization (113).  Further investigation into the reactivity of M1dG 
with oxidative enzymes will be discussed in Chapter 2. 
In single-stranded oligonucleotides, M1dG is present in the ring-closed form 
(109).  Interestingly, in duplex DNA the conformation of M1dG is sequence-dependent.  
When positioned opposite dC residues in double-stranded DNA, M1dG ring opens to 
OPdG; however, when opposite dT residues, M1dG remains as a pyrimidopurinone (114, 
115).  It has been hypothesized that duplex annealing is responsible for catalyzing ring 
opening to OPdG suggesting that the exocyclic N4-amino group on the dC residue on the 
complimentary strand functions to activate water and direct the addition to C8 of M1dG 
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prior to stacking of the incoming nucleotides (109).  Once positioned in DNA, OPdG 
extends into the minor grove where it may react with DNA-binding proteins and affect 
protein-DNA interactions.  Of note, the minor grove is also the location where MDA and 
base propenals are believed to react with the N2-amino group on dG residues for initial 
1,2-addition to OPdG (105).  Preliminary studies on the ability of M1dG to disrupt 
protein-DNA interactions suggested the dynamic equilibrium of M1dG and OPdG may 
impact protein-DNA interactions as witnessed by the impaired ability of restriction 
enzymes to cleave at consensus sites containing M1dG (116). 
Many DNA binding proteins are rich in basic amino acids such as lysine (lys), 
histidine (his) and arginine (arg), with the resulting net positive charge of these residues 
providing a means of associating with the negatively charged DNA helix.  Amines are 
reasonable nucleophiles and have been characterized to react with M1dG (104, 111).  
Therefore, to model the potential interactions of oxopropenyl-nucleoside adducts with 
DNA, reactions with N-α-acetyl-lys (a model nucleophile) were examined (117).  The 
reaction of N-α-acetyl-lys with M1dG produced a Schiff base adduct and was rapidly 
hydrolyzed at neutral pH (similar to what was seen upon reaction with tris-
(hydroxymethyl)-aminomethane (Tris) (111)).  The ring-opened OPdG, bearing a full 
negative charge on N1, did not react with N-α-acetyl-lys.  To eliminate the effect of the 
negative charge on the reaction of N-α-acetyl-lys, OPdG was reacted with iodomethane 
to yield (N1-methyl)-OPdG and displayed an increase in the pKa to 8.2.  Removal of the 
negative charge resulted in enhanced reactivity of OPdG with N-α-acetyl-lys and 
produced a reversible, but stable, Schiff base conjugate (t1/2 = 12 h).  Based on these 
results, it was hypothesized that the other oxopropenyl deoxynucleoside adducts, OPdA 
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(pKa = 10.0) and OPdC (pKa = 10.5), which do not carry a negative charge at neutral pH, 
would form stable crosslinks in reactions with N-α-acetyl-lys.  Subsequent reaction of 
either OPdA or OPdC with N-α-acetyl-lys demonstrated stable crosslinks with similar 
characteristics seen with (N1-methyl)-OPdG.  These data suggest that the acidity of the 
oxopropenyl deoxynucleoside is a key determinant of its reactivity.  Thus, under 
physiological conditions, one can reasonably assume that either OPdA or OPdC are the 
most likely MDA-modified oxopropenyl derivatives to react and form stable DNA-
protein crosslinks. 
 
M1dG as a premutagenic lesion 
Initial studies on the biological effects of MDA and β-substituted acroleins were 
performed in tester strains of the bacterium Salmonella typhimurium.  These studies 
suggested MDA and β-substituted acroleins induced base pair substitutions and 
frameshift mutations (83, 88, 91, 118).  More detailed sequence information on the 
mutagenicity of MDA was obtained by transforming MDA-modified single stranded 
phage DNA into Escherichia coli.  Following replication of the viral genome, sequence 
analysis was performed which revealed base-pair substitutions (G → T, C → T, and A → 
G) and frameshift mutations (mainly single base additions occurring in runs of reiterated 
bases) (119).  It is important to note from the data that specific types of adducts formed in 
these experiments cannot unequivocally be linked to their genetic consequences (i.e., it 
was unknown which adducts induced a particular mutation).  However, the base-pair 
substitution data from latter experiment is suggestive of specific types of MDA-induced 
lesions (i.e., a G → T transversion would imply modification of G by MDA). 
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A significant advancement in the mutational analysis of M1dG was made by 
Reddy and Marnett, who successfully incorporated the pyrimidopurinone ring adduct into 
an oligonucleotide (108).  Shortly to follow was the ligation of these oligonucleotides 
into gapped duplex DNA for use in bacterial and mammalian cells.  Initial reports from 
E. coli demonstrated that M1dG, within the sequence context of 5´-GGT(M1dG)TCCG-
3´, was an efficient premutagenic lesion that induced base-pair substitutions (M1dG → A 
~ M1dG → T > M1dG → C).  No frameshift mutations were detected in this experiment, 
but the site-specific position of the adduct was not in a reiterated repeat sequence.  
However, M1dG was found to be a strong block to replication, and when correcting for 
strand bias M1dG was shown to have a mutation frequency of 18% (120). 
VanderVeen et al. later demonstrated that the mutational spectrum of M1dG was 
sequence dependent in both E. coli and mammalian cells (121).  M1dG was incorporated 
into one of several positions on a single-stranded vector within the context of a reiterated 
sequence (5´-GGTGTCCG1CG2CG3CG4GCATG-3´).  Following sequence analysis of 
the replicated plasmids it was revealed that M1dG induced mostly -2 and some -1 
deletions (frameshift mutations).  Base-pair substitutions were also found (M1dG → A ~ 
M1dG → T > M1dG → C).  Insertion of M1dG at position-3 resulted in the highest 
mutation frequency.  A non-reiterative sequence (5´-GGT(M1dG)TCCG-3´) used in 
mammalian cells produced no deletion mutants, which strongly implicated the sequence 
context of DNA in which M1dG resides to be a determining factor for its mutational 
spectrum (121). 
 
 
 30 
Repair mechanisms for M1dG 
The repair of M1dG from genomic DNA is mediated by the nucleotide excision 
repair (NER) pathway.  Bacterial cells deficient in NER display an increased mutation 
frequency compared to NER-competent cells when transformed with M13 vectors 
containing site-specifically positioned M1dG (120).  Similar results were observed in 
bacteria upon site-specific incorporation of propano-dG (PdG, tetrahydro-
pyrimidopurinone-dG, which is a structural analog of M1dG) using NER-deficient and 
proficient cells (122).  Additionally, PdG was found to be a substrate for NER repair in 
vitro using recombinant bacterial repair proteins or mammalian cell extracts (122).  
Based on the close structural similarity between PdG and M1dG, it appears likely that the 
NER pathway in mammalian cells also repairs M1dG.  Currently, there is no evidence 
supporting a role for base excision repair in the repair of M1dG. 
In eukaryotes, NER is carried-out by a complex network of proteins designed to 
identify and remove lesions from DNA.  A more simplified complex of three proteins 
(UvrA, UvrB, and UvrC) is involved in prokaryotic NER.   This repair mechanism is 
typically associated with the removal of large, bulky adducts such as intrastrand 
crosslinks, DNA-protein crosslinks and chemical modification by large molecules 
(B[a]P, cisplatin).  However, NER is also involved with the repair of small lesions such 
as O6-methyl-dG, 8-oxo-Gua, abasic sites, and the pyrimidopurinone adduct, M1dG (123-
125).  Independent of the type of lesion present for NER-mediated excision, a similar 
cascade of molecular interactions occurs, which involves (1) recognition of the lesion, (2) 
unwinding of the DNA, (3) dual-incision around the lesion on the damaged strand, (4) 
removal of an oligonucleotide, (5) DNA synthesis, and (6) ligation (Figure 14). 
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Figure 14.  NER-dependent release of M1dG from DNA in eukaryotes (Figure 
adapted from (124)). 
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In eukaryotes, the lesion is recognized by replication protein A (RPA), xeroderma 
pigmentosum-A (XPA), XPC-TFIIH (transcription factor IIH), XPB, and XPD, which 
assemble at the lesion site.  In the presence of damage, the helix is unwound in an ATP-
dependent process by XPB and XPD.  XPG replaces XPC in the complex followed by the 
recruitment of XPF-ERCC1 (excision repair cross complementary group 1).  The 
damaged strand is incised at the 3´-end by XPG and at the 5´-end by XPF-ERCC1.  A 24-
32 unit oligonucleotide is released and the gap is repaired by a DNA replication complex 
involving either polymerase δ or ε.  DNA ligase then joins the newly synthesized DNA to 
the existing duplex (Figure 14) (124).  Defects in any of the XP proteins A-G result in a 
genetic predisposition to cancer and neurological abnormalities.  These defects are 
principally attributed to a reduced or abolished NER mechanism (126).  
Of no small importance is the fate of the lesion-containing oligonucleotide 
produced from NER.  Following removal from DNA, the oligonucleotide is subject to 
hydrolysis, which results in the formation of free deoxynucleosides.  Thus, lesions 
repaired by NER are removed from cells in the form of deoxynucleosides.  
 
Analytical assessment of DNA lesions 
Characterizing the reactivity of MDA and related β-substituted acroleins with 
nucleosides and DNA in vitro is an important step towards understanding the chemical 
reactivity of these endogenously produced electrophiles.  Relating adduct formation to a 
biological outcome (i.e., mutation) is also critical to understanding the consequences of 
DNA modification.  Additionally, another very important factor to investigate is the level 
of DNA adduct formation in vivo.  The ability to accurately quantify M1dG levels may 
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offer a means of identifying changes in adduct levels across different populations and in 
relation to varied pathological conditions.  Thus, assessing endogenous adduct levels may 
offer insight into the contribution of oxidative damage observed in genomic DNA. MDA 
and β-substituted acroleins have been characterized to form multiple nucleoside adducts.  
However, the principal adduct formed at physiological pH is M1dG.  Thus, the 
quantification of M1dG has been the focus of research directed at assessing genomic 
exposure to oxidative damage. 
Two main approaches exist for the analysis of DNA adducts in human 
populations: direct detection from genomic DNA and analysis of DNA adducts in 
biological waste products.  Genomic DNA may be isolated from cells, hydrolyzed to 
individual nucleosides, purified, and quantified by various analytical techniques.  This 
tactic requires access to cells, which may originate from tissue or blood.  Analysis of this 
type is typically regarded as an invasive approach.  Its main advantage is that it represents 
a very direct analysis technique (DNA adducts are associated with a specific tissue), but 
it is limited by access to the sample.  The analysis of DNA adducts in biological waste 
products (urine, feces) represents non-invasive means of assessing DNA adduct levels.  
However, this approach represents an indirect method of analysis, since the true origin 
(tissue-specificity, dietary components, etc.) of the adduct is difficult to determine.  
However, the appearance of DNA adducts in urine is often attributed to their repair-
dependent removal from DNA.  
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Analytical assessment of aflatoxin-N7-Gua lesions 
The best example of correlating urinary DNA adduct levels with carcinogen 
exposure is seen with the aflatoxin B1 guanine adduct (aflatoxin-N7-Gua).  Aflatoxin B1 is 
a fungal metabolite found in contaminated foods such as corn, peanuts, and soy beans 
that are risk factors for the development of hepatocellular carcinoma in humans (127). 
Absorption of aflatoxin B1 from contaminated food leads to the metabolic activation of 
aflatoxin B1 in the liver by CYPs to aflatoxin-B1-8,9-oxide (128, 129).  The exo 
stereoisomer reacts with dG residues in DNA to produce aflatoxin-N7-dG (129-132).  
This adduct is unstable and undergoes depurination in DNA, and is released as the base 
adduct (aflatoxin-N7-Gua), which is eliminated in urine (Figure 15) (133). 
Treatment of rats with aflatoxin B1 produces a dose-dependent increase in both 
the elimination of aflatoxin-N7-Gua in the urine and the amount of aflatoxin-N7-dG in 
genomic DNA (133, 134).  No other urinary metabolites of aflatoxin B1 were found to 
correlate with aflatoxin B1 exposure.  Similar observations were made from 
epidemiological studies in human populations at risk for dietary aflatoxin B1 exposure.  
Population-based studies in China and West Africa have revealed strong associations 
between dietary intake of aflatoxin B1 and the urinary elimination of aflatoxin-N7-Gua 
(135-138). A 2- to 3-fold greater risk for developing hepatocellular carcinoma was 
observed with individuals who had aflatoxin-N7-Gua in their urine (139). Additionally, 
individuals who test positive for hepatitis B are approximately 8 times more likely to 
develop hepatocellular carcinoma when exposed to dietary aflatoxin B1 than non-infected 
individuals.  In infected and non-infected individuals, strong correlations are observed 
between the urinary levels of aflatoxin-N7-Gua and the onset of cancer (139, 140). Thus, 
 35 
the elimination of DNA adducts in urine can be reflective of exposure to genotoxic 
chemicals and identify individuals at risk for cancer. 
 
 
 
 
Figure 15. Generation of aflatoxin-B1-N7-Gua.  Oxidaiton of aflatoxin B1 produces 
exo-aflatoxin B1-8,9-oxide, which reacts with dG residues in DNA to generate aflatoxin-
B1-N7-dG.  Aflatoxin-B1-N7-Gua spontaneously depurinates from DNA and is eliminated 
in the urine. 
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Analytical assessment of M1dG lesions 
Initial observations for the covalent modification of DNA by MDA were made by 
absorbance and fluorescence measurements (93).  Seto et al. later determined by 
chromatographic separation that the bulk of the fluorescence produced in the reaction of 
MDA with DNA was not covalently bound to nucleic acid (> 70%), and only 6% of the 
material was attributed to M1dG (141).  The conjugated structure of M1dG provides 
modest fluorescence (2% quantum yield) with an excitation maximum at 363 nm and an 
emission wavelength at 511 nm.  Fluorescence measurements of M1dG levels have been 
performed on DNA isolated from rat liver and in human urine, but the reported levels 
were quite high (142-144), presumably due to the inherent non-specificity of fluorescence 
detection within the context of a complex medium. 
Mass spectrometry (MS) analysis offers an enhanced linear range of analytical 
detection and improved analyte selectivity when compared to fluorescence analysis.  The 
selectivity is particularly evident upon coupling chromatographic separation to MS 
detection. An initial MS approach was undertaken to determine the level of M1G (the free 
base of M1dG) in human urine samples (145). M1G is a putative product of DNA repair 
by DNA glycosylases and, therefore, may appear in urine following repair-dependent 
removal from DNA.  This methodology utilized liquid chromatography-mass 
spectrometry analysis (LC-MS) and implemented the use of a di-deuterium labeled M1dG 
internal standard ([2H2]-M1dG).  The use of an isotopically labeled internal standard in 
mass spectrometry analysis allows for corrections in recovery during sample work-up and 
provides a reference for quantitation.  M1G was enriched during the sample work-up by 
C18 solid phase extraction (SPE) and HPLC collection.  Furthermore, the sample was 
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reacted with sodium borohydride to reduce the 5,6-double bond on the pyrimido ring to 
yield 5,6-dihydro-M1G (Figure 16), which enhanced chemical ionization and improved 
chromatographic separation (145, 146).  This method of analysis had a limit of sensitivity 
of 250 fmol (on column), but the level of M1G in urine was below the limit of detection 
for the assay (< 500 fmol/mL). 
 
 
 
 
 
 
 
 
Figure 16. Reduction of M1dG with sodium borohydride to yield 5,6-dihydro-M1dG. 
 
Further method development was undertaken to enhance the assay sensitivity with 
the purpose of evaluating the level of M1dG in genomic DNA.  Two similar assays were 
developed utilizing gas chromatography electron capture negative chemical ionization 
MS (GC-ECNCI-MS), which utilized the [2H2]-M1dG internal standard (147, 148).  One 
approach implemented sodium borohydride reduction to yield 5,6-dihydro-M1dG, which 
was then successively derivatized, first with pentafluorphenylbromine (PFB-Br, to 
enhance ionization) and second with N-methyl-N-tert-butyldimethylsilyl 
trifluoroacetamide (tBDMS, to enhance GC mobility).  Following several SPE clean-up 
 38 
steps (and derivatizations), the resulting M1G-PFB-BDMS derivative was then analyzed 
by GC-ECNCI-MS with a limit of detection of 30 fmol on column and revealed the 
presence of 5 adducts per 107 bases in rat liver (147).  The second approach neither 
reduced M1dG to 5,6-dihydro-M1dG nor derivatized to the BDMS conjugate.  Rather, a 
mild acid hydrolysis of the deoxynucleosides from rat liver was implemented to 
hydrolyze to the free purines and pyrimidines.  These samples were then derivatized with 
PFB-Br, which produces a mixture of isomers at N1 and N3 of M1G that are separable by 
GC.  Implementing additional SPE steps during sample work-up enabled a limit of 
detection 3 adducts per 109 bases.  Upon analysis of human liver DNA the level of 
endogenous M1dG was found to be present at an average of 9 adducts per 107 bases 
(approximately 5400 adducts per cell) (148).  This represented the first analytical 
evidence for the formation of lipid peroxidation-derived DNA adducts in healthy humans. 
Immunochemical methodologies have been developed both to directly analyze 
M1dG in ELISA assays and as an enrichment step prior to mass spectrometry analysis 
(104, 105, 113, 149, 150).  The latter was implemented by Rouzer et al. and for use in the 
GC-ECNCI/MS and also adapted to a LC-MS/MS analysis using electrospray ionization 
(ESI) to analyze M1dG in DNA isolated from leukocytes (149).  Both analytical methods 
readily detected the presence of M1dG in leukocyte DNA; however the GC-ECNCI/MS 
analysis proved to be more sensitive than the LC-MS/MS analysis.  Interestingly, the 
level of M1dG found in human leukocyte DNA was considerably lower than the level of 
M1dG in human liver.  Approximately 6 adducts per 108 bases were detected by GC-
ECNCI-MS in human leukocytes. 
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More recently, Jeong and Swenberg have developed another method of analysis 
for the detection of M1dG in DNA (151).  Their approach takes advantage of the 
chemical reactivity of M1dG in reactions with nucleophiles.  M1dG was derivatized with 
a dual-functionality reagent containing a biotin moiety linked to a hydroxylamine.  When 
reacted with DNA the hydroxylamine portion adds directly to the ring-closed M1dG to 
produce a stable oxime.  The enhanced hydrophobicity of the biotin linker allows for 
greater fold-purity during SPE work-up, enhanced retention on a reverse phase C18 
column, and lower background signal in the mass analyzer.  This method also utilizes 
uniformly labeled [15N]-DNA, with a known amount of M1dG adducts, as an internal 
standard during sample work-up.  The accuracy and precision of this assay is remarkable, 
with the calculated y-intercept for the calibration curve nearly passing through the origin.  
The observed LC-MS/MS limit of detection for M1dG on column was between 200-500 
amol.  Based on 200 µg of DNA, 2 adducts per 108 bases can be reliably detected with 
this analysis.  The application of this method to the analysis of rat tissue samples 
demonstrated M1dG levels of approximately 1 to 4 adducts per 108 bases (152).  This is 
currently the most accurate and precise method for the analysis of M1dG in DNA. 
A separate analytical approach was developed to probe for the presence of M1dG 
in human urine.  Since M1dG is principally repaired by the NER machinery (rather than 
via DNA glycosylases) it was reasoned that the deoxynucleoside would be the most 
abundant form of the adduct in urine. Otteneder et al. utilized immunoaffinity capture to 
isolate M1dG from urine, and sodium borohydride reduction to enhance ionization (153). 
5,6-dihydro-M1dG was analyzed by ESI positive ion LC-MS/MS analysis with a lower 
limit of detection of 50 fmol on column.  In all urine samples analyzed, however, the 
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level of analyte was below the limit of detection.  A modified analytical procedure was 
implemented by Hoberg et al., who utilized atmospheric pressure chemical ionization in 
place of ESI during the analysis (154).  This afforded an enhanced limit of sensitivity and 
lowered the limit of detection to 500 amol on column (a 100-fold improvement).  
Analysis of human urine samples revealed an M1dG elimination rate of 12 fmol/kg/24 h 
(154). 
The low rate of M1dG elimination in human urine was unexpected.  Other 
commonly monitored urinary DNA adducts such as 8-oxo-Gua and 8-oxo-dG are 
eliminated at rates of 2 nmol/kg/24 h and 0.4 nmol/kg/24 h, respectively (155, 156).  
There are several possibilities for the observed decreased elimination rate observed for 
M1dG.  Perhaps the most obvious possibilities are that M1dG is formed at lower levels in 
DNA than 8-oxo-dG, or repaired at reduced rates.  It is also possible that the amount of 
M1dG observed in urine may be affected by alternative routes of metabolic processing 
following NER-dependent removal from DNA.  Therefore, Otteneder et al. hypothesized 
that M1dG may undergo biotransformation to alternative metabolic products prior to 
urinary elimination (157).  Initial reports revealed that M1dG was oxidized in vitro and in 
vivo to a novel metabolite, 6-oxo-M1dG.  Based on these initial observations a series of 
experiments were undertaken to determine the total metabolic profile of M1dG.  These 
studies will be the focus of Chapters 2, 3, and 4.  The metabolic stability of M1G (a 
putative product of base excision repair by DNA glycosylase) will be described in 
Chapter 5. 
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Other Major Endogenously Formed DNA Adducts 
In addition to their reactivity with PUFAs, ROS also may react with other cellular 
macromolecules including protein and nucleic acids.  These reactions are considered 
direct effects of ROS and produce oxidized nucleic acids.  Alternatively, an abundant 
pool of secondary reaction products are derive from ROS-mediated lipid peroxidation 
reactions.  Lipid peroxidation-derived bifunctional electrophiles also react with cellular 
nucleophiles throughout cell, and of particular interest are their reactions with nucleic 
acids.  The bifunctional nature of many lipid peroxidation products provides two reactive 
centers.  Addition reactions to pyrimidines and purines often produce exocyclic structures 
on nucleobases, which form across the Watson-Crick basepairing interface.  Exocyclic 
rings are either 5- or 6-membered, with varying degree of saturation.  These lesions are 
highly mutagenic and repaired by multiple mechanisms. 
 
Oxidation of nucleosides by ROS 
ROS can directly modify DNA bases, with hydroxyl radical thought to be the 
principal mediator of damage.  dG is more susceptible to oxidation than other nucleosides 
due to its low oxidation potential (158).  The primary product arising from direct 
oxidation of dG is 8-oxo-7,8-dihydrodeoxyguanosine (8-oxo-dG).  8-Oxo-dG is subject 
to additional oxidations and can ring open to a minor product, 2,6-diamino-5-
formamidino-4-hydroxypyrimidine (159). 
Direct oxidation of adenine is also targeted to the imidazole ring to produce 8-
oxo-7,8-dihydrodeoxyadenosine (8-oxo-dA) (159, 160).  Pyrimidine oxidation occurs 
across the 5,6-double bond to produce glycols (thymidine glycol, cytidine glycol) (161).  
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Oxidation of cytidine at the 5- and 6-positions commonly results in deamination of the 
exocyclic N4 amino group producing uracil derivatives.  In the case of thymidine, 
oxidation may also occur on the exocyclic methyl group (Figure 17) (159, 160).  For a 
thorough overview of DNA base oxidation, the reader is referred to review articles by 
Burrows (159), Cadet (160), and Neeley (162). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17.  DNA adducts arising from direct oxidation of DNA by ROS. 
 
Propano adducts 
Acrolein is the prototype α,β-unsaturated aldehyde, which reacts across N2 and 
N1 of dG to add three carbons and generate the exocyclic propano ring.  The reaction 
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occurs via Michael addition of the olefin to either N1 or N2 followed by 1,2-addition of 
the aldehyde to N2 or N1, respectively.  1,N2-8-Hydroxy-propanodeoxyguanosine (γ-OH-
PdG) and 1,N2-6-OH-PdG (α-OH-PdG) are the principal products with the former being 
the major isomer (Figure 18) (163, 164).  Reaction of dG with crotonaldehyde produces 
a similar propano ring.  However, addition occurs exclusively at the β-carbon of 
crotonaldehyde with N2 of dG followed by reaction with the aldehyde at N1 yielding α-
CH3-γ-OH-PdG  (Figure 18) (164, 165).  4-Hydroxy-2-nonenal addition to dG is 
identical to that seen for crotonaldehyde, resulting in the formation of α-hydroxyhexyl-γ-
OH-PdG (Figure 18) (166).  Reactions of crotonaldehyde and 4-hydroxy-2-nonenal with 
dG produce 4 diastereomers at the chiral centers (C6 and C8) of the propano ring.  It is 
proposed that the stereochemistry of propano adducts affects their biological reactivity in 
the context of DNA (167). 
 
 
 
 
 
 
 
 
 
 
Figure 18.  Propano DNA adducts of dG derived from lipid peroxidation products. 
 44 
The propano ring is unsaturated and puckered in structure, which is distinctly 
different from the planar and aromatic character of the pyrimidopurinone ring of M1dG.  
Like M1dG, the propano rings derived from acrolein, crotonaldehyde, and 4-hydroxy-2-
nonenal have been shown to ring open in duplex DNA (Figure 19) (164, 168-170).  In 
the ring-opened state the extended oxopropyl side-chain may interact with neighboring 
nucleic acids and protein to form crosslinks.  Several intra- and interstrand crosslinks 
have been identified for the propano adducts (171-176).  The interchanging conformation 
of the propano adducts is believed to contribute to the broad array of genetic mutation 
exhibited by these adducts (177-181). 
 
 
 
Figure 19.  Hydrolytic ring opening of γ-OH-PdG to 3-oxo-1-propyl-dG. 
 
Etheno adducts 
The addition of two carbons across the exocyclic and ring nitrogens of dA, dG 
and dC produces an etheno bridge.  Etheno addition grants fluorescent properties to the 
nucleosides.  Originally, etheno adducts were the synthetic target of Leonard and 
colleagues, who were interested in obtaining fluorescent nucleotide derivatives to probe 
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for the biological activity and structure of nucleotide-containing enzymes and tRNA 
molecules (182-184).  Some of the reagents commonly used to synthesize etheno adducts 
were found to be mutagens, such as chloroacetaldehyde (185). Chloroacetaldehyde was 
identified as a metabolite of the industrial contaminant, vinyl chloride (186).  Later 1-
chlorooxirane (another metabolite of vinyl chloride) was found to be more reactive with 
DNA than chloroacetaldehyde (187).  Further study into the metabolism and reactivity of 
other alkyl halides revealed many of these molecules were either directly damaging to 
DNA or underwent metabolic transformation to reactive electrophiles capable of 
modifying DNA; etheno DNA adducts were an abundant and important product of their 
reactivity. 
Four etheno adducts arise from exposure to alkyl halides: 1,N6-ε-dA, 1,N2-ε-dG, 
N2-3-ε-dG, and 3,N4-ε-dC (Figure 20).  However, etheno adducts have also been found 
in genomic DNA of humans and animals in the absence of exposure to alkyl halides 
(188-190).  Therefore, it was reasoned that etheno adducts must also have an endogenous 
origin.  Based on previous work demonstrating the reactivity of substituted 2,3-epoxy-
aldehydes (191, 192), Sodum and Chung demonstrated the formation of 1,N2-ε-dG upon 
reacting dG with an epoxide derived from 4-hydroxy-2-nonenal (2,3-epoxy-4-hydroxy-
nonenal) (193).  El Ghissassi et al. later found that transition metal-mediated 
decomposition of microsomes supplemented with arachidonic acid in the presence of dA 
and dC led to the production of etheno adducts 1,N6-ε-dA and 3,N4-ε-dC (194).  They 
hypothesized a similar mechanism for etheno adduct formation (194).  However, it was 
later demonstrated that formation of 2,3-epoxy-4-hydroxy-nonenal in cells was unlikely 
(195). 
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Figure 20.  Unsubstituted and substituted etheno adducts. 
 
Another mechanism of etheno adduct formation was proposed by Lee and Blair 
(196, 197).  Lee and Blair in addition to Schneider and Brash have identified several 
highly reactive bifunctional electrophiles produced from the transition metal-mediated 
decomposition of lipid hydroperoxides (Figure 8) (51-53).  Both 4-hydroperoxy-2-
nonenal and 4,5-epoxy-2-decenal were characterized to react with dG and dA to form two 
unsubstituted etheno adducts, 1,N6-ε-dA and 1,N2-ε-dG (196, 197).  The proposed 
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mechanism of addition by 4-hydroperoxy-2-nonenal proceeds by 1,2-addition of the 
exocyclic N-amino group to the aldehyde, followed by intramolecular cyclization to an 
epoxide intermediate, which either decomposes directly or sequentially dehydrates to the 
etheno product (Figure 21) (196). 
Substituted etheno adducts have also been characterized from the addition of lipid 
peroxidation products to nucleosides.  Reactions of 4-oxo-2-nonenal with dG, dA, and dC 
produce substituted etheno adducts containing a heptanone chain extended from the 
etheno carbon proximal to the ring nitrogen (Figure 20) (198-200).  4-Oxo-2-nonenal 
appears to be most reactive with dC (200, 201).  This type of reaction is indicative of 1,2-
addition of the exocyclic N-amino group to aldehyde followed by intramolecular 
cyclization on the ring nitrogen (Figure 22).  Other substituted etheno adducts have been 
characterized in reactions of nucleic acids with lipid peroxidation products (50, 202, 
203). 
Etheno addition forms across the Watson-Crick base-pairing surface, and all 
etheno adducts that have been investigated exhibit miscoding properties.  Etheno adducts 
are mutagenic in bacterial and mammalian cells (188, 204-209), and they mainly yield 
base-pair substitutions.  Unlike the propano and pyrimidopurinone adducts, the etheno 
adducts are not subject to ring-opening; although, etheno adducts may react under basic 
or acidic conditions to produce hydrated derivatives (210). 
Etheno adducts have been analyzed in the DNA and urine of animals and humans. 
1,N6-ε-dA is found in human liver DNA at levels of 0.2 – 3.0 per 108 bases and 1,N6-ε-
Ade has been quantified in human urine at levels of 40 – 3000 pg/mL (189, 211, 212).  
3,N4-ε-dC was found in human liver DNA at levels of 0.8 – 3.0 per 108 bases.  In human 
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urine, 3,N4-ε-Cyd is reported to be present at 0.6 – 3.0 ng/kg/mg creatinine and 3,N4-ε-dC 
at concentrations of 0.0 – 800 pM (213, 214).  The genomic levels of 1,N2-ε-dG have 
been determined in rat liver at levels of 50 per 108 bases (215); however, the genomic and 
urinary levels of 1,N2-ε-dG and 1,N2-ε-Gua have escaped detection in humans.  The 
levels of substituted etheno adducts have not been reported in urine samples.  However, 
heptanone-1,N2-ε-dG and heptanone-3,N4-ε-dC have been found in mouse intestine at 
levels of 6 – 18 per 108 bases and 1 – 10 per 108 bases, respectively (216). 
The repair mechanisms for the unsubstituted etheno adducts are unknown.  
However, NER is likely to be involved.  Each unsubstituted etheno adduct is subject to 
base excision repair by DNA glycosylases. 1,N6-ε-dA is repaired by alkylpurine-DNA-N-
glycosylase in mammalian cells (217, 218), as is 1,N2-ε-dG (217, 219).  N2,3-ε-dG is a 
substrate for 3-methyl-adenine DNA glycosylase (220), and 3,N4-ε-dC is removed by the 
mismatch specific thymine-DNA glycosylase (221-223).  Glycosylases catalyze the 
hydrolytic removal of the adducted base from the DNA helix and leave an 
apurinic/apyridinic site.  The remaining abasic site is nicked, removed, filled in by a 
polymerase, and re-ligated to the helix (224).  Cleavage products formed by glycosylase 
action are, therefore, released from DNA as base adducts. The metabolic stability of 
etheno adducts will be evaluated in Chapter 6. 
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Figure 21.  Proposed mechanism of formation for 1,N2-ε-dG from reaction of 4-
hydroperoxy-2-nonenal with dG (Figure adapted from (196)).  
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Figure 22.  Proposed mechanism of formation for heptanone-1,N2-ε-dG from 
reaction of 4-oxo-2-nonenal with dG (Figure adapted from (199)). 
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Dissertation Aims 
The goal of this dissertation is to address the hypothesis that endogenously 
formed DNA adducts are subject to oxidative metabolism.  Particular emphasis will be 
placed on defining the in vitro and in vivo metabolism of M1dG.  Chapter 2 will evaluate 
the enzymology and kinetics of M1dG metabolism in the rat.   In Chapter 3 a definitive 
evaluation of the metabolism and elimination of M1dG in the rat will be reported by the 
use of carbon-14 labeled M1dG.  The metabolism and elimination of M1dG at near-
physiological levels will be addressed in Chapter 4 by the use of accelerator mass 
spectrometry.  Evaluation of the in vitro and in vivo metabolism of free base, M1G, will 
be discussed in Chapter 5.  Chapter 6 will address the metabolism of other structural 
analogs of M1dG and M1G. 
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CHAPTER II 
 
METABOLISM OF M1dG IN VITRO AND IN VIVO 
 
Summary 
M1dG is an endogenous DNA adduct arising from the reaction of dG with the 
lipid peroxidation product, MDA, or the DNA peroxidation product, base propenal.  
M1dG is mutagenic in bacteria and mammalian cells and is present in genomic DNA of 
healthy human beings.  It is also detectable at low levels in the urine of healthy 
individuals, which may make it a useful biomarker of DNA damage linked to oxidative 
stress.  We investigated the possibility that the low urinary levels of M1dG reflects 
metabolic conversion to others derivatives.  M1dG was rapidly removed from plasma (t1/2 
= 10 min) following intravenous (iv) administration to rats.  A single urinary metabolite 
was detected and identified as 6-oxo-M1dG by mass spectrometry, NMR spectroscopy, 
and independent chemical synthesis.  6-Oxo-M1dG was generated in vitro by incubation 
of M1dG with rat liver cytosol.  Experiments with chemical inhibitors in vitro and in vivo, 
in addition to studies with partially purified enzymes, suggested that xanthine 
oxidoreductase (XOR) and aldehyde oxidase (AO) are involved in the oxidative 
metabolism.  M1dG was also metabolized by three separate human liver cytosol 
preparations indicating 6-oxo-M1dG is a likely metabolite in humans.  This represents the 
first report of the oxidative metabolism of an endogenous DNA adduct and raises the 
possibility that other endogenous DNA adducts are metabolized by oxidative pathways.  
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6-Oxo-M1dG may be a useful biomarker of endogenous DNA damage associated with 
inflammation, oxidative stress, and certain types of cancer chemotherapy. 
 
Introduction 
M1dG is an adduct found at varying levels in genomic DNA of rodents and 
humans (149, 152, 225).  It is derived from the lipid peroxidation product, MDA, or the 
DNA peroxidation product, base propenal (Figure 23) (58, 96).  M1dG is miscoding 
when assayed by in vitro DNA replication and is mutagenic in bacterial and mammalian 
cells (120, 121, 226).  It induces base pair substitutions (M1dG→T and M1dG→A) and 
frameshift mutations in reiterated sequences (e.g., CGn) when shuttle vectors containing a 
site-specific lesion are replicated in COS-7 cells (227).  Genetic and biochemical 
experiments indicate that M1dG is removed by NER in both bacterial and mammalian 
cells (120, 122). 
As a prerequisite for preclinical, clinical, and population-based studies of the 
factors that contribute to the production of M1dG, we are developing assays to quantify 
the adduct in urine.  We recently described a highly sensitive and specific analytical 
method based on immunoaffinity purification and LC-MS/MS analysis (154).  
Application of this technique reveals that M1dG is detectable in the urine of healthy 
human volunteers in amounts corresponding to 10-20 fmol/kg/24 h (154).  These values 
are several orders of magnitude lower than the levels reported for another oxidative DNA 
lesion, 8-oxo-dG (~400 pmol/kg/24 h) (155, 156).  The lower levels of M1dG may reflect 
lower levels in genomic DNA, less efficient repair, or differential processing before 
excretion.  Previous studies have established that DNA adducts from xenobiotics 
 54 
(ethylene dibromide) or drugs that are based on nucleobases (O6-benzylguanine, 
allopurinol) are metabolized by hydrolytic processing to mercapturic acids or by 
oxidation, respectively (228, 229).  However, no reports suggest that endogenous DNA 
lesions are metabolized following repair.  We report here that M1dG is oxidized in rats to 
a novel 6-oxo derivative and that enzymes of the purine salvage pathway appear to play a 
role.  Based on in vitro and in vivo experiments with chemical inhibitors and with 
partially purified enzymes, both XOR and AO were found to be involved in the metabolic 
processing of M1dG.  Several other endogenously formed exocyclic adducts are 
structurally similar to M1dG.  This suggests the possibility that other endogenous DNA 
lesions may be metabolized after they are repaired and that an additional, as yet 
unaccounted for, population of adducts may exist in urine that could serve as biomarkers 
of endogenous DNA damage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23.  Endogenous formation of M1dG from MDA or base propenal.  M1dG is 
produced from the reaction of dG with either the lipid peroxidation product, MDA, or the 
DNA peroxidation product, base propenal. 
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Experimental Procedures 
 
Chemicals and reagents 
All chemicals were obtained from commercial sources and used as received.  
Solvents were of HPLC grade purity or higher. M1dG was synthesized as described 
(230).  Human liver cytosol preparations were purchased from BD Bioscience (Woburn, 
MA).  Rat liver cytosol was prepared by established methods (231) or purchased from 
BD Bioscience (Woburn, MA), Xenotech (Lenexa, KA), or InvitroTechnologies 
(Baltimore, MA).  Bovine XO (from buttermilk) was obtained from CalBiochem (La 
Jolla, CA).  HPLC separations were performed using a Waters 2695 autosampler and 
binary pump with a Waters 2487 dual wavelength UV detector.  LC-MS/MS spectra were 
obtained on a Finnigan TSQ 7000 instrument . 
 
Administration of M1dG to rats 
Animal protocols were performed under approval of Vanderbilt University and in 
accordance with the Institutional Animal Care and Use Committee policies.  Male 
Sprague Dawley rats (225-250 g) uncatheterized or catheterized in the femoral and 
jugular veins were obtained from Charles River Laboratories (Wilmington, MA) and 
housed in shoebox cages.  Animals were transferred to metabolism cages prior to dosing 
and allowed to feed ad libitum throughout the experiment.  The dosing solution was 
prepared in sterile saline solution and administered in the jugular vein of catheterized rats 
at 2 mg/kg in approximately 0.5 mL of total volume.  The dose was delivered over 45 s 
and the catheter was flushed with 0.4 mL of sterile heparinized saline. A portion of whole 
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blood (0.5 mL) was removed at intervals (0.17, 0.33, 0.5, 1, 2, 4, 6, and 24 h) post-dose 
from the femoral vein and placed on ice.  To maintain constant circulatory volume, 0.5 
mL of heparinized saline was injected following blood draws.  Plasma was separated by 
centrifugation and removed.  Urine was collected over intervals (pre-dose, 0-4, 4-6, 6-16, 
and 16-24 h).  A standard curve was prepared by spiking known concentrations of M1dG 
into whole blood obtained from unaltered, male Sprague Dawley rats and processed as 
above. All samples were stored at -80 °C until sample work-up. 
 
Sample work-up and analysis 
A sample of urine (0.4 mL) was extracted by adding 0.8 mL ethanol followed by 
0.8 mL chloroform.  Following vigorous mixing, the phases were separated by 
centrifugation.  The organic layer was removed, and the remaining aqueous layer was 
extracted with an additional 0.8 mL chloroform. The organic layers were pooled, dried 
under nitrogen, and reconstituted in potassium phosphate (0.2 M, pH 7.5).  Plasma (0.15 
mL) was diluted to 0.25 mL with 0.2 M potassium phosphate, pH 7.5, and processed as 
above.  Samples (10 µL) were loaded onto a Phenomenex  Luna C18(2) column (2.0 x 
250 mm, 5 µm) (Torrence, CA) equilibrated with 90% solvent A (0.5% formic acid in 
H2O) and 10% solvent B (0.5% formic acid in methanol) at a flow rate of 0.3 mL/min.  
The solvent was programmed as follows: a linear gradient from the starting solvent to 
20% B in 10 min, holding at 20% B for 10 min increasing to 80% B in 0.1 min, holding 
for 5 min, decreasing to 10% B in 0.1 min, and re-equilibrating at initial conditions for 5 
min.  Eluting compounds were detected by UV absorbance at 254 nm or by liquid 
chromatography/mass spectrometry (LC/MS).  Positive ion ESI was employed with the 
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following parameters: spray voltage = 4.5 kV; capillary temperature = 200 °C; sheath gas 
= 60 psi; CID pressure = 2.3 mTorr (nitrogen gas); and 15 eV collision energy.  Samples 
were analyzed by selected reaction monitoring, which followed the neutral loss of 
deoxyribose from M1dG (m/z = 304.3 → 188.3).  The method was adapted to scan for the 
presence of an additional oxygen atom in the pyrimidopurinone ring by scanning eluting 
peaks for the transition m/z 320.3 → 204.3. 
 
Co-administration of allopurinol and M1dG to rats 
Six male Sprague Dawley rats (225-250 g) catheterized in the femoral and jugular 
veins were obtained from Charles River Laboratories (Wilmington, MA) and housed in 
shoebox cages.  M1dG dosing solution (5 mg/mL) was prepared in sterile saline solution 
and administered via the jugular vein catheter in approximately 0.4 mL of total volume 
and delivered over 45 s.  Allopurinol dosing solution (10 mg/mL) was prepared in sterile 
saline solution, to which was added one equivalent of sodium hydroxide to bring the 
allopurinol into solution, and administered via the jugular vein catheter in approximately 
0.4 mL of total volume and delivered over 45 s.  Upon arrival animals either received an 
iv dose of allopurinol (n = 3) or vehicle control (saline solution, n = 3).  This dosing 
procedure was repeated after 24 h.  Animals were transferred to metabolism cages prior 
to M1dG dosing and allowed to feed ad libitum throughout the experiment.  One h prior 
to M1dG dosing, animals either received a final administration of either allopurinol or 
vehicle control dosing solution. M1dG dosing solution was administered via the jugular 
vein catheter in approximately 0.4 mL of total volume.  Following administration of 
M1dG a portion of whole blood (0.5 mL) was removed at intervals (0.17, 0.33, 0.5, 1, 2, 
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4, 6, and 24 h) from the femoral vein post-dose and placed on ice.  To maintain constant 
circulatory volume, 0.5 mL of heparinized saline was injected following blood draws.  
Plasma was separated by centrifugation and removed.  Urine was collected over intervals 
(pre-dose, 0-4, 4-8, 8-24, and 24-30 h).  A standard curve was prepared by spiking known 
concentrations of M1dG into whole blood obtained from unaltered, male Sprague Dawley 
rats and processed as above. All samples were stored at -80 °C until sample work-up. 
 
Analytical analysis of in vivo allopurinol co-administration samples 
A sample of urine (0.4 mL) was extracted by adding 0.8 mL ethanol followed by 
0.8 mL chloroform.  Following vigorous mixing, the phases were separated by 
centrifugation.  The organic layer was removed, and the remaining aqueous layer was 
extracted with an additional 0.8 mL chloroform. The organic layers were pooled, dried 
under nitrogen and reconstituted in potassium phosphate (0.2 M, pH 7.5).  Plasma (0.15 
mL) was diluted to 0.25 mL with 0.2 M potassium phosphate, pH 7.5, and processed as 
above.  Samples (10 µL) were loaded onto a Phenomenex (Torrence, CA) Luna C18(2) 
column (2.0 x 250 mm, 5 µm) equilibrated with 90% solvent A (0.5% formic acid in 
H2O) and 10% solvent B (0.5% formic acid in methanol) at a flow rate of 0.3 mL/min.  
The solvent was programmed as follows: a linear gradient from the starting solvent to 
20% B in 10 min, holding at 20% B for 10 min, increasing to 80% B in 0.1 min, holding 
for 5 min, decreasing to 10% B in 0.1, min and re-equilibrating at initial conditions for 5 
min.  Eluting compounds were detected by UV absorbance at 254 nm or by LC/MS.  
Positive ion ESI was employed with the following parameters: spray voltage = 4.5 kV; 
capillary temperature = 200 °C; sheath gas = 60 psi; CID pressure = 2.3 mTorr (nitrogen 
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gas); and 15 eV collision energy.  Samples were analyzed by selected reaction 
monitoring, which followed the neutral loss of deoxyribose from M1dG (m/z = 304.3 → 
188.3).  The method was adapted to scan for the presence of an additional oxygen atom in 
the pyrimidopurinone ring by scanning eluting peaks for the transition m/z 320.3 → 
204.3. 
 
Biochemical synthesis of the M1dG metabolite 
Rat liver cytosol (20 mL solution of 20 mg protein/mL) was incubated with 10 mg 
of M1dG and allowed to react to completion.  The reaction was monitored by HPLC 
(conditions described below) and terminated by the addition of one volume of acetonitrile 
to precipitate the protein.  The resulting mixture was centrifuged and the supernatant was 
lyophilized overnight.  The residue was reconstituted in water and applied to a 
preconditioned C18 solid phase extraction column (Waters Oasis® HLB), which was 
washed twice with water and eluted with methanol.  The purified sample was evaporated 
to dryness and analyzed by NMR. 1H-NMR (300 MHz, D2O): δ 8.71 (d, 1H J = 8 Hz, 
H8), 8.13 (s, 1H, H2), 6.4-6.3 (m, 2H, H7  and H1′), 4.61 (m, 1H, H3′), 4.05 (m, 1H, H4′), 
3.73 (m, 2H, H5′, H5′′), 2.85-2.51 (m, 2H, H2′, H2′′). 13C-NMR (500.13 MHz, D2O): δ 
84.3 (C1′), 109.5 (C7), 116.6 (C10a), 135.4 (C8), 140.1 (C2), 149.8 (C6), 150.4 (C3a), 154.5 
(C10) and 168.8 (C5a).  
 
Chemical synthesis of 3-(2-Deoxy-β-D-erythropentofuranosyl)-pyrimido[1,2-
f]purine-6,10(3H,5H)-dione (6-oxo-M1dG) 
 
Ethyl 2-amino-9-(2-deoxy-β-D-erythropentofuranosyl)-6,9-dihydro-6-oxo-1H-
purine-1-acrylate.  dG hydrate was dried in an Abderhalden apparatus overnight at 78 °C 
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under vacuum.  A mixture of anhydrous dG (134 mg, (0.5 mmol), K2CO3 (104 mg, 0.75 
mmol), and ethyl cis-3-bromoacrylate (135 mg, 0.75 mmol) in anhydrous N,N-
dimethylformamide (DMF, 10 mL) was added to a flame-dried round bottom flask and 
stirred overnight at 64 °C.  HPLC analysis of the reaction mixture showed that nearly all 
of the dG had been consumed.  The mixture was cooled to room temperature, filtered, 
and the filtrate was concentrated under high vacuum.  In general, the crude product was 
used in the next step without further purification.  A portion of the product was purified 
by C18 reversed-phase HPLC for characterization..  1H NMR (CD3OD): d 8.00 (s, 1H), 
7.56 (d, J = 14.4 Hz, 1H), 6.61 (d, J = 14.4 Hz, 1H), 6.27 (t, J = 6.9 Hz, 1H), 4.52 (m, 
1H), 4.19 (q, J = 7.2 Hz, 2H), 4.00 (m, 1H), 3.75 (m, 2H), 2.68 (m, 1H), 2.35 (m, 1H), 
1.27 (t, J = 7.2 Hz, 3H). 
3-(2-Deoxy-β-D-erythropentofuranosyl)-pyrimido[1,2-f]purine-6,10(3H,5H)-
dione (6-oxo-M1dG). The crude acrylate (vide supra) was suspended in anhydrous 
methanol (4 mL). Sodium methoxide (0.5 mmol, 1 mL of a 0.5 M solution in methanol) 
was added dropwise to the stirred suspension, resulting in a clear solution. HPLC analysis 
showed the completed conversion of the starting material after stirring at room 
temperature for 1 h.  The reaction mixture was neutralized by the addition of acetic acid 
(30 mL, 0.5 mmol) and evaporated under reduced pressure.  The residue was dissolved in 
a 1:1 mixture of methanol and water (0.5-1 mL) and purified on a BIOTAGE system 
using a C18 reversed-phase column (C18HS 12+M) with a linear gradient from 0% to 
20% acetonitrile in water to give the desired product (71 mg, 44 % yield from dG).  The 
proton NMR spectrum was identical to that of the biochemically synthesized metabolite 
from rat liver cytosol described above. 
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Liver cytosol incubations and analysis 
All sample preparation was performed on ice at 4 °C.  The final incubation 
conditions for the kinetic determinations contained rat liver cytosol (5 mg/mL), varied 
concentrations of M1dG (20, 40, 50, 60, 80, 100, 120, 200, 400, or 800 µM), and 0.4% 
DMSO in 0.2 M potassium phosphate buffer, pH 7.4.  The final incubation conditions for 
the inhibition studies were performed with rat liver cytosol (5 mg/mL) or human liver 
cytosol (5 mg/mL), 370 µM M1dG, 160 µM inhibitor (allopurinol or menadione), and 
0.4% DMSO in 0.2 M potassium phosphate, pH 7.4.  The inhibitors were diluted in 
DMSO.  IC50 determinations were performed with rat liver cytosol (5 mg/mL), 370 µM 
M1dG, with inhibitor (allopurinol, menadione, raloxifene) adjusted to logarithmic 
intervals between 1 nM and 500 µM.  The buffer contained 0.4% DMSO in 0.2 M 
potassium phosphate (pH 7.4).  In all experiments reagents were equilibrated to 37 °C for 
5 min, initiated by the addition of substrate, and terminated after 60 min by the addition 
of two volumes of ice-cold ethanol.  Samples were then extracted twice with two 
volumes of chloroform.  The extracts were evaporated under nitrogen, reconstituted in 
0.2 M potassium phosphate, pH 7.4, and analyzed by HPLC as described above.  Samples 
from the kinetic determination were analyzed for M1dG content by comparison to a 
standard curve prepared by spiking known concentrations of M1dG into rat liver cytosol 
solutions (5 mg/mL) followed immediately by termination, extraction, and analysis.  
Percent inhibition of inhibitors was determined in reference to 0 and 60 min standards.  
Vmax, Km, and IC50 values were calculated with Prism software (Version 4.0c) using 
nonlinear regression one-site binding and one-site competition models, respectively.  All 
experiments were performed in triplicate. 
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Bovine XO incubations and analysis 
Purified bovine XO from buttermilk (CalBiochem) was used for in vitro 
incubations. All sample preparation was performed on ice at 4 °C.  The final incubation 
conditions for the kinetic determinations contained XO (0.05 mg/mL) and varied 
concentrations of M1dG (10, 25, 50, 100, 200, 350, 500, 600, 700, or 800 µM) in 0.2 M 
potassium phosphate (pH 7.8).  IC50 determinations were performed with XO (0.05 
mg/mL), 370 µM M1dG, and allopurinol adjusted to logarithmic intervals between 1 nM 
and 500 µM in a 0.2 M potassium phosphate (pH 7.8).  In all experiments reagents were 
equilibrated to 37 °C for 5 min, initiated by the addition of substrate, and terminated after 
30 min by the addition of 100 µL ice-cold methanol, vortexed, and placed on ice.  
Samples (300 µL) from each incubation were transferred to separate vials and centrifuged 
at 200,000 g for 20 min at 4 °C. Aliquots (200 µL) were removed and placed into 
autosampler vials for analysis by HPLC with UV detection.  Samples from the kinetic 
determination were quantified based on substrate consumption in reference to an M1dG 
standard curve.  The standard curve was prepared by spiking known concentrations of 
M1dG into XO solutions (0.05 mg/mL) on ice previously spiked with 100 µL methanol 
and processed as above.  Percent inhibition during IC50 analysis was determined in 
reference to 0 and 30 min standards.  Vmax, Km, and IC50 values were calculated with 
Prism software (Version 4.0c) using nonlinear regression one-site binding and one-site 
competition models, respectively.  All experiments were performed in triplicate. 
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Purification of XOR and AO from rat liver 
The purification of XOR and AO was based on several literature references (232-
238). Approximately 100 g of liver were excised from anesthetized Sprague Dawley rats, 
pooled, and homogenized in 50 mM potassium phosphate, pH 7.8, containing 0.2 mM 
phenylmethanesulfonyl fluoride (PMSF).  The homogenate was spun at 500 g for 10 min 
to remove nuclei and cell debris. The remaining supernatant was heated gradually to 55 
°C and maintained at 55 °C for 10 min.  The solution was then centrifuged at 10,000 g for 
3 h.  The supernatant was removed and brought to 60% saturation with ammonium 
sulfate and allowed to stir overnight.  This solution was then centrifuged at 10,000 g for 
30 min.  The supernatant was discarded and the pellet was dissolved in a minimum 
amount of 100 mM potassium phosphate, pH 7.8, and centrifuged at 250,000 g for 3 h.  
The remaining supernatant was then concentrated with an Amicon filtration device to 5% 
total volume twice and applied to a ceramic hydroxyapatite column (CHT, BioRad, 2.6 x 
30 cm) equilibrated in 100 mM potassium phosphate (pH 7.8).  The column was washed 
with 3 column volumes of 100 mM potassium phosphate, pH 7.8, and the retained protein 
was eluted with a linear gradient of 100 to 400 mM potassium phosphate, pH 7.8 over 2 
column volumes. Fractions were collected and analyzed for AO and XOR activity as 
described above.  Fractions containing AO and XOR activity were pooled separately, 
concentrated, and buffer-exchanged into 100 mM Tris-HCl, pH 7.8, with 0.001 M EDTA 
and applied separately to a MonoQ anion exchange column (GE Healthcare, 1.6 x 10 cm) 
equilibrated in 100 mM Tris-HCl (pH 7.8) containing 0.001 M EDTA.  The column was 
washed with 3 column volumes of equilibration buffer and eluted with a linear gradient 
of 0.0 to 0.5 M NaCl in equilibration buffer.  Fractions containing AO and XOR activity 
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were pooled separately.  AO fractions were exchanged into 0.1 M Tris-glycine, pH 9.0, 
containing 0.001 M EDTA and applied to a Benzamidine-Sepharose 6B affinity column 
(GE Healthcare, 1.6 x 10 cm) equilibrated in 0.1 M Tris-glycine containing 0.001 M 
EDTA (pH 9.0).  The column was eluted with 50 mM p-aminobenzamidine dissolved in 
equilibration buffer.  XOR containing fractions were exchanged into 0.1 M potassium 
phosphate, pH 7.8, containing 0.001 M EDTA and loaded onto a HiTrap Sephadex 200 
gel filtration column (GE Healthcare, 1.6 x 60 cm).  Fractions containing XOR activity 
were pooled and saved. 
  
Analytical analysis of protein samples 
Column fractions (~100 µL) were incubated with 200 µM M1dG at 37 °C in 0.2 
M potassium phosphate, pH 7.4, for 60 min and terminated with 2x volume of ethanol.  
The samples were extracted into chloroform (2x volume) and separated by centrifugation.  
The organic layer was removed and the remaining aqueous layer was extracted with an 
additional 2x volume of chloroform. The organic layers were pooled, dried under 
nitrogen, and reconstituted in potassium phosphate (0.2 M, pH 7.4).  Samples (20 µL) 
were loaded onto a Phenomenex (Torrence, CA) Luna C18(2) column (4.6 x 250 mm, 5 
µm) equilibrated with 90% solvent A (0.5% formic acid in H2O) and 10% solvent B 
(0.5% formic acid in methanol) at a flow rate of 1.0 mL/min.  The solvent was 
programmed as follows: a linear gradient from the starting solvent to 20% B in 10 min, 
holding at 20% B for 10 min, increasing to 80% B in 0.1 min, holding for 5 min, 
decreasing to 10% B in 0.1 min, and re-equilibrating at initial conditions for 5 min.  
Eluting compounds were detected by UV absorbance at 254 nm. 
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Activity assays 
XOR activity was assessed by monitoring the conversion of xanthine to uric acid 
at 295 nM (ε295 95000 M-1cm-1) in 0.1 M potassium phosphate, pH 7.8, at room 
temperature. AO activity was assessed by monitoring the disappearance of 4-
(dimethylamino)-cinnamaldehyde at 398 nM (ε398 30500 M-1cm-1) in 0.1 M potassium 
phosphate, pH 7.8, at room temperature. 
 
Results 
 
Administration of M1dG to rats 
Sprague Dawley rats, cannulated in the femoral and jugular veins, were obtained 
commercially and housed in metabolic cages during the course of the experiment. M1dG 
(2 mg/kg) was administered iv in the jugular vein and whole blood was drawn at intervals 
from the femoral vein.  Additionally, urine was collected over the time-course of the 
study to monitor the excretion of M1dG.  Plasma and urine extracts were separated by 
reversed-phase HPLC and eluting peaks were detected by either UV absorbance or 
positive ion ESI LC-MS/MS.  M1dG in plasma samples was analyzed by selective 
reaction monitoring following the neutral loss of deoxyribose from M1dG (m/z 304.3 → 
188.3) and quantified against a standard curve. 
Figure 24 displays the time-course of M1dG disappearance from plasma 
following iv administration.  M1dG was rapidly removed from plasma with a half-life of 
approximately 10 min.  Parallel analysis of urine samples revealed that the disappearance 
of M1dG was not solely accounted for by rapid elimination of M1dG in the urine.  
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Approximately 80% of the total excreted M1dG was recovered during the first 4 h of 
urine collection (Figure 24, inset) and M1dG was detectable as long as 24 h after 
administration. 
The rapid disappearance of M1dG from plasma suggested it was rapidly 
distributed to tissue and subject to biotransformation.  Urine and plasma samples were 
probed for the presence of metabolites containing an additional oxygen atom by 
performing HPLC with selected reaction monitoring of m/z 320.3 → 204.3. Figure 25 
displays a representative profile from a urine extract collected from 0 to 4 h following 
administration of M1dG. A single peak that eluted shortly after M1dG was detected. UV 
profiles from pre-dose urine showed nearly identical background traces to those from the 
dosed samples, with the exception of peaks eluting at 12.8 and 13.5 min (corresponding 
to M1dG and the putative metabolite, respectively).  The putative metabolite was also 
observed in plasma one h following administration.  M1dG was stable in urine and did not 
exhibit conversion to the putative metabolite on standing for up to 24 h.  Attempts to 
discover additional metabolites in the urine samples were unsuccessful.  For example, 
treatment with β-glucuronidase yielded neither M1dG nor the later eluting product, 
suggesting that neither of these compounds was a substrate for glucuronidation in vivo. 
 
Oxidation of M1dG in vitro 
These in vivo studies suggested M1dG was subject to oxidation prior to excretion.  
In an attempt to characterize the pathway(s) responsible for metabolism, M1dG was 
incubated with liver microsomal and cytosol fractions prepared from Sprague Dawley 
rats.  Microsomal fractions  failed  to metabolize M1dG either in the absence  or  presence 
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Figure 24.  Time-course of M1dG disappearance from plasma following iv 
administration.  M1dG (2 mg/kg) was administered to male Sprague Dawley rats (n = 
3).  Quantification was performed by LC-MS/MS with selected reaction monitoring of 
M1dG following the m/z transition of 304.3 → 188.3.  Inset, the time-course for 
appearance of M1dG in urine following iv administration of M1dG (n = 3). 
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Figure 25.  LC-UV and LC–MS/MS analysis of urine from rats treated with M1dG.  
M1dG (2 mg/kg) was administered to Sprague Dawley and urine collected from 0 – 4 h.  
M1dG was monitored by the transition m/z 304.3 → 188.3 and the putative oxidized 
metabolite by the transition m/z 320.3 → 204.3. 
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 of NADPH.  However, cytosolic fractions rapidly converted M1dG to a single product 
that exhibited an HPLC retention time and mass spectrum identical to the product 
detected in urine.  Metabolite formation was dependent on substrate concentration, 
protein concentration, and the time of incubation.  Oxidation of M1dG by rat liver cytosol 
exhibited a Km of 370 µM and a Vmax of 104 pmol/min/mg protein (Figure 26, Top).  
Figure 26 (Bottom) displays the M1dG concentration-dependence of product formation.  
There was a close correspondence between the concentration-dependence of M1dG 
consumption and that for product formation.  The latter demonstrated a Km of 330 µM. 
 
Biochemical synthesis of the M1dG metabolite 
To identify the product of in vitro enzymatic oxidation, 20 mL of concentrated rat 
liver cytosol (20 mg/mL) was incubated with 10 mg of M1dG, and oxidation allowed to 
proceed to completion.  The metabolite was purified and dissolved in D2O for NMR 
analysis.  A small amount of unreacted M1dG was apparent in the 1H-NMR spectrum of 
the purified product (Figure 27).  Detection of the singlet at 8.13 ppm in the product 
spectrum, corresponding to the H2 proton, indicated that oxidation had not occurred on 
the imidazole ring.  By comparison to the M1dG spectrum it was apparent that only two 
of the three pyrimido ring protons (H6, H7, H8) remained in the product spectrum 
indicating that oxidation had occurred in this ring. The doublets at 8.71 and 6.35 ppm 
were coupled (confirmed by a COSY experiment), indicating the presence of a double 
bond conjugated to a carbonyl group.  This implied oxidation at either the 6- or 8-position 
of the pyrimidopurinone ring.  13C-NMR revealed a shift of the peak corresponding to C6 
(162 ppm) in the M1dG spectrum and appearance of a new peak at 149.8 ppm in the 
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Figure 26.  Concentration dependence of M1dG oxidation by rat liver cytosol. (Top) 
M1dG consumption; (Bottom) M1dG metabolite formation.  Incubations were conducted 
for 60 min with rat liver cytosol (5 mg protein/mL) prepared from male Sprague Dawley 
rats.  M1dG consumption was calculated by reference to a standard curve (Km = 370 µM 
and Vmax = 104 pmol/min/mg protein) whereas product formation was based on peak area 
production (Km of 330 µM). 
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Figure 27.  1H-NMR spectrum of M1dG (top) and the M1dG metabolite prepared 
using rat liver cytosol (bottom). 
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 product spectrum.  A heteronuclear multiple bond correlation (HMBC) NMR experiment 
identified strong, three-bond proton-carbon correlations between the proton assigned as 
H8 and carbons C4a, C6, and C10, which enabled the assignment of the structure as 6-oxo-
M1dG (Figure 28). 
 
 
 
Figure 28.  HMBC spectrum of the M1dG metabolite prepared from rat liver 
cytosol. 
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Chemical synthesis of 6-oxo-M1dG 
To confirm the assigned structure of the metabolite, a synthesis of 6-oxo-M1dG 
was designed and executed (Figure 29).  3-Bromo-ethylacrylate was reacted with dG 
under basic conditions, producing N1-ethyl-3-carboxyethenyl-dG.  Subsequent treatment 
with sodium methoxide to promoted double bond isomerization and lactam formation by 
intramolecular cyclization.  The synthesized product displayed identical mass, UV, and 
NMR spectra to the biochemically produced metabolite, and the two co-chromatographed 
by reversed-phase HPLC.  These results unambiguously identified the major in vitro 
metabolite of M1dG as 6-oxo-M1dG.  The mass spectrum and chromatographic behavior 
of synthetic 6-oxo-M1dG were identical to those of the in vivo M1dG metabolite. 
 
 
 
 
 
 
 
 
 
Figure 29.  Chemical synthesis of 6-oxo-M1dG.  Reaction of dG in the presence of a 
mild base (K2CO3) with 3-bromo-ethylacrolate leads to the formation of a dG-propenoic 
ethyl ester intermediate, which undergoes cyclization upon addition of NaOMe to 
produce 6-oxo-M1dG. 
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Inhibition of M1dG metabolism in vitro in rat liver cytosol 
In an attempt to provide a preliminary characterization of the enzymes responsible 
for M1dG oxidation, incubations with separate lots of cytosol prepared from 3 strains of 
rats (Sprague Dawley, Fischer, Wistar) were conducted in the presence of allopurinol 
(160 µM) or menadione (160 µM) to inhibit XOR or AO, respectively (Figure 30).  All 
rat liver cytosol lots were incubated at 5 mg/mL with 370 µM M1dG for 60 min, and each 
lot produced 6-oxo-M1dG.  The extent of metabolism varied between preparations (20-
55% consumption), and each lot displayed varied sensitivities to the inhibitors (5-90% 
inhibition).  Menadione inhibited metabolism, in some instances, while in other cases it 
stimulated metabolism.   XOR is a single gene product that exists as a dehydrogenase 
(XD) under physiological conditions (239).  Ex vivo manipulations of the enzyme leads to 
irreversible proteolytic cleavage or reversible oxidation (formation of disulfides), 
generating the oxidase form (XO) (240, 241).  Both forms of the enzyme are catalytically 
competent and capable of using molecular oxygen as a terminal electron acceptor; 
although, XO is more efficient that XD at utilizing O2 (242). XD can use NAD+, which 
increases the efficiency of catalysis.  NAD+ has no effect on XO turnover (242).  
Menadione and other quinones can be reduced by flavoproteins such as XO during the 
oxidation of reducing substrates (243), thereby stimulating oxidation (244). Preliminary 
evaluation of rat liver cytosol did not reveal enhanced metabolism in the presence of 
NAD+, suggesting the oxidase form is responsible for the oxidation of M1dG in the liver 
cytosols evaluated. 
Rat liver cytosol lot 5 was chosen for further in vitro characterization of M1dG 
metabolism by performing an IC50 determination with allopurinol.  Co-administration of 
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increasing concentrations of allopurinol in the presence of M1dG (370 µM) revealed an 
IC50 value of 120 nM. Of interest, the inhibition of M1dG metabolism was not complete, 
as noted by the inability to completely inhibit 6-oxo-M1dG formation at saturating 
concentrations of allopurinol (Figure 31A). 
 
 
 
 
Figure 30.  Investigation of M1dG metabolism with several lots of rat liver cytosol.  
(A) Percent metabolism of M1dG (370 µM) incubated in different lots of rat liver cytosol 
(5 mg/mL for 60 min).  (B) Percent inhibition of M1dG metabolism co-incubated with 
allopurinol (160 µM, inhibitor of XOR) in different lots of rat liver cytosol (5 mg/mL for 
60 min with 370 µM M1dG).  (C) Percent inhibition of M1dG metabolism co-incubated 
with menadione (160 µM, inhibitor of AO) in different lots of rat liver cytosol (5 mg/mL 
for 60 min with 370 µM M1dG). 
 
The contribution of AO to the production of 6-oxo-M1dG in rat liver cytosol lot 4 
was confounded by the observed stimulatory effects, thereby masking any inhibition of 
AO.  To mitigate the stimulatory effects of menadione observed in the metabolism of 
M1dG we selected an alternative inhibitor of AO.  Raloxifene was recently characterized 
as an inhibitor AO in human liver cytosol (245).  Mild inhibition of 6-oxo-M1dG 
production was observed in rat liver cytosol in the presence of raloxifene.  However, in 
the presence of saturating concentrations of allopurinol (40 µM) and increasing 
concentrations of raloxifene the production of 6-oxo-M1dG was almost completely 
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inhibited (Figure 31B), and an IC50 of 4 µM was determined. Thus, preliminary in vitro 
data implicated XOR as the major enzyme contributing to the oxidation of M1dG in rat 
liver cytosol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31.  IC50 determinations in rat liver cytosol and purified XO with allopurinol 
or raloxifene using M1dG as a substrate.  (A) Using M1dG (370 µM) as substrate, IC50 
values were determined based on 6-oxo-M1dG inhibition with increasing concentrations 
of allopurinol in rat liver cytosol (blue) or purified XO (red).  (B) Using M1dG (370 µM) 
as a substrate, IC50 values were determined based on 6-oxo-M1dG inhibition in the 
presence of 40 µM allopurinol and increasing concentrations of raloxifene in rat liver 
cytosol. 
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Metabolism of M1dG in vitro with purified XO 
 Based on results obtained from rat liver cytosol incubations, which suggested the 
involvement of XOR and AO in the metabolism of M1dG, we further investigated the 
role of XOR using purified XO from cow’s buttermilk.  6-oxo-M1dG production was 
dependent on substrate consumption and linearized with respect to time and protein 
concentration. XO was found to be efficient at metabolizing M1dG (Vmax = 0.044 µmol 
min-1 mg XO-1, Km = 186 µM) and produced a single product, 6-oxo-M1dG.  6-Oxo-
M1dG production in XO was completely inhibited by allopurinol (IC50 = 12 µM) (Figure 
31A). 
 
Co-administration of allopurinol and M1dG in the rat 
 Based on our in vitro observations in rat liver cytosol and with purified XO, we 
set out to determine the in vivo contribution of XOR to M1dG metabolism.  Allopurinol is 
a specific, tight binding inhibitor of XOR in vitro (228, 246).  Co-administration of 
allopurinol with other therapeutics can be used as an index of XOR activity in vivo (247, 
248).  Therefore, we monitored the effect on allopurinol on the metabolism of M1dG in 
the rat.  Six male Sprague Dawley rats were obtained from Charles River Laboratories 
with catheters surgically implanted in the femoral and jugular veins.  The animals were 
housed in shoebox cages and allowed to feed ad libitum prior to experimentation.  Upon 
arrival allopurinol was administered iv through the jugular vein (10 mg/kg) to a subset of 
animals (n = 3) and repeated at 24 h intervals prior to the dosing of M1dG (249, 250).  
Animals not receiving allopurinol (n = 3) were administered a vehicle dose (saline 
solution) at the same intervals.  Allopurinol (or vehicle control) was then administered to 
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1 h prior to dosing with M1dG (5 mg/mL).  Whole blood and urine were collected over 
the course of the experiment and analyzed by LC-MS/MS for the presence of M1dG and 
6-oxo-M1dG.  (Figure 32) shows the plasma time-course of M1dG and 6-oxo-M1dG 
during the first 2 h.  Animals pretreated with allopurinol showed a marketed increase in 
plasma M1dG levels as well as a substantial decrease in plasma 6-oxo-M1dG levels in 
comparison to control animals.   Analysis of urine samples (Figure 33) demonstrated a 4- 
to 5-fold increase in the M1dG levels found in the urines of animals pretreated with 
allopurinol during the 0 to 4 h collection.   
 
 
 
 
 
Figure 32.  LC-MS/MS analysis of plasma 6-oxo-M1dG and M1dG levels following iv 
administration of M1dG. Sprague Dawley rats were pretreated with allopurinol () or 
vehicle control () prior to iv administration of M1dG (5 mg/kg). 
 
 
 
 
 
 
 
Figure 33.  Percent recovery of M1dG and 6-oxo-M1dG in urine following iv 
administration of M1dG.  Sprague Dawley rats were pretreated with allopurinol  or 
vehicle control prior to iv administration of  M1dG (5 mg/kg).  Percent M1dG () and 6-
oxo-M1dG () in reference to vehicle control was determined by LC-MS/MS analysis. 
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Metabolism of M1dG in vitro in human liver cytosol 
Three separate human liver cytosol preparations (HG23, HK27, and HG64) were 
obtained from commercial sources and evaluated for their ability to oxidize M1dG in the 
presence or absence of either allopurinol or menadione (Figure 34).  All 3 preparations 
oxidized M1dG to 6-oxo-M1dG but the variation in activities was significant.  Some 
inhibition of oxidation was observed in the presence of allopurinol but greater inhibition 
was observed with menadione.  This suggests that AO as well as XOR plays a significant 
role in the metabolism of M1dG in humans.  Further experiments are necessary to more 
completely characterize the enzymology of metabolism of M1dG in humans, but our 
results indicate that human liver cytosols are capable of catalyzing M1dG oxidation in a 
fashion qualitatively similar to rat liver cytosols. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34.  Oxidation of M1dG by human liver cytosol.  M1dG (370 µM) was 
incubated with 3 separate preparations of human liver cytosol (5 mg/mL, 60 min): HG23 
(gray), HK27 (black), and HG64 (white). 
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Enrichment of XOR and AO from rat liver 
 We continued our investigation of M1dG metabolism in the rat by enriching XOR 
and AO activity from rat liver through a series protein purification steps.  We based our 
study on several literature procedures for the purification of XOR and AO from 
biological matrices.  XOR was originally purified by in 1939 (232). Subsequent revision 
and modifications to the general protocol have been assembled over the years (233, 235, 
238).  AO was first purified in 1962 (234), and more recently modified (236-238). 
Following heat denaturation and ammonium sulfate precipitation, separation on 
the ceramic hydroxyapatite column allowed for the resolution of AO activity from XOR 
activity (Figure 35) and quickly associated M1dG metabolism with both the AO and the 
XOR containing fractions.  Following separate applications on the MonoQ resin the AO 
and XOR containing fractions were further purified.  Each sample was pooled 
(separately) and targeted for purification by separate affinity chromatography steps. 
XOR can be further purified by affinity chromatography on resin derivatized with 
folic acid.  Preparation of the folate affinity matrix was carried out as previously 
described (235).  However, XOR did not bind to the folate resin.  The reason for the lack 
of XOR interaction with the folate resin was unknown, but likely resulted from 
incomplete derivatization of the affinity matrix.  The XOR fractions from rat liver were 
then purified by gel filtration on a HiTrap Sephadex 200 column to approximately 25% 
purity.  Further purification of AO activity by affinity chromatography on benzamidine 
sepharose was unsuccessful.  The overall purification of XOR and AO from rat liver 
resulted in 24-fold purification for XOR (Table 1) and 5-fold purification for AO (Table 
2). 
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Figure 35.  Elution of XOR and AO (from rat liver homogenate) on a 
hydroxyapatite column.  Protein was eluted from a hydroxyapatite column by an 
increasing gradient of potassium phosphate, pH 7.8 (100 – 400 mM).   Protein 
absorbance (gold), XOR activity (green), AO activity (blue) and M1dG metabolism (red) 
was monitored from eluting fractions.  XOR activity was assessed by UV, monitoring 
conversion of xanthine to uric acid (ε295 95000 M-1 cm-1).  AO activity was assessed by 
UV, monitoring the disappearance of 4-dimethylamino-cinnamaldehyde (ε398 30500 M-1 
cm-1).  M1dG activity was assessed by HPLC-UV in reference to buffer control. 
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Table 1.  XOR purification from rat liver homogenate: Unit Activity = 1 µmol 
xanthine consumed min-1. 
 
 
 
 
 
 
 
 
Table 2.    AO   purification  from   rat  liver  homogenate:   Unit  Activity  =  1 µmol 
4-(dimethylamino)-cinnamaldehyde consumed min-1. 
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Discussion 
Considerable effort has been expended to develop biomarkers of DNA damage 
for use in human clinical and population-based studies as well as in animal investigations.  
Quantification of repaired adducts in urine represents a particularly attractive approach.  
Various methodologies have been described for quantification of alkylated 
deoxynucleosides and nucleobases, oxidized deoxynucleosides and nucleobases, 
polycyclic hydrocarbon-derived adducts, aflatoxin-derived adducts, and cis-Pt-derived 
adducts (251). The oxidized guanine adducts 8-oxo-Gua and 8-oxo-dG have been 
reported to be present in the urine of healthy human donors at levels of ~2 nmol/kg/24 h 
and 0.4 nmol/kg/24 h, respectively (155, 156).  Attempts to quantify M1dG indicated that 
it is present at much lower concentrations in human urine, raising the possibility that it is 
metabolized prior to excretion (154). 
In the present study, we report that M1dG is rapidly oxidized following iv 
administration to rats. The sole product was 6-oxo-M1dG; neither evidence for multiple 
oxidations was observed nor was there any evidence for the production of glucuronide 
conjugates. However, we cannot definitively rule out the possibility for the formation of 
additional metabolites or alternative routes of biological processing in vivo (i.e., biliary 
elimination).  The extent of metabolism could not be rigorously determined, but it was 
estimated that approximately 20% to 30% of the exogenously administered M1dG was 
converted to the metabolite, 6-oxo-M1dG, in vivo.  The incomplete conversion of M1dG 
to 6-oxo-M1dG implies that oxidative metabolism is not the sole reason for the low levels 
of M1dG in human urine.  However, such a conclusion may be premature because the 
level of M1dG administered was likely higher than the steady-state level produced from 
 84 
DNA following repair.  Thus, the percentage conversion of M1dG to 6-oxo-M1dG may be 
greater under physiological conditions than the percentage conversion observed in the 
present experiments.  It is also important to consider the possibility that other unknown 
factors besides oxidative metabolism (e.g., enterohepatic recycling of M1dG or 
alternative pathways of DNA repair) are responsible for the low endogenous levels in 
urine. 
The structure of 6-oxo-M1dG was elucidated by mass spectrometry and NMR 
spectroscopy (proton and carbon) and confirmed by independent chemical synthesis.  
Oxidation of M1dG to 6-oxo-M1dG was catalyzed by cytosolic preparations of both rat 
and human liver indicating that this is a metabolic pathway common to both species.  
Based on in vitro and in vivo experiments with chemical inhibitors and partially purified 
enzymes, both XOR and AO were identified in the metabolism of M1dG.  During the 
purification of rat liver homogenate only fractions that corresponded to XOR and AO 
displayed M1dG metabolism.  Thus, it appears unlikely that other enzymes are involved 
in the production of 6-oxo-M1dG.  Additionally, there was no evidence for oxidation of 
M1dG by CYPs in liver microsomal preparations. 
Comparing inhibition results between human and rat liver cytosols suggested AO 
played a more significant role in the metabolism of M1dG in human liver cytosol than in 
rat liver cytosol.  XOR was involved in both species.  The precise role of AO in the 
production of 6-oxo-M1dG in rat liver cytosol was slightly confounded by the stimulatory 
effect of menadione (although, not seen in human liver cytosol incubations).  Substituting 
raloxifene for menadione effectively inhibited 6-oxo-M1dG in rat liver cytosol.  When 
both allopurinol and raloxifene were co-incubated with rat liver cytosol 6-oxo-M1dG 
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production nearly eliminated.  It should be noted that the relative amount of AO to XOR 
activity in Sprague Dawley rat liver cytosol is low.  Other species, such as guinea pig and 
rabbit, often contain higher ratios of AO to XOR (252).  Therefore, the total contribution 
of AO towards the metabolism of M1dG may be underestimated in these studies with rat 
liver cytosol. 
The role of XOR in vivo in the rat appears to be significant.  Pretreating animals 
with allopurinol prior to dosing with M1dG resulted in a considerable reduction in 6-oxo-
M1dG plasma levels and concomitant increase in M1dG plasma levels. Recovery data in 
urine also demonstrated the effect of XOR inhibition on 6-oxo-M1dG production as 
marked by a 5-fold decrease in metabolite recovery.  The total inhibition of M1dG was 
not observed following allopurinol pre-treatment of rats, which would suggest either 
incomplete inhibition of XOR or the involvement of additional enzymes, such as AO.  It 
is important to note that the role of allopurinol on other possible aspects of M1dG 
metabolism (disposition, transport, etc.) is unknown.  Allopurinol is a commonly used in 
the clinic to treat individuals with gout, or other forms of hyperuricemia.  When 
evaluating urinary levels of M1dG and 6-oxo-M1dG in human populations, it may be 
important to consider those individuals taking therapeutic regiments of allopurinol, as it 
may alter their elimination of M1dG. 
Prior studies have demonstrated that alkylated adducts, polycyclic hydrocarbon 
adducts, and aflatoxin adducts are stable in vivo whereas the chemotherapeutic agent O6-
benzylguanine is oxidized (133, 229, 253, 254).  The position of oxidation of O6-
benzylguanine is the 8-position of the imidazole ring, which is different than the site of 
oxidation on M1dG.  The pyrimido ring of M1dG has been previously demonstrated to be 
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highly reactive to nucleophiles and hydride reducing agents so the present observations 
indicate it is also subject to oxidation (109, 112, 153).  It will be interesting to elucidate 
the mechanism of enzyme-catalyzed oxidation. 
Our findings raise the possibility that other DNA adducts from endogenous 
sources are oxidized or otherwise metabolized following repair-dependent removal from 
the genome or from mitochondrial DNA.  8-Oxo-dG appears to be stable to metabolism 
and recent reports have demonstrated the presence of another endogenous adduct, 1,N6-ε-
Ade and its nucleobase (1,N6-ε-dA), in urine (255).  However, a growing number of 
endogenous adducts have been formed in in vitro experiments that contain an exocyclic 
ring that blocks the Watson-Crick base-pairing region (165, 197, 200, 256).  It will be 
important to determine the metabolic fate of these lesions as part of any attempt to 
develop convenient biomarkers suitable for clinical or population-based studies. 
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CHAPTER III 
 
[14C]M1dG METABOLISM IN THE RAT 
 
Summary
Endogenously occurring damage to DNA is a contributing factor to the onset of 
several genetic diseases including cancer.  Monitoring urinary levels of DNA adducts is 
one approach to assess genomic exposure to endogenous damage.  However, metabolism 
and alternate routes of elimination have not been considered as factors that may limit the 
detection of DNA adducts in urine. We recently demonstrated that the peroxidation-
derived dG adduct, M1dG, is subject to enzymatic oxidation in vivo resulting in the 
formation of a major metabolite, 6-oxo-M1dG.  We now report, based on the 
administration of [14C]M1dG to Sprague Dawley rats that 6-oxo-M1dG is the principal 
metabolite of M1dG in vivo representing 45% of the total administered dose.  When 
[14C]6-oxo-M1dG was administered to Sprague Dawley rats, 6-oxo-M1dG was recovered 
unchanged (>97% stability).  These studies also revealed that M1dG and 6-oxo-M1dG are 
subject to biliary elimination.  Additionally, both M1dG and 6-oxo-M1dG exhibited a 
long residence time following administration (>48 h), and the major species observed in 
urine at late collections was 6-oxo-M1dG. 
  
Introduction 
M1dG is an endogenous pyrimidopurinone adduct formed by the reaction of dG 
with MDA, a product of enzymatic and non-enzymatic lipid peroxidation reactions, or 
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base propenal, a DNA peroxidation product (42, 58, 96-98, 106, 107, 257).  This adduct 
is mutagenic in bacteria and mammalian cells (88, 120, 121, 258) and is a substrate for 
NER (120, 122).  It is also one of the first endogenously occurring DNA damage 
products to be detected in DNA of healthy humans (148).  Prior attempts to quantify the 
levels of M1dG in human urine demonstrated an excretion rate of 12 fmol/kg/24 h (154).  
The rate of M1dG elimination in rats could not be determined, since the levels were 
below the limit of detection for the analytical method (153).  The low rate of elimination 
in human populations and the absence of observed material in the urine of rats led us to 
hypothesize that factors such as metabolism (oxidation, conjugation, etc.) or alternative 
routes of elimination may limit the appearance of M1dG in urine. 
We recently demonstrated that M1dG is subject to oxidative metabolism in the rat 
to a principal metabolite, 6-oxo-M1dG (157).  However, the total recovery and extent of 
metabolism in these studies could not definitively be determined. To unambiguously 
monitor the metabolism and elimination of M1dG in vivo, we synthesized M1dG 
containing carbon-14 incorporated into the purine ring for use in animal studies.  This 
tracer allowed us to quantitatively monitor the metabolism and elimination of M1dG and 
its principal metabolite, 6-oxo-M1dG, in the rat.  The results of this investigation are 
described herein. 
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Experimental Procedures 
 
Chemicals and reagents 
All chemicals were obtained from commercial sources and used as received.  
Solvents were of HPLC grade purity or higher.  [8-14C]-2′-dG ([14C]dG) was purchased 
from Sigma (St. Louis, MO).  Purified bovine XO was purchased from CalBiochem (La 
Jolla, CA).  Catheterized male Sprague Dawley rats were obtained from Charles River 
Laboratories (Wilmington, MA).  HPLC-UV βRAM separations were performed on a 
Waters 2695 autosampler and binary pump with a Waters 2487 dual wavelength UV 
detector (Milford, MA) and an IN/US Systems Model 2 βRAM (Tampa, FL). Liquid 
scintillation counting was performed with a Beckman LS 6500 Multi-Purpose 
Scintillation Counter (Fullerton, CA). 
 
Chemical synthesis of [14C]M1dG 
[14C]M1dG synthesis was carried out as previously described (259). Briefly, 
[14C]dG was obtained from Sigma-Aldrich (0.2 mCi, 55 mCi/mmol) as a solution in 
ethanol: water (1:1).  Iodoacrolein was freshly prepared from ethyl cis 3-iodoacrylate as 
previously described and dissolved in anhydrous DMF (260).  Freshly prepared 
iodoacrolein was analyzed by [1H]-NMR and determined to be >95% pure. [14C]dG (0.2 
mCi, 1 mg) was diluted with excess ethanol and evaporated to dryness under reduced 
pressure.  The remaining residue was dissolved in DMF (0.4 mL) in the presence of 1.5 
equivalents, K2CO3 and heated to 65 °C.  To this solution, 1 equivalent of freshly 
prepared iodoacrolein was added each h over 5 h of reaction (Figure 36).  The resulting 
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solution was evaporated under reduced pressure and dissolved in 1.0 mL of 0.01 M 
potassium phosphate.  The mixture was purified by HPLC using a Phenomenex Luna 
C18(2) column (250 x 4.6 mm, 5 µm) equilibrated with 100% solvent A (0.01 M 
potassium phosphate, pH 7.8) at a flow rate of 1.0 mL/min.  The following gradient 
elution was applied: 100% solvent A with 0% solvent B (methanol) for 5 min followed 
by a linear increase to 20% B over 30 min, holding at 20% B for 5 min, increasing to 
85% B in 1 min, holding at 85% B for 5 min, decreasing to 0% B in 1 min and re-
equilibrating at initial conditions for 5 min.  Fractions corresponding to M1dG (~35 min) 
were collected, pooled and concentrated to a minimal volume.  Purity was assessed by 
HPLC-UV with βRAM detection.  The radiochemical purity was assessed to be >95%, 
with a minor impurity of residual [14C]dG.  A final yield of 15% was obtained.  ESI MS: 
m/z 306.4. 
 
Chemical synthesis of [14C]6-oxo-M1dG 
A solution of [14C]M1dG was diluted in 0.6 mL of 0.1 M potassium phosphate, 
pH 7.8, and allowed to incubate with 2 Units of purified bovine XO for 1 h; after which 
an additional 2 Units was added and allowed to incubate for an additional h (Figure 36).  
The resulting solution was purified by HPLC as described for [14C]M1dG.  Fractions 
containing [14C]6-oxo-M1dG (~26 min) were collected, pooled and concentrated to a 
minimal volume.  The resulting sample exhibited >99% radiochemical purity and final 
yield of 10% was obtained. ESI MS: m/z 322.4. 
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Administration of [14C]M1dG and [14C]6-oxo-M1dG to male Sprague Dawley rats 
Animal protocols were performed under the approval of Vanderbilt University 
and in accordance with the Institutional Animal Care and Use Committee policies.  Male 
Sprague Dawley rats (225 – 250 g) with catheters surgically implanted into the jugular 
vein and bile duct were obtained from Charles River Laboratories and housed in shoebox 
cages.  Prior to the experiment the animals were transferred into metabolism cages and 
allowed to feed ad libitum.  The dosing solution was prepared in sterile saline solution, 
administered through the jugular vein over 45 s in an approximate volume of 0.4 mL, and 
flushed with 0.4 mL of sterile heparinized saline.  Four animals were used in each 
experiment (2 animals with and 2 animals without bile catheters).  [14C]M1dG was dosed 
at 22 µCi/kg (123 µg/kg) and [14C]6-oxo-M1dG was dosed at 15 µCi/kg (83 µg/kg) in 
separate experiments.  All animals were housed in metabolism cages throughout the 
duration of the experiment to collect urine and feces over the following intervals: Pre-
dose, 0-4, 4-8, 8-12, 12-16, 16-20, 20-24, 24-32, 32-40, 40-48, and 48-64 h.  Bile was 
also collected (from 2 animals) as outlined above; although, the first interval was broken 
down as follows: 0-0.5, 0.5-1, 1-2, and 2-4 h.  All samples were collected into pre-tared 
tubes and weighed following the collection interval to determine the mass of sample 
collected (feces was first dried on the bench top).  All samples were stored at -20 °C until 
analysis. 
 
Radiochemical analysis of biological samples 
Biological samples were processed as suggested by PerkinElmer.  Urine (0.1-1.0 
mL) and bile (0.1 – 0.3 mL) samples were added directly to 10 mL of Pico-Fluor40 and 
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analyzed by liquid scintillation counting (10 min counts).  Fecal samples were dried on 
the bench top for a minimum of 24 h.  The fecal material was broken into small pieces, 
mixed, and approximately 20 mg of feces (dry weight) was transferred to scintillation 
vials (n = 4) and re-hydrated with 0.2 mL of water.  To each sample 0.5 mL of Soluene®-
350 was added, mixed, and heated to 40 °C for 1.5 h.  A 0.5 mL aliquot of isopropanol 
was added and swirled, followed by drop-wise addition of 0.2 mL H2O2.  The resulting 
mixture was heated to 40 °C for 2 h, cooled, and 10 mL of Hionic-Fluor scintillation 
cocktail was added.  Samples were stored in the dark for a minimum of 36 h prior to 
analysis by liquid scintillation counting (10 min counts).   Urine and bile samples were 
profiled by HPLC-UV with βRAM detection, and centrifuged at 200,000 g for 1 h prior 
to analysis.  Injections (0.025 – 0.3 mL) were made onto a Phenomenex Luna C18(2) 
column (250 x 4.6 mm, 5 µm) equilibrated with 100% solvent A (0.5% formic acid in 
H2O) at a flow rate of 1.0 mL/min.  The following gradient elution was applied: 100% 
solvent A with 0% solvent B (0.5% formic acid in methanol) for 5 min followed by a 
linear increase to 20% B over 30 min, holding at 20% B for 5 min, increasing to 85% B 
in 1 min, holding at 85% B for 5 min, decreasing to 0% B in 1 min and re-equilibrating at 
initial conditions for 5 min.  Column eluent first passed through the UV detector (254 
nm) and onto the βRAM, where it mixed with IN-FLOW 2:1 (IN/US Systems) at a 
ratio of 1:1.1 (HPLC eluent: cocktail), and was analyzed in 0.5 mL flow cell with a dwell 
time of 0.2 s. 
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LC-MS/MS analysis of biological samples 
Tandem mass spectrometry employing selected reaction monitoring was used to 
verify the molecular ions attributed to the main source or radioactivity in the biological 
samples. Approximately 500 – 1000 dpm were analyzed per injection.  Urine and bile 
samples were diluted to an approximate concentration of 50,000 dpm/mL and injected 
onto a Phenomenex Luna C18(2) column (250 x 2.0 mm, 5 µm) equilibrated with 100% 
solvent A (0.5% formic acid in H2O) at a flow rate of 0.3 mL/min.  The following 
gradient elution was applied: 100% solvent A with 0% solvent B (0.5% formic acid in 
methanol) for 5 min followed by a linear increase to 20% B over 30 min, holding at 20% 
B for 5 min, increasing to 85% B in 1 min, holding at 85% B for 5 min, decreasing to 0% 
B in 1 min and re-equilibrating at initial conditions for 5 min.  A ThermoElectron 
Quantum triple-quadrupole instrument with an electrospray source operated in positive 
ion mode was used during the analysis.  The following instrument parameters were set: 
spray voltage 4.3 kV; capillary temperature = 250 °C; sheath gas = 33 psi; auxiliary gas = 
25; source CID off; collision pressure 1.5 mTorr. 
 
Results 
 
Recovery of [14C]M1dG 
[14C]M1dG was synthesized from [14C]dG in a reaction with iodoacrolein in the 
presence of a mild base (K2CO3) (Figure 36) (259).  The material was purified by HPLC 
and the radiochemical purity was determined to be >95% (Figure 37).  A small amount 
(<5%) of unreacted starting material ([14C]dG) was observed in the dosing solution.  
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[14C]M1dG was diluted in sterile saline solution and administered iv (22 µCi/kg, 123 
µg/kg) to male Sprague Dawley rats (n = 4) via catheters surgically implanted in the 
jugular vein.  Two animals contained additional catheters surgically implanted into the 
bile duct.  The animals were housed in metabolism cages throughout the duration of the 
experiment to collect urine, feces, and bile (where applicable).  The collected biological 
samples were analyzed for total radioactivity by liquid scintillation counting and the data 
are summarized in Table 3.  Approximately 50% of the radioactivity was recovered in 
the urine of both bile-catheterized and non-bile-catheterized animals.    Greater than 90% 
of the urinary recovery was collected during the first 8 h (Figure 38).  The remaining 
radioactivity was recovered in the feces of non-bile-catheterized animals and in the bile 
of bile-catheterized animals (Figure 38). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 36. Chemical synthesis of [14C]M1dG and [14C]6-oxo-M1dG.  The convention 
used for numbering the atoms of exocyclic dG adducts labels the 8-position of dG as the 
2-position of the exocyclic dG adduct. 
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Figure 37.  HPLC-UV and HPLC-βRAM analysis of the [14C]M1dG dosing solution. 
(Top) HPLC-UV analysis at 254 nm and (Bottom) radiochemical analysis with βRAM 
detection. 
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Table 3. Total radioactivity recovered following administration of [14C]M1dG. 
[14C]M1dG (22 µCi/kg) was administered iv to male Sprague Dawley rats with (n = 2) or 
without (n =2) surgically implanted bile catheters. 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. [14C]Recovery following administration of [14C]M1dG. Male Sprague 
Dawley rats were dosed iv with [14C]M1dG (22 µCi/kg) and housed in metabolism cages 
to collect urine, bile and feces during the experiment. A, [14C]Recovery in urine from 
bile-catheterized and non-bile-catheterized animals.  B, [14C]Recovery in feces from bile-
catheterized and non-bile-catheterized animals.  C, [14C]Recovery in bile from bile-
catheterized animals. 
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Analysis of [14C]M1dG metabolism in urine and bile 
Urine and bile samples were profiled by HPLC with radiochemical detection. 
Representative chromatograms from urine and bile are shown in Figure 39.  The urine 
profiles from both the bile-catheterized and non-bile-catheterized rats were identical.  The 
major metabolite observed in all radiochemical profiles eluted with the authentic 
retention time for 6-oxo-M1dG, and accounted for 20% of the radioactivity recovered in 
urine. The analysis of bile samples revealed that 70% of the radioactivity in bile was 
attributed to the metabolite, 6-oxo-M1dG. Selected reaction monitoring analysis of these 
samples revealed the expected transitions for M1dG (m/z 306.4 → 190.4) and 6-oxo-
M1dG (m/z 322.4 → 206.4), thereby confirming their identity.  The bile and urine HPLC 
profiles demonstrated that 90% of the recovered radioactivity could be attributed to the 
combination of M1dG and 6-oxo-M1dG. The remaining 10% of the radioactivity was 
distributed among 5 distinct peaks in the radiochemical profiles; part of which (~5%) was 
attributed to the [14C]dG in the dosing solution.  Thus, metabolites other than 6-oxo-
M1dG collectively accounted for <6% of the total radioactivity. 6-Oxo-M1dG accounted 
for 45% of the total recovered radioactivity. 
Analysis of late time-point urine collections (post 24 h) from both non-bile-
catheterized and bile-catheterized animals suggested 6-oxo-M1dG was present at the 
same or higher abundance than M1dG (Figure 40).  This was especially apparent in the 
LC/MS-MS analysis of the bile-catheterized animals where the radioactivity present in 
the sample could almost entirely be attributed to 6-oxo-M1dG. 
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Figure 39. HPLC-radiochemical and -MS/MS profiles of urine and bile samples 
following administration of [14C]M1dG.  Male Sprague Dawley rats received a single iv 
dose of [14C]M1dG (22 µCi/kg).  A, Representative urine sample (0-4 h) from a non-bile-
catheterized animal was profiled by radiochemical detection and separately by LC-
MS/MS using selected reaction monitoring following the transitions for the parent 
molecule M1dG (m/z 306.4 → 190.4) and the principal metabolite, 6-oxo-M1dG (m/z 
322.4 → 206.4). B, Representative urine sample (0-4 h) from a bile-catheterized animal 
was profiled by radiochemical detection and separately by LC-MS/MS using selected 
reaction monitoring following the transitions for the parent molecule M1dG (m/z 306.4 → 
190.4) and the principal metabolite, 6-oxo-M1dG (m/z 322.4 → 206.4). B, a 
representative bile sample (0-0.5 h) from a bile-catheterized animal was profiled by 
radiochemical detection and separately by LC-MS/MS using selected reaction monitoring 
following the transitions for the parent molecule M1dG (m/z 306.4 → 190.4) and the 
principal metabolite, 6-oxo-M1dG (m/z 322.4 → 206.4). 
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Figure 40. Analysis of late time-point urine samples following administration of 
either [14C]M1dG or [14C]6-oxo-M1dG. LC-MS/MS analysis of a 32-40 h urine sample 
from a non-bile-catheterized rat monitoring the transitions for: A, [14C]M1dG (m/z 306.4 
→ 190.4) and B, [14C]6-oxo-M1dG (m/z 322.4 → 206.4). LC-MS/MS analysis of a 32-40 
h urine sample from a bile-catheterized rat monitoring the transition for: C, [14C]M1dG 
(m/z 306.4 → 190.4) and D, [14C]6-oxo-M1dG (m/z 322.4 → 206.4). E, LC-MS/MS 
analysis of a 32-40 h urine sample from a non-bile-catheterized rat monitoring the 
transition of [14C]6-oxo-M1dG (m/z 322.4 → 206.4) following an iv dose of [14C]6-oxo-
M1dG. 
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Recovery of [14C]6-oxo-M1dG 
Based on the long residence time of the [14C]M1dG dose and the significant 
conversion of M1dG to 6-oxo-M1dG, we continued experiments to study the metabolism 
and elimination of the principal metabolite, 6-oxo-M1dG.  We hypothesized that 6-oxo-
M1dG would have significant biliary clearance, and a long residence time similar to the 
parent molecule, M1dG.  Furthermore, this experiment would clarify the ultimate source 
of the minor metabolites observed in the [14C]M1dG study (i.e., derived from M1dG or 6-
oxo-M1dG). 
[14C]6-Oxo-M1dG was prepared from [14C]M1dG (described above) by enzymatic 
oxidation at the 6-position of the pyrimido ring with purified bovine XO (Figure 36).  
The material was purified by HPLC and exhibited radiochemical purity of >99% (Figure 
41).  Freshly prepared [14C]6-oxo-M1dG was diluted in sterile saline solution and 
administered iv (15 µCi/kg, 83 µg/kg) to male Sprague Dawley rats (n = 4) via the 
jugular catheter.  Two animals also contained catheters surgically implanted into the bile 
duct.  The animals were housed in metabolism cages throughout the duration of the 
experiment to collect urine, feces, and bile (where available) at intervals.  All samples 
were collected into pre-tared tubes and weighed following collection to determine the 
mass of sample collected.  The biological samples were processed by liquid scintillation 
counting (Figure 42) and the results from the elimination data are summarized in Table 
4.  The non-bile-catheterized rats eliminated 30 ± 5% of the dose in the urine, while 70 ± 
5% was recovered in the feces.  In bile-catheterized animals, 45 ± 7% was recovered in 
urine, 1% in feces, and 54 ± 2% in bile. 
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Figure 41.  HPLC-UV and HPLC-βRAM analysis of the [14C]6-oxo-M1dG dosing 
solution. (Top) HPLC-UV analysis at 254 nm and (Bottom) radiochemical analysis with 
βRAM detection. 
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Figure 42.  [14C]Recovery following administration of [14C]6-oxo-M1dG.  Male 
Sprague Dawley rats were dosed iv with [14C]6-oxo-M1dG (15 µCi/kg) and housed in 
metabolism cages to collect urine, bile and feces during the experiment. A, 
[14C]Recovery in urine from bile-catheterized and non-bile-catheterized animals.  B, 
[14C]Recovery in feces from bile-catheterized and non-bile-catheterized animals.  C, 
[14C]Recovery in bile from bile-catheterized animals. 
 
 
 
 
 
 
Table 4. Total radioactivity recovered following administration of [14C]6-oxo-M1dG. 
[14C]6-Oxo-M1dG (15 µCi/kg) was administered iv to male Sprague Dawley rats with (n 
= 2) or without (n =2) surgically implanted bile catheters. 
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Analysis of [14C]6-oxo-M1dG metabolism in urine and bile 
In all HPLC radiochemical profiles, the principal peak observed eluted with the 
retention time of 6-oxo-M1dG (Figure 43).  No significant secondary metabolites of 6-
oxo-M1dG were observed during any collection interval.  Therefore, 6-oxo-M1dG was 
determined to be metabolically stable (>97%) and not subject to further metabolism in 
vivo.  These data suggest that the minor metabolites observed in the  [14C]M1dG study 
arose directly from M1dG and did not represent further metabolism of 6-oxo-M1dG. 
[14C]6-Oxo-M1dG also exhibited significant biliary clearance (as seen in the 
[14C]M1dG study), which suggested 6-oxo-M1dG was absorbed by the liver and subject to 
transport into bile.  As seen in the [14C]M1dG study, [14C]6-oxo-M1dG also exhibited a 
long residence time (>48 h) following iv administration.  The identity of 6-oxo-M1dG 
was verified by selected reaction monitoring analysis of the late time-point urine 
collections (Figure 40). 
 
Discussion 
The endogenous peroxidation-derived DNA adduct, M1dG, was recently found to 
undergo metabolism in vivo to a single, oxidized metabolite, 6-oxo-M1dG (157).  Our 
laboratory has now performed definitive in vivo analysis of the metabolism and excretion 
of M1dG and its major metabolite, 6-oxo-M1dG, by the incorporation of stable carbon-14 
tracers into these molecules.  Male Sprague Dawley rats with (n = 2) and without (n = 2) 
bile catheters were dosed iv with [14C]M1dG at 22 µCi/kg (123 µg/kg). Approximately 
50% of the administered dose was recovered in the urine while the remainder  was  
recovered in  the  feces and  bile  (Figure 38).   6-Oxo-M1dG  accounted  for  45% of  the 
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Figure 43.  HPLC-radiochemical and -MS/MS profiles of urine and bile samples 
following administration of [14C]6-oxo-M1dG. Male Sprague Dawley rats received a 
single iv dose of [14C]6-oxo-M1dG (15 µCi/kg).  A, Representative urine sample (0-4 h) 
from a non-bile-catheterized animal was profiled by radiochemical detection and 
separately by LC-MS/MS using selected reaction monitoring selected reaction 
monitoring following the transition for 6-oxo-M1dG (m/z 322.4 → 206.4). B, 
Representative urine sample (0-4 h) from a bile-catheterized animal was profiled by 
radiochemical detection and separately by LC-MS/MS using selected reaction monitoring 
following the transition for 6-oxo-M1dG (m/z 322.4  → 206.4). C, Representative bile 
sample (0-0.5 h) from a bile-catheterized animal was profiled by radiochemical detection 
and separately by LC-MS/MS using selected reaction monitoring following the 
transitions for 6-oxo-M1dG (m/z 322.4 → 206.4). 
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recovered radioactivity.  The significant conversion of M1dG to 6-oxo-M1dG prompted 
additional metabolism and elimination studies on the metabolite.  Upon dosing [14C]6-
oxo-M1dG (15 µCi/kg, 83 µg/kg), 30 ± 6% of the radioactivity was recovered in the urine 
while 71 ± 6% was excreted in the feces of non-bile-catheterized animals.  Rats 
containing bile catheters deposited 45 ± 7% of the radioactivity into the urine, 54 ± 2% 
into the bile, and 1% into the feces.  Profiling bile and urine samples revealed that the 
metabolite, [14C]6-oxo-M1dG, was cleared unchanged (>97%) with no significant 
metabolism to secondary metabolites. 
The simplicity of M1dG metabolism and elimination is noteworthy (Figure 44).  
A single metabolite is formed that is neither conjugated nor further metabolized.  In our 
study, 6-oxo-M1dG represents a significant contribution (45% of the total dose) in the 
overall mass balance of M1dG.  It was previously hypothesized that depurination 
reactions may give rise to the free base, M1G, as an alternate metabolic pathway (261); 
however, no accumulation of this compound or its metabolites was observed in our 
analysis. Furthermore, our investigation of 6-oxo-M1dG metabolism revealed that it was 
exceptionally stable in vivo (>97%) and not metabolized to additional products.  It should 
be noted that 6-oxo-M1dG contains a possible Michael acceptor on the pyrimido ring (at 
C8), but no evidence for nucleophilic addition or conjugation (glutathione addition) was 
observed in the recovered samples. 
Considering that the main metabolite of M1dG is a singly oxidized species, the 
extent to which M1dG and 6-oxo-M1dG were cleared through biliary excretion was 
unexpected.  The iv administration of M1dG and 6-oxo-M1dG and subsequent appearance 
of these products in bile and feces strongly suggests the role of transporters in the 
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disposition of M1dG and 6-oxo-M1dG in vivo. Nucleosides and nucleoside derivatives are 
reported substrates for transport proteins, such as organic anion transporters (262) and the 
concentrative Na+-dependent (CNT) and equilibrative Na+-independent nucleoside 
transporters (ENT) (263).  Indeed, ENT isoforms appear to be involved in nucleoside 
transport into hepatocytes (264), whereas the CNT isoforms are expressed along the bile 
canalicular membrane and are likely involved in biliary transport (265).  It would be 
interesting to evaluate their involvement in DNA adduct disposition in future studies. 
The notion that DNA adducts were subject to biliary elimination was first 
suggested by the work of Wang and Hecht (266).  Following an iv administration of 
N7,C-8 N-nitrosopyrrolidine guanine adduct to F344 rats, 52.2% of the administered 
radioactivity was recovered in the urine.  Ninety percent of the urinary radioactivity was 
attributed to the parent molecule.  The remaining 47.8% of the radioactivity was either 
retained in the animal or cleared through the biliary elimination pathway.  However, 
neither biliary elimination nor fecal elimination was measured in their study. It is 
tempting to speculate that either the N7,C-8 N-nitrosopyrrolidine guanine adduct was a 
direct substrate for biliary transport or that the adduct underwent metabolism that 
rendered the molecule a substrate for transport into bile.  Our findings, in addition to 
those of Wang and Hecht, suggest that disposition of adducts may be a key limiting factor 
in the analysis of urinary DNA adducts and their metabolites. 
The amount of M1dG administered in our study (approximately 31 µg per animal) 
was lower than our previous investigation (approximately 500 µg per animal) (157).  
However, the administered dose is still higher than the anticipated physiological levels of 
M1dG in the rat (154).  Administration of µg levels of M1dG and 6-oxo-M1dG in these 
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studies was necessary to obtain a reliable mass balance and metabolite profile from which 
to proceed with future physiological determinations. 
Administration of [14C]M1dG and [14C]6-oxo-M1dG resulted in rapid elimination 
of the administered material in the first 4 h, followed by an extended slow release of the 
remaining dose.  During the LC-MS/MS analysis of late time-point urine collections from 
the [14C]M1dG administration study, we observed that 6-oxo-M1dG was as abundant or 
more abundant than the parent molecule M1dG. Considering the likely involvement of 
transporters in the disposition of M1dG, it remains possible that transport may afford an 
effectively high concentration at the site of metabolism to facilitate the production of 6-
oxo-M1dG even at low concentrations.  Inspection of the relative urinary elimination rate 
for M1dG and 6-oxo-M1dG suggests this increase cannot simply be explained by a slower 
rate of elimination for 6-oxo-M1dG, since the elimination profiles for M1dG and 6-oxo-
M1dG are nearly identical.  Ongoing efforts in our laboratory are directed towards 
assessing the contribution of 6-oxo-M1dG to the overall levels of M1dG in human and 
animal studies. 
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Figure 44.  Metabolic processing of M1dG.  RLC, rat liver cytosol. 
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CHAPTER IV 
 
ANALYSIS OF [14C]M1dG METABOLISM IN THE RAT BY 
ACCELERATOR MASS SPECTROMETRY 
 
Summary 
Our laboratory is investigating the in vitro and in vivo metabolic processing of 
endogenously formed DNA adducts as a means of evaluating candidate urinary 
biomarkers.  In particular, we have focused our studies on the metabolism and disposition 
of the peroxidation-derived pyrimidopurinone dG adduct, M1dG, and its principal 
metabolite, 6-oxo-M1dG.  We now report the metabolic processing of M1dG at 
concentrations 4 to 8 orders of magnitude lower in concentration than previously 
analyzed, by the use of accelerator mass spectrometry analysis.  Administration of 2.0 
nCi/kg [14C]M1dG resulted in 49% of the 14C recovered in urine whereas 51% was 
recovered in feces.  In urine samples, approximately 40% of the 14C corresponded to the 
metabolite, 6-oxo-M1dG.  Following iv administration of 0.5 and 54 pCi/kg [14C]M1dG, 
approximately 25% of the urinary recovery corresponded to the metabolite, 6-oxo-M1dG.  
Thus, upon administration of trace amounts of M1dG, a significant percentage of 6-oxo-
M1dG was produced suggesting that 6-oxo-M1dG may be a useful urinary marker of 
exposure to endogenous oxidative damage. 
 
Introduction 
Results from in vitro and in vivo metabolism experiments have demonstrated that 
M1dG is subject to enzymatic oxidation to the metabolite, 6-oxo-M1dG (157).  In vivo 
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radiochemical tracer studies performed with [14C]M1dG revealed that following iv 
administration, 45% of the isotope was recovered as the metabolite, 6-oxo-M1dG (267). 
6-Oxo-M1dG accounted for 20% of the total radioactivity in the early time-point urine 
samples; however, at late time-points, there was an approximate equal ratio of M1dG to 
6-oxo-M1dG.  The increase in observed metabolism was unexpected given the calculated 
Km for M1dG metabolism in vitro in rat liver cytosol is 370 µM (157).  Additionally, 
since endogenously formed adducts are produced in very low amounts, we were curious 
to know if M1dG would be metabolized when administered at very low quantities, which 
might approximate physiological levels.  To address this question, we employed nCi and 
pCi dosing procedures with [14C]M1dG and monitored metabolism and elimination.  
Analysis of biological samples from these studies was possible by the use of accelerator 
mass spectrometry (AMS). 
  
Experimental Procedures 
 
Chemicals and reagents 
 All chemicals were obtained from commercial sources and used as received.   
Solvents were of HPLC grade purity or higher. [14C]dG was purchased from Sigma (St. 
Louis, MO). [14C]M1dG was synthesized as previously described (259).  HPLC-UV 
separations were performed with either a Waters 2695 autosampler and binary pump or a 
Waters 1585 binary pump and 717plus autosampler, and a Waters 2487 dual wavelength 
UV detector (Milford, MA). 
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Administration of [14C]M1dG to Sprague Dawley rats 
Animal protocols were performed under approval of Vanderbilt University and in 
accordance with the Institutional Animal Care and Use Committee policies.  Male 
Sprague Dawley rats (225-250 g), with vascular catheters surgically implanted in the 
jugular vein were obtained from Charles River Laboratories (Wilmington, MA) and 
housed in shoebox cages.  Animals were transferred to metabolism cages prior to dosing 
and allowed to feed ad libitum throughout the experiment.  The [14C]M1dG dosing 
solution (>99% pure) was prepared in sterile saline to the desired specific activity (3.0 
dpm/µL, 0.1 dpm/µL and 0.001 dpm/µL) and administered via the jugular catheter in 
approximately 0.3 mL of total volume over 45 s. All doses were followed by 0.4 mL of 
sterile heparinized saline to flush the catheters. 
One cohort of four animals was used for the 2.0 nCi/kg (11 ng/kg) dosing.  Three 
animals received the [14C]M1dG dosing solution (3.0 dpm/µL), and 1 animal received a 
vehicle control (sterile saline). Urine was collected over intervals (pre-dose, 0-4, 4-8, 8-
12, 12-16, 16-20, and 20-24 h).  All samples were stored at –20 °C following collection. 
A second cohort of 4 animals was used for the 0.5 pCi/kg (3.0 pg/kg) and 54 
pCi/kg (300 pg/kg) studies.  Three animals received the 0.5 pCi/kg [14C]M1dG dosing 
solution (0.001 dpm/µL), and 1 animal received the vehicle control (saline).  After 12 h, 
the animals were removed from the metabolism cages and returned to shoebox cages 
overnight.  Metabolism cages were thoroughly washed following the 0.5 pCi/kg dose.  
Approximately 24 h after receiving the 0.5 pCi/kg dose, the same 3 experimental animals 
received 54 pCi/kg [14C]M1dG dosing solution (0.1 dpm/µL) and the same control animal 
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received a vehicle administration (saline).  Urine was collected over intervals (pre-dose, 
0-2 and 2-4, and 4-8).  All samples were stored at –20 °C. 
Fecal samples were dried on the bench top overnight.  All pellets from a given 
time-point were pooled, placed in a sealable plastic bag, crushed with a rubber mallet, 
and stored at -20°C.  For AMS analysis, fecal samples were weighed, diluted in 1 N 
NaOH, and stored at -20 °C. 
 
HPLC fraction collection 
Urine samples were centrifuged for 10 min at 14,000 g.  Supernatants were 
removed and directly injected onto a Phenomenex Luna C18(2) column (4.6 x 250 nm, 5 
µm) equilibrated with 90% solvent A (10 mM potassium phosphate in H2O, pH 7.8) and 
10% solvent B (methanol) at a flow rate of 1.0 mL/min.  The solvent was programmed as 
follows: a linear gradient from the equilibration conditions to 20% B in 10 min, holding 
at 20% B for 10 min, increasing to 90% B in 0.1 min, holding for 5 min, decreasing to 
10% B in 0.1 min and re-equilibrating to initial conditions.  Standards applied to this 
gradient eluted at 12.7 min (6-oxo-M1dG) and 15.8 min (M1dG).  Standards spiked into 
blank urine samples demonstrated slight shifts in retention to 11.5 min (6-oxo-M1dG) and 
15.7 min (M1dG).  300 µL injections were made for the 2.0 nCi/kg study and 200 µL 
injections were made for the 54 pCi/kg and 0.5 pCi/kg studies.  Fractions were collected 
from 10.5 min to 12.5 min for 6-oxo-M1dG and from 15 to 17 min for M1dG.  Samples 
were evaporated to dryness under a stream of nitrogen in a heated water bath and stored 
at -20 °C. 
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AMS analysis 
AMS analyses were conducted at the MIT BEAMS Laboratory using the 
instrument and procedures described elsewhere (268-271). Urine samples and fecal 
extracts were diluted as required to bring the total carbon and 14C concentrations within 
the dynamic range of the AMS system and analyzed without further processing. HPLC 
fractions were reconstituted with appropriate measured volumes of H2O. Aliquots of 
urine, fecal, and HPLC samples (1.50 µL) were absorbed into pellets of packed CuO 
powder that had previously been exposed for 30 min to an atmosphere of O2 at 720 °C. 
After drying briefly in a vacuum oven, the sample-loaded CuO pellets in their holders 
were transferred to a laser-induced combustion interface for subsequent AMS analysis. 
Each run of samples was organized to include quantitation standards (0.0030 dpm/µL) 
and blanks (1 µg/µL albumin). Quantitation was performed by integrating peaks 
produced in the continuous trace of 14C detector count rate vs. time generated during 
operation of the combustion interface, which produces and delivers the CO2 of 
combustion to the AMS ion source, and taking the product of the sample:standard peak 
area ratio multiplied by the standard concentration as the concentration of the sample. All 
samples were analyzed in duplicate. 
 
Results 
 
nCi dosing of [14C]M1dG 
[14C]M1dG was synthesized and purified as previously described (259, 267).  The 
purified material was diluted in sterile saline to a specific activity of 3.0 dpm/µL for a 
  114 
final dosing load of 2.0 nCi/kg.  The resulting solution was administered to male Sprague 
Dawley rats via a catheter surgically implanted in the jugular vein.  Three animals 
received [14C]M1dG dosing solution, while a fourth animal received a vehicle control 
(saline).  Animals were housed in metabolism cages to collect urine and feces at intervals 
over the course of the experiment. 
Urine and fecal samples were subject to AMS analysis for total [14C]recovery 
(Table 5).  Forty-nine percent of the recovered 14C was found in urine while 51% was 
found in feces.  Approximately 84% of the urinary radioactivity was collected in the first 
4 h and isotope was observed out to 24 h of collection (Figure 45).  This elimination 
profile was very similar to the previously observed time-course from the µCi dosing of 
[14C]M1dG (267).  No 14C was detected in any biological samples from the vehicle 
control animal at levels measurably above the background levels (standard isotopic 
abundance) of 14C present in biological samples. 
To determine the contribution of M1dG and 6-oxo-M1dG to the total 14C content 
in the urine samples fraction collection analysis was performed. Urine samples were 
injected directly onto a C18 HPLC column and fractions corresponding to either M1dG or 
6-oxo-M1dG were collected (Figure 46A). The collected fractions were then analyzed by 
AMS (Figure 46B).  The average observed ratio of M1dG to 6-oxo-M1dG over the 24-h 
collection was 1.4:1, which demonstrated 40% of the urinary radioactivity corresponded 
to 6-oxo-M1dG.  The mean [14C]recovery from fraction analysis was 82% with a standard 
deviation of 12%. 
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Table 5. Total [14C]recovery in urine and feces following administration of 2.0 
nCi/kg [14C]M1dG to male Sprague Dawley rats (n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45. [14C]Recovery in urine following administration of 2.0 nCi/kg [14C]M1dG 
to male Sprague Dawley rats (n = 3). 
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Figure 46. Fraction collection analysis of 6-oxo-M1dG and M1dG in rat urine. (A) 
Reverse phase HPLC separation of M1dG and 6-oxo-M1dG standards on a C18 column 
with a potassium phosphate, pH 7.8, and methanol gradient.  (B) Ratio of M1dG to 6-oxo-
M1dG in rat urine over time following administration of 2.0 nCi/kg [14C]M1dG to male 
Sprague Dawley rats (n = 3). 
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pCi dosing of [14C]M1dG 
Based on our [14C]M1dG nCi dosing results we lowered the dose to our AMS 
limit of detection for 14C in urine.  We formulated dosing solutions at 0.001 and 0.1 
dpm/µL for a final dosing load of 0.5 and 54 pCi/kg, respectively.  Three male Sprague 
Dawley rats were dosed first at 0.5 pCi/kg [14C]M1dG via catheters surgically implanted 
into the jugular vein.  A fourth animal received vehicle (saline) control. The animals were 
housed in metabolism cages during the course of the experiment to collect urine at 
intervals.  After 12 h, the animals were removed from the metabolism cages and placed 
into standard shoebox cages. The same animals were returned to metabolism cages and 
again dosed at 54 pCi/kg with [14C]M1dG (n = 3) or vehicle control (n = 1) approximately 
24 h following the 0.5 pCi/kg injection.  Urine was collected at intervals during the 
experiment. 
Total 14C content in urine samples was assessed directly by AMS analysis.  The 
urinary data from the 54 pCi/kg dosing is summarized in Figure 47; approximately 42% 
of the administered 14C was recovered in urine.  Direct AMS analysis of urine samples 
from the 0.5 pCi/kg dose did not offer significant signal above background, and no total 
urinary [14C]recovery could be determined.  Significant 14C enrichment was observed in 
all fractions following HPLC purification.  Analyte was detected in some urine samples 
following AMS analysis of the 0.5 pCi/kg samples, albeit at a low signal-to-noise.  Only 
samples that displayed a signal-to-noise ≥ 3 were considered in this analysis.  The 
average observed ratio of M1dG to 6-oxo-M1dG was approximately 3:1 following 
administration at either 54 pCi/kg or 0.5 pCi/kg [14C]M1dG (Table 6), which implies 
25% of the total 14C was recovered as 6-oxo-M1dG following administration of M1dG at 
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the AMS limit of detection.  The mean [14C]recovery from fraction analysis performed on 
the 54 pCi/kg urine samples was 55% with a standard deviation of 20%. A similar 
decrease in recovery was observed with late time-point urine collections in the nCi 
dosing study.  Recoveries of nearly 86-99% were obtained during the first 8 h of 
collection and recoveries of 56-78% were obtained during the final 8 h of collection 
following administration of 2.0 nCi/kg M1dG. Thus, due to the very low analyte levels, 
the lower recovery was attributed to non-specific loss. 
 
 
 
 
 
 
 
 
 
 
 
Figure 47. [14C]Recovery in urine following administration of 54 pCi/kg [14C]M1dG 
to male Sprague Dawley rats (n = 3). 
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Table 6. Percent of [14C]M1dG converted to [14C]6-oxo-M1dG in urine following 
administration of 0.5 pCi/kg or 54 pCi/kg [14C]M1dG to male Sprague Dawley rats 
(n = 3). 
 
 
 
 
 
 
 
 
Discussion 
14C-Incorporation for use in metabolism and elimination studies provides 
unambiguous tracking of the isotopically labeled molecule.  Analysis of 14C is most 
frequently performed by measurement of radioactivity.  The use of 14C in DNA adduct 
analysis has been limited, principally due to the poor yields in synthesis, coupled to the 
need of sufficient amounts of material for traditional liquid scintillation counting.  The 
advent of AMS analysis has greatly reduced the required isotope levels for experimental 
analysis, by altering the mode of detection from decay counting to mass analysis (271).  
Our study suggests that less than 1000 dpm per animal are required for sound in vivo 
metabolism and elimination studies involved in evaluating candidate urinary biomarkers.  
Results from this type of analysis provide, at a minimum, recovery and elimination data; 
and when coupled to fraction collection analysis offers an estimation of percent 
metabolism of the administered material.  Thus, AMS analysis may be applicable to 
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many toxicology problems and significantly impact the development and evaluation of 
biomarkers. 
The use of a 14C radiochemical tracer stably incorporated into M1dG for use in 
vivo in rats has allowed us to investigate the metabolic processing at very low adduct 
concentrations.  Analysis was performed at the limit of detection by AMS measurements.  
Our findings revealed that when [14C]M1dG was administered at 0.5 and 54 pCi/kg 
(approximately 750 fg and 75 pg per animal, respectively) approximately 25% of the 
urinary 14C was recovered as 6-oxo-M1dG.  Interestingly, when [14C]M1dG was 
administered at 2.0 nCi/kg (approximately 2.5 ng per animal) approximately 40% of the 
urinary 14C was recovered as 6-oxo-M1dG.  Total 14C elimination was determined 
following 2.0 nCi/kg dosing and revealed that 49% of the recovered 14C appeared in urine 
and 51% was found in feces. 
The observed contribution of 6-oxo-M1dG to the total M1dG in rat urine 
approximated our previous estimations based on 14C content (267).  The fact that 25-40% 
of the administered [14C]M1dG was recovered from urine as 6-oxo-M1dG in the present 
studies strongly suggests that M1dG metabolism is likely to occur under physiological 
conditions of M1dG production.  A prior estimate of the M1dG elimination rate in human 
urine demonstrated the adduct was eliminated at 12 fmol/kg/24 h (154).  This elimination 
rate corresponds to approximately 3.6 pg/kg/24 h.  Our administration of [14C]M1dG at 
0.5 and 54 pCi/kg (750 fg and 75 pg, respectively) brackets the anticipated daily 
physiological clearance of M1dG.  The rate of elimination for M1dG in the rat has not 
been determined.  However, if we assume the average elimination rate to be similar in 
  121 
rats as observed in humans, then based on the elimination of 30 mL of urine per day, a 
total clearance of 100 fg may be anticipated in the rat. 
It should be noted that our discussion of the percent conversion to 6-oxo-M1dG 
following nCi and pCi dosing is limited to urinary analysis.  Prior studies have shown 
that biliary elimination is a key route of excretion for 6-oxo-M1dG (267).  Following 
administration of 6-oxo-M1dG to Sprague Dawley rats, 55-70% of the dose was cleared 
in either bile or feces.  And following administration of M1dG to Sprague Dawley rats, 
70% of the dose cleared in bile corresponded to 6-oxo-M1dG.  If we apply the same 
biliary conversion to the nCi and pCi dosing studies, then greater than 50% of the 
administered material in the current studies would have been converted to 6-oxo-M1dG.  
This represents a significant portion of the total M1dG. 
The reasons for the observed differences in percent conversion at different dosing 
levels are unknown.  However, several factors may have influenced the outcome.  First, 
while all animals investigated were Sprague Dawley rats, it is possible that small changes 
in expression of enzymes that either metabolize or transport M1dG might affect the 
percent conversion between cohorts.  XOR and AO have been implicated in M1dG 
metabolism, and decreased expression or activity of these enzymes could decrease the 
production of 6-oxo-M1dG.  Alternatively, an increase or decrease in expression of 
transport proteins that affect the disposition of M1dG or 6-oxo-M1dG may alter the 
observed ratio of M1dG and 6-oxo-M1dG in rat urine. 
A second possibility for decreased conversion of M1dG to 6-oxo-M1dG may be 
related to enzyme efficiency. Based on the calculated Km for M1dG metabolism in rat 
liver cytosol (370 µM) (157), in vivo metabolism at very low concentrations may not be 
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expected.  However, at doses as low as 750 fg, a clear conversion to 6-oxo-M1dG was 
observed.  It is possible that at the lower level of administration (0.5 pCi/kg and 54 
pCi/kg) the effective concentration at the site of metabolism was not sufficient to 
promote turnover at saturating conditions.  Thus, a decrease in the percent conversion 
may be observed at lower levels of abundance. 
Based on these and prior experiments, it is clear that iv administered M1dG is 
taken up, and likely accumulates, in the liver.  The physiological explanation for this is 
unknown, but it is reasonable to assume that transport proteins are involved in the 
disposition of M1dG and 6-oxo-M1dG.  The result of this process leads to oxidative 
metabolism of exogenously administered M1dG, even at concentrations that approach the 
analytical limit of sensitivity by AMS. Thus, there exists a distinct possibility that 
metabolism occurs at the projected rates of M1dG formation in animals and humans.  Our 
laboratory is currently developing analytical methods to probe for the appearance of 
M1dG and 6-oxo-M1dG in human elimination products. 
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CHAPTER V 
 
M1G METABOLISM IN VITRO AND IN VIVO 
 
Summary 
Oxidative damage is considered a major contributing factor to genetic diseases 
including cancer.  Our laboratory is evaluating endogenously formed DNA adducts as 
genomic biomarkers of oxidative injury.  Recent efforts have focused on investigating the 
metabolic stability of adducts in vitro and in vivo.  Here, we demonstrate that the base 
adduct, M1G, undergoes oxidative metabolism in vitro in rat liver cytosol (Km = 105 µM 
and Vmax/Km = 0.005 min-1 mg-1) and in vivo when administered iv to male Sprague 
Dawley rats.  LC-MS analysis revealed 2 metabolites containing successive additions of 
16 amu.  One- and two-dimensional NMR experiments showed oxidation occurred first at 
the 6-position of the pyrimido ring forming 6-oxo-M1G, then at the 2-position of the 
imidazole ring yielding 2,6-dioxo-M1G.  Authentic 6-oxo-M1G was chemically 
synthesized and observed to undergo metabolism to 2,6-dioxo-M1G in rat liver cytosol 
(Km = 210 µM and Vmax/Km = 0.005 min-1 mg-1).  Allopurinol partially inhibited M1G 
metabolism (75%) and completely inhibited 6-oxo-M1G metabolism in rat liver cytosol. 
These inhibition studies suggest XOR is the principal enzyme acting on M1G in rat liver 
cytosol and the only enzyme that converts 6-oxo-M1G to 2,6-dioxo-M1G.  Both M1G and 
6-oxo-M1G are better substrates (5-fold) for oxidative metabolism in rat liver cytosol than 
the deoxynucleoside, M1dG.  Alternative repair pathways or biological processing of 
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M1dG makes the fate of M1G of interest as a potential marker of oxidative damage in 
vivo. 
 
Introduction 
Many endogenously produced exocyclic ring adducts are substrates for base 
excision repair (30).  Some adducts are subject to multiple repair pathways (i.e., 8-oxo-
dG is repaired by base excision repair and presumably NER machinery (125, 272)).  
Etheno adducts bearing structural similarity to M1dG (e.g., 1,N2-ε-dG, 1,N6-ε-dA, and 
3,N4-ε-dC) are substrates for DNA glycosylases (217-219, 221, 273, 274).  The structural 
resemblance between M1dG and the etheno adducts might suggest that similar, yet 
unknown, repair pathways are also involved in the repair of M1dG.  Emerging discoveries 
regarding induction of base excision repair enzymes in vivo in response to stress has 
made alternate routes of repair of particular interest (275, 276). 
Our laboratory recently demonstrated that M1dG was oxidized to 6-oxo-M1dG in 
rats and that XOR and AO were the likely enzymes responsible (157). M1dG oxidation 
was detected in rat and human liver cytosol and was in purified bovine XO.  In all cases, 
6-oxo-M1dG was the sole product and there was no evidence for oxidation on the 
imidazole ring.  This was surprising because the imidazole ring is the primary site for 
chemical oxidation on dG, and a site for oxidation on xanthine by XOR.  The present 
report describes the in vitro and in vivo oxidation of the base, M1G, a putative product of 
repair in M1dG-containing DNA by glycosylase action (Figure 48).  Results from our 
metabolism studies on M1G show that it is a better substrate for enzymatic oxidation than 
M1dG.  Furthermore, its initial oxidation product, 6-oxo-M1G, is susceptible to further 
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oxidation on the imidazole ring.  When administered to Sprague Dawley rats, M1G and 
both of the oxidized metabolites were excreted in urine.  Thus, a family of oxidized 
metabolites may serve as biomarkers of M1dG formation in genomic DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48.  Formation of M1dG from endogenous sources and possible routes of 
release from DNA. 
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Experimental Procedures 
 
Chemicals and reagents 
All chemicals were obtained from commercial sources and used as received.  
Solvents were of HPLC grade purity or higher.  M1G was synthesized as previously 
described (230).  Rat liver cytosol was prepared by established methods (231). Purified 
bovine XO was purchased from CalBiochem (La Jolla, CA).  HPLC-UV separations were 
performed on a Waters 2695 autosampler and binary pump with a Waters 2487 dual 
wavelength UV detector (Milford, MA).  LC-MS/MS spectra were obtained on a 
ThermoFinnigan LCQ Deca-XP Ion Trap (San Jose, CA) with an inline Agilent 1100 
series dual binary pump (Santa Clara, CA).  Synthetic chemicals were purified by flash 
chromatography on a Biotage SP1 Instrument (Uppsala, Sweden). 
 
M1G treatment of rats 
Animal protocols were performed under approval of Vanderbilt University and in 
accordance with the Institutional Animal Care and Use Committee policies.  Male 
Sprague Dawley rats (225-250 g) with vascular catheters surgically implanted in the 
femoral and jugular veins were obtained from Charles River Laboratories (Wilmington, 
MA) and housed in shoebox cages.  Animals were transferred to metabolism cages prior 
to dosing and allowed to feed ad libitum throughout the experiment.  The M1G dosing 
solution (5 mg/kg) was prepared in sterile saline and administered in the jugular catheter 
in approximately 0.5 mL of total volume over 45 s and flushed with 0.4 mL of sterile 
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heparinized saline.  Urine and feces were collected over intervals (pre-dose, 0-4, 4-6, 6-
10, and 10-24 h).  All samples were stored at -80 °C until sample work-up. 
 
Sample work-up and analysis 
A sample of urine (25% of the total collected volume) was extracted by adding 2x 
volumes ethanol followed by 2x volumes chloroform and mixed vigorously.  The phases 
were separated by centrifugation, the bottom organic layer was removed, and the 
remaining aqueous layer was extracted again with 2x volume of chloroform. The organic 
layers were pooled, dried under nitrogen, and reconstituted in potassium phosphate (0.2 
M, pH 7.8). Samples (10 µL) were loaded onto a Phenomenex Luna C18(2) column (2.0 
x 250 mm, 5 µm, Torrence, CA) equilibrated with 90% solvent A (0.5% formic acid in 
H2O) and 10% solvent B (0.5% formic acid in methanol) at a flow rate of 0.3 mL/min.  
The solvent was programmed as follows: a linear gradient from equilibration conditions 
to 20% B in 10 min, holding at 20% B for 10 min, increasing to 80% B in 0.1 min, 
holding for 5 min, decreasing to 10% B in 0.1 min and, re-equilibrating to initial 
conditions.  Eluting compounds were detected by LC/MS.  Positive ion ESI was 
employed with the following parameters: spray voltage = 4.0 kV; capillary temperature = 
325 °C; sheath gas = 52 psi; tube lens offset = 46 V; auxiliary gas = 56.  Samples were 
analyzed by selected-ion monitoring. 
 
Liver cytosol incubations 
All sample preparations were performed at 4 °C.  The final incubation conditions 
for the kinetic determinations contained 5 mg/mL rat liver cytosol, varied concentrations 
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of either M1G (0.5, 10, 25, 50, 100, 150, 200, and 250 µM) or 6-oxo-M1G (5, 20, 40, 60, 
80, 100, 150, 200, 400, 600, and 900 µM) and 0.4% DMSO in 0.2 M potassium 
phosphate (pH 7.8). IC50 determinations were carried out in 0.2 M potassium phosphate 
(pH 7.8), and 5 mg/mL rat liver cytosol at the calculated Km for each substrate (M1G = 
105 µM and 6-oxo-M1G = 210 µM).  The inhibitors were diluted in DMSO (0.4% total 
reaction volume).  Reagents were equilibrated to 37 °C for 5 min and the reaction 
initiated by addition of substrate.  Reactions were terminated after 60 min by adding 2 
volumes of ice-cold ethanol, vortexed, and extracted twice with 2 volumes of chloroform.  
The extracts were evaporated under nitrogen, reconstituted in H2O, and analyzed by 
HPLC-UV.  Extraction of M1G from rat liver cytosol into ethanol: chloroform resulted in 
a 60 to 70% recovery from rat liver cytosol incubations.  Samples were separated on a 
Phenomenex Luna C18(2) column (4.6 x 250 nm, 5 µm) equilibrated with 90% solvent A 
(0.5% formic acid in H2O) and 10% solvent B (0.5% formic acid in methanol) at a flow 
rate of 1.0 mL/min.  The solvent was programmed as follows: a linear gradient from the 
equilibration conditions to 20% B in 10 min, holding at 20% B for 10 min, increasing to 
80% B in 0.1 min, holding for 5 min, decreasing to 10% B in 0.1 min, and re-
equilibrating to initial conditions. Samples from the kinetic determinations were 
quantified in reference to a standard curve prepared by spiking known concentrations of 
either M1G (0.5. 25, 50, 100, 200, 300 µM) or 6-oxo-M1G (5, 50, 100, 300, 500, 700, 900 
µM) into 5 mg/mL rat liver cytosol solutions followed immediately by termination, 
extraction, and analysis as outlined above. Extraction of M1G from rat liver cytosol into 
ethanol: chloroform resulted in a 40 to 50% recovery from rat liver cytosol incubations.  
All incubations and standards were performed in triplicate.  The IC50 values were 
  129 
calculated based on inhibition of substrate consumption (M1G) or product production 
(2,6-dioxo-M1G) in reference to the vehicle (DMSO) control. Vmax/Km and IC50 values 
were calculated with Prism software (Version 4.0c) using a nonlinear regression one-site 
binding and one-site competition models, respectively. 
 
Biochemical synthesis of M1G metabolites 
M1G was incubated at 250 µM in purified bovine XO (0.1 U) and allowed to react 
for 60 min.  Incubations were pooled in a separatory funnel and mixed with 100 mL of 
ethanol, followed by 100 mL chloroform and shaken vigorously.  The bottom organic 
layer was removed and the extraction was repeated a second time.  The organic layers 
were pooled, dried with magnesium sulfate, and evaporated to dryness.  The remaining 
residue was dissolved in HPLC-grade H2O and purified by semi-preparative HPLC on a 
Phenomenex Luna C18(2) column (10 x 250, 10 µm).  Isocratic elution (5 mL/min, 95:5 
(H2O: methanol), containing 0.5% formic acid) provided baseline resolution for eluting 
peaks: M1G (~20 min), 6-oxo-M1G (~24 min), and 2,6-dioxo-M1G (~30 min).  Each peak 
was collected, pooled, and extracted as above (twice with 2x volume ethanol/chloroform, 
pooled, dried and evaporated).  The remaining product was attached to a vacuum pump to 
remove residual formic acid carried over from HPLC mobile phase.  Samples were 
dissolved in d6-DMSO and analyzed on a 400 MHz NMR. 
Pyrimido[1,2-f]purin-6,10(3H,5H)-dione (6-oxo-M1G). 1H-NMR (400 MHz, d6-
DMSO): δ 8.64 (d, 1H, J = 8 Hz, H8), 8.06 (s, 1H, H2), 6.21 (m, 1H, J = 8 Hz, H7).  ESI-
MS m/z: 204.3. 
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Pyrimido[1,2-f]purin-2,6,10(1H,3H,5H)-trione (2,6-dioxo-M1G). 1H-NMR (400 
MHz, d6-DMSO): δ 10.73 (s, 2.5H, N1/N3-H), 8.56 (d, 1H, J = 8 Hz, H8), 6.18 (m, 1H, J 
= 8 Hz, H7).  1H-NMR (400 MHz, d6-DMSO with D2O): δ 8.57 (d, 1H, J = 8 Hz, H7), 
6.20 (m, 1H, J = 8 Hz, H7). ESI-MS m/z: 220.3. 
Chemical synthesis of pyrimido[1,2-f]purin-6,10(3H,5H)-dione (6-oxo-M1G).  
6-Oxo-M1dG synthesis was carried out as described with minor modifications (157).  The 
resulting product, 6-oxo-M1dG, was purified by reversed phase chromatography on a C-
18 Biotage cartridge (25+S).  The pooled fractions were subjected to acid hydrolysis (0.1 
N HCl for 60 min) and re-purified on a C-18 Biotage cartridge.  The resulting product 
was analyzed by LC-MS and NMR spectroscopy to confirm the structure.  1H-NMR (400 
MHz, d6-DMSO): δ 8.62 (d, 1H, J = 8 Hz, H8), 8.04 (s, 1H, H2), 6.18 (d, 1H, J = 8 Hz, 
H7).  ESI-MS m/z: 204.3. 
HMBC analysis of M1G-M1 (6-oxo-M1G). HMBC experiments were acquired 
using an 11.7 T Oxford magnet equipped with a Bruker DRX console operating at 500.13 
MHz and a 5 mm cryogenically cooled NMR probe.  J1(C-H) filtered HMBC experiments 
were acquired using a 2048 x 256 data matrix, a J1(C-H) value of 9 Hz for detection of 
long range couplings resulting in an evolution delay of 55ms,  J1(C-H) filter delay of 145 
Hz (34 ms) for the suppression of one-bond couplings, a recycle delay of 1.5 s and 64 
scans per increment. The HMBC data was processed using a p/2 shifted squared sine 
window function and displayed in magnitude mode. 
Saturation transfer NMR analysis of M1G-M1 (6-oxo-M1G). Routine (black 
trace) and saturation transfer (red trace) 1H-NMR experiments were acquired using a 9.4 
T Oxford magnet equipped with a Bruker AV-I console operating at 400.13 MHz.  
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Experimental conditions for standard 1H-NMR experiments included 12 ppm spectral 
sweep width, recycle delay of 1.5 s and 16 number of scans.  Experimental parameters for 
the saturation transfer experiment included a 6 ppm spectral window, 8k data points and 
1.5 s recycle delay.  Saturation was achieved using presaturation with a normal Bruker 
presaturation pulse program. 
 
Results 
 
Metabolism of M1G in rat liver cytosol 
Based on our previous studies with M1dG, we began our investigation of M1G 
metabolism with liver cytosol.  We hypothesized that M1G would undergo metabolism in 
a manner qualitatively similar to that of M1dG and that XOR and AO would be involved 
in the metabolism.  To test these hypotheses, we performed incubations in the presence of 
characteristic inhibitors of XOR and AO (allopurinol and menadione, respectively).  
Chemically synthesized M1G was incubated at 50 µM in rat liver cytosol (5 mg/mL) for 
varied times (0, 15, 30, and 60 min).  Allopurinol and menadione (160 µM) were also 
added to selected reactions and stopped after 30 min.  Metabolism of M1G was monitored 
by reversed phase HPLC coupled to UV detection, which allowed for the separation and 
detection of incubation products.  This analysis demonstrated a time-dependant decrease 
in M1G peak area (Figure 49) throughout the duration of the incubation.  The HPLC 
product profile revealed the appearance of a single metabolite (M1G-M1) following 15 
min of incubation.  Further analysis revealed the appearance of a second metabolite 
(M1G-M2) after 30 min of incubation and continued production of both metabolites at 60 
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min. Allopurinol co-incubation resulted in the total inhibition of metabolism, whereas the 
menadione-containing sample exhibited an increase in total metabolism (Figure 49) as 
seen for M1dG (157) and other XOR substrates (245, 277).  The HPLC-UV traces did not 
reveal any additional peaks associated with M1G metabolism in the presence or absence 
of inhibitors.  Subsequent analysis of the incubation mixtures by LC-MS revealed 
successive additions of 16 amu to M1G, which resulted in the following increases: M1G 
(m/z = 188.3) → M1G-M1 (m/z = 204.3) → M1G-M2 (m/z = 220.3)  (Figure 50). 
 
Identification of M1G metabolites 
As suggested by our in vitro observations in rat liver cytosol, M1G was 
investigated for its ability to undergo metabolism in incubations containing purified 
bovine XO. M1G was rapidly oxidized by purified XO producing both M1G-M1 and 
M1G-M2 (Figure 50); therefore, purified bovine XO served as a platform to generate the 
metabolites for purification.  The reaction was scaled up to 50 mL of total reaction 
volume and divided into separate 5 mL incubations.  M1G was incubated at a 
concentration of 250 µM and allowed to react for 60 min.  Incubations were pooled, 
extracted, purified by semi-preparative HPLC, and analyzed on a 400 MHz NMR. 
Preliminary 1H-NMR analysis of M1G-M1 (m/z = 204.3) revealed a spectrum  
rather similar to the previously characterized 6-oxo-M1dG (Figure 51).  The appearance 
of correlated peaks at 8.64 ppm (doublet) and 6.21 ppm (multiplet) suggested oxidation 
on the pyrimido ring, since the singlet assigned as H2 (8.06 ppm) remained in the 
spectrum. Further NMR studies by HMBC analysis clearly revealed three-bond couplings 
of the proton assigned as H8 to C4a, C6 and C10 (Figure 52).  To verify the assignment 
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Figure 49.  Time-course of M1G consumption in rat liver cytosol and the effect of 
allopurinol and menadione on M1G metabolism.  All samples were incubated at 37 °C 
with 5 mg/mL rat liver cytosol and 50 µM M1G. (A) Time-dependent decrease in M1G 
peak area following incubation in rat liver cytosol.  (B) Effect of vehicle (DMSO), 
allopurinol, and menadione on M1G consumption after 30 min of incubation in rat liver 
cytosol. 
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Figure 50.  LC/MS chromatograms from in vitro and in vivo metabolism of M1G.  
Samples were analyzed by selected-ion monitoring of m/z = 188.3 (), 204.3 (---) and 
220.3 (…).  LC/MS profiling of in vitro incubations with rat liver cytosol (A) and bovine 
XO (B) revealed the successive additions of 16 amu to the parent ion M1G (m/z = 188.3).  
(C) LC/MS analysis of urine collected from male Sprague Dawley rats that received iv 
M1G (5 mg/kg). 
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Figure 51.  1H-NMR of M1G metabolites derived from biochemical or chemical 
synthesis.  All samples were analyzed on a 400 MHz NMR in d6-DMSO.  (A) 6-oxo-
M1G was biochemically synthesized with bovine XO and (B) generated through chemical 
sythesis.  (C) 2,6-dioxo-M1G was biochemically synthesized with bovine XO.  (D) 
Addition of D2O to the 2,6-dioxo-M1G sample resulted in the loss of the chemical shift at 
10.73 ppm indicating an exchangeable proton. 
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Figure 52.  HMBC spectrum of biochemically synthesized 6-oxo-M1G (M1G-M1). 
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of this structure, an authentic standard of 6-oxo-M1G was synthesized. The synthetic 
standard displayed identical spectral properties to M1G-M1 (Figure 51).  Together, these 
data confirmed the structure of M1G-M1 as 6-oxo-M1G. 
The peaks appearing at 7.27 and 6.84 ppm in the biochemically purified 6-oxo-
M1G spectrum were determined to arise from impurities in the sample.  This was 
confirmed by HMBC (Figure 52) and saturation transfer experiments (Figure 53).  The 
HMBC revealed no three-bond couplings of these peaks to corresponding nuclei in the 
carbon spectrum, while the saturation transfer experiment determined these peaks did not 
arise from a chemical equilibrium (i.e., equilibrium between the amide and imin-ol about 
C6 and N5 on the pyrimido ring).  Furthermore, no trace of these peaks was observed in 
the authentic standard of 6-oxo-M1G.  Therefore, the peaks at 7.27 and 6.84 ppm were 
reasoned to be impurities derived from the purification process.  The observed singlet at 
6.21 ppm also appeared to be an impurity overlapping the signal from the H7 doublet.  
However, its designation was not identified completely due to the overlap (this was also 
observed with the M1G-M2 sample, see below). 
1H-NMR analysis of M1G-M2 (m/z = 220.3) identified correlated peaks at 8.56 
ppm (doublet) and 6.18 ppm (singlet) suggesting that the C7 and C8 protons remained on 
the pyrimido ring. Notably, the singlet at 8.06 ppm from the 6-oxo-M1G spectrum was 
not present in the M1G-M2 sample, and a new singlet arose downfield at 10.73 ppm 
(Figure 51).  The downfield peak appearance and the disappearance of the singlet at 8.06 
ppm are consistent with oxidation at C2.  The addition of D2O to the sample resulted in 
the disappearance of the peak at 10.73 ppm suggesting that this is an exchangeable proton 
(Figure 51). Oxidation at C2 on the imidazole ring of 6-oxo-M1G is similar to oxidation 
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Figure 53.  Saturation transfer 1H-NMR spectra of biochemically synthesized 6-oxo-
M1G. 
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at C8 on dG in the formation of 8-oxo-dG.  8-Oxo-dG was used as a reference when 
assigning the positions of oxidation on M1G.  The oxidation of dG at C8 led to the 
appearance of a downfield peak at 10.75 ppm (in d6-DMSO) attributed to the N7-proton 
(278).  Therefore, the chemical shift of 10.73 ppm was assigned to N1/N3-H’s and the 
structure of M1G-M2 was assigned as 2,6-dioxo-M1G. 
Peak impurities were also found in the 2,6-dioxo-M1G spectrum.  Most notable 
was the appearance of the singlet at 6.18 ppm, which also appeared in the spectrum of the 
biochemically synthesized 6-oxo-M1G.  In the 2,6-dioxo-M1G spectrum, the singlet was 
likely overlapping with the doublet attributed to the H7 proton at 6.18 ppm, which was 
inferred from the correlation seen in the 2D 1H-NMR analysis.  The amount of material in 
the 2,6-dioxo-M1G was low, and some impurity signals were evident. 
 
In vivo administration of M1G to male Sprague Dawley rats 
To determine whether the enzymatic oxidations could occur in vivo, male Sprague 
Dawley rats were dosed iv with 5 mg/kg M1G.  The animals (n = 3) were housed in 
metabolic cages to collect urine and feces over the course of the experiment.  Urine 
samples were extracted, chromatographed on a reversed phase column and analyzed by 
LC-MS using selected ion monitoring. The parent compound (M1G, m/z = 188.3) and the 
metabolites 6-oxo-M1G (m/z = 204.3) and 2,6-dioxo-M1G (m/z = 220.3) were monitored 
on separate channels of the same run.  Analysis of the in vivo urine samples revealed 
molecular ions corresponding to M1G (7.9 min), 6-oxo-M1G (8.9 min), and 2,6-dioxo-
M1G (9.9 min).  The molecular ions displayed identical retention times as the in vitro-
generated metabolites from XOR and rat liver cytosol incubations (Figure 50), and the 
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authentic standard for M1G and 6-oxo-M1G.  The in vivo samples contained a background 
peak with a molecular ion of 220.3 (m/z) that eluted at 9.4 min.  This peak also appeared 
in pre-dose and late time-point urine samples and did not correlate with 2,6-dioxo-M1G 
production. 
 
 
 
 
 
 
 
 
 
 
 
Figure 54.  Sequential metabolism of M1G to 6-oxo-M1G and 2,6-dioxo-M1G. 
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Kinetic determinations in rat liver cytosol with M1G and 6-oxo-M1G 
Following the characterization of the M1G metabolites (Figure 54), an 
investigation into their rates of formation was undertaken in vitro with rat liver cytosol.  
Our preliminary data suggested M1G consumption in rat liver cytosol lead to the 
production of 6-oxo-M1G, which then underwent an additional oxidation to 2,6-dioxo-
M1G.  Based on inhibition experiments, XOR appeared to be involved in the metabolism.  
M1G consumption was dependent on protein concentration and time of incubation 
in rat liver cytosol.  At 5 mg/mL rat liver cytosol, M1G consumption was linear out to 60 
min of incubation.  The kinetic determinations were performed by incubating M1G at 
varied concentrations for 60 min in the presence of 5 mg/mL rat liver cytosol.  The 
resulting products were extracted, separated by reversed phase chromatography, and 
analyzed by UV absorbance. M1G consumption was quantified by reference to a standard 
curve that was prepared by spiking known concentrations of M1G into rat liver cytosol 
and terminating the reaction at time-zero.  This was followed by extraction and analysis 
identical to the incubated samples. 
Figure 55 shows the velocity vs. substrate concentration (v vs. [S]) plot for the 
consumption of M1G.  The Km was calculated to be 105 µM and the Vmax at 126 pmol 
min-1 mg-1.  The total peak area of metabolites (both 6-oxo-M1G and 2,6-dioxo-M1G peak 
areas) vs. [S] was also plotted (Figure 55) to determine a Km of 118 µM, which was in 
good agreement with that for substrate consumption.  A plot of the peak areas for each 
metabolite vs. [S] (Figure 55) revealed that as the M1G concentration increased, the ratio 
of 2,6-dioxo-M1G to 6-oxo-M1G decreased.  This suggested M1G is capable of out-
competing 6-oxo-M1G at concentrations at or above its Km in rat liver cytosol. 
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Figure 55.  Kinetic determinations for M1G consumption in rat liver cytosol.  (A) 
M1G was incubated in rat liver cytosol (5 mg/mL at 37 °C for 60 min) and quantified by 
reference to a standard curve.  The data was analyzed by non-linear regression and fit to a 
one-site binding model: Km = 105 µM and Vmax = 126 pmol min-1 mg-1 (Vmax/Km = 0.005 
min-1 mg-1).  (B) Plot of total metabolite peak area (both 6-oxo-M1G and 2,6-dioxo-M1G) 
vs. [S] (Km = 118 µM).  (C) Plot of peak areas vs. [M1G] for 6-oxo-M1G () and 2,6-
dioxo-M1G (). 
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Since the exact concentration of enzyme(s) in the rat liver cytosol was unknown, 
the relative catalytic efficiency for turnover was calculated by dividing the Vmax by the Km 
and normalizing the total protein concentration.  Performing this analysis on the above 
data yielded a Vmax/Km of 0.005 min-1 mg-1 for M1G consumption in rat liver cytosol.  An 
additional v vs. [S] determination of M1G consumption was also performed in a separate 
preparation of rat liver cytosol, which yielded a Km of 79 µM, a Vmax of 84 pmol min-1 
mg-1 and a Vmax/Km of 0.004 min-1 mg-1.  The relative catalytic efficiencies of the turnover 
were in good agreement, while the Km and Vmax were not.   This likely reflects the 
differences in makeup between the two separate preparations of rat liver cytosol.  
Therefore, one may imply the relative amounts of XOR and AO (and any other enzyme 
that may be involved) in each preparation vary to a degree, resulting in altered kinetic 
parameters. 
Kinetic determinations were also performed on the transformation of 6-oxo-M1G 
to 2,6-dioxo-M1G in rat liver cytosol.  Synthetic 6-oxo-M1G was synthesized and used in 
v vs. [S] determinations.  The incubations and analyses were performed as described for 
M1G.  Based on substrate consumption, a Km for 6-oxo-M1G was calculated at 210 µM 
and a Vmax at 257 pmol min-1 mg-1.  The Vmax/Km was 0.005 min-1 mg-1, which was the 
same value calculated for M1G consumption in rat liver cytosol.  Therefore, it appears 
that both substrates are equally efficient in their turnover; however, M1G possesses a 
higher apparent affinity (lower Km) for the active site(s).  This would allow M1G to out-
compete 6-oxo-M1G at concentrations at or above the Km for M1G consumption, which 
was observed in the product profile from the M1G kinetic determinations. 
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Figure 56.  IC50 determinations in rat liver cytosol with allopurinol using M1G and 
6-oxo-M1G as substrates.  (A) Using M1G as a substrate, IC50 values were determined 
based on substrate (M1G) consumption (960 nM) and (B) inhibition of 2,6-dioxo-M1G 
production (500 nM).  (C) Using 6-oxo-M1G as a substrate, the IC50 value was 
determined based on inhibition of 2,6-dioxo-M1G production (360 nM). 
 
 
 
IC50 determinations with allopurinol in rat liver cytosol 
IC50 determinations were performed using varied concentrations of allopurinol in 
rat liver cytosol in the presence of M1G and 6-oxo-M1G.  All substrates were incubated at 
their predetermined Km. The percent inhibition was measured by inhibition of substrate 
consumption or product production.  These studies attempted to demonstrate the 
involvement of XOR and AO in the metabolism of M1G and 6-oxo-M1G.  An IC50 
determination was first carried out with allopurinol using M1G as a substrate.  The 
amount of M1G consumption at each concentration of allopurinol was determined based 
on peak area absorbance of M1G and referenced to the vehicle control (no allopurinol) for 
percent consumption.  Based on the inhibition of substrate consumption, an IC50 of 960 
nM was determined (Figure 56).  At saturating concentrations of allopurinol (> 20 µM), 
25% of the M1G was still consumed.  This implied an additional enzyme(s) other than 
XOR metabolized M1G (presumably AO).  Analysis of the product profile revealed two 
findings.  First, no correlation existed between 6-oxo-M1G production and allopurinol 
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concentration (i.e., IC50 determination based on the inhibition of 6-oxo-M1G production 
could not be determined).  Second, at saturating concentrations of allopurinol (> 20 µM), 
there was incomplete inhibition of 6-oxo-M1G and total inhibition of 2,6-dioxo-M1G 
production (IC50 = 500 nM).  Together, these data suggested that XOR catalyzed the 
conversion of M1G to both 6-oxo-M1G and 2,6-dioxo-M1G, whereas the remaining 
enzyme activity, presumably AO, only converted M1G to 6-oxo-M1G. 
Following these results, the IC50 was then determined with allopurinol using 6-
oxo-M1G as a substrate.  The amount of 2,6-dioxo-M1G produced at each concentration 
of allopurinol was determined based on peak area absorbance and referenced to the 
vehicle control (no allopurinol) for percent inhibition.  This resulted in an IC50 
determination of 360 nM.  These data confirmed that at saturating concentrations of 
allopurinol (> 10 µM), no 2,6-dioxo-M1G was produced and further implied that XOR, 
and not AO, was the enzyme that acted on 6-oxo-M1G in vitro.  In a separate set of 
experiments, we investigated the contribution of AO to the metabolism of M1G in rat 
liver cytosol. Samples were incubated in the presence of M1G (105 µM) and a saturating 
concentration of allopurinol (40 µM).  To these reactions, increasing concentrations of 
menadione were added to generate an IC50 curve.  A dose-dependent decrease in M1G 
metabolism was observed with increasing concentrations of menadione (IC50 = 5 µM), 
which resulted in total inhibition of both 6-oxo-M1G and 2,6-dioxo-M1G formation at 
saturating concentrations of menadione (>300 µM). 
The IC50 with allopurinol was also calculated with the M1dG.  The kinetic 
determinations for M1dG conversion to 6-oxo-M1dG in rat liver cytosol were determined 
previously (157).  Upon co-incubation of M1dG (370 µM) with increasing concentrations 
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of allopurinol, an IC50 of 120 nM was determined.  It should be noted that at saturating 
concentrations of allopurinol (> 5 µM); the 6-oxo-M1dG production was minimized, but 
not completely inhibited.  This suggests that AO is also contributing to the enzymatic 
oxidation of M1dG in rat liver cytosol. 
 
Discussion 
DNA adducts arise directly from, and downstream of, exposure to endogenously 
produced ROS.  In the absence of repair, these adducts may lead to mutations (point and 
frameshift), strand breaks, arrest in cell division, and induction of apoptosis.  Successful 
repair of adducts leads to their removal from genomic DNA; thus, averting these 
deleterious effects.  Little is known about the fate of DNA adducts following their release 
from DNA.  Our results suggest that exposure of DNA adducts to endogenous oxidative 
enzymes results in metabolism (oxidation) of the adducts.  Oxidative metabolism of both 
deoxynucleoside-containing (157) and base adducts have now been observed. 
The base adduct, M1G, underwent sequential oxidative metabolism in vitro in rat 
liver cytosol to two separate metabolites – 6-oxo-M1G and 2,6-dioxo-M1G.  The 
production of each metabolite was also seen in vivo upon iv administration of M1G to 
male Sprague Dawley rats.  M1G, 6-oxo-M1G, and 2,6-dioxo-M1G were all excreted in 
the urine, suggesting that these metabolites may be suitable for evaluation as urinary 
biomarkers under physiological conditions.  The kinetic parameters of M1G and 6-oxo-
M1G metabolism were evaluated in rat liver cytosol.  These studies demonstrated that 
M1G has a lower Km than 6-oxo-M1G in rat liver cytosol, but each are metabolized with 
the same relative efficiency (Vmax/Km = 0.005 min-1 mg-1).  In comparison to M1dG, both 
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M1G and 6-oxo-M1G are better substrates (Vmax/Km for M1dG = 0.001 min-1 mg-1) and 
exhibited a lower Km (Table 7).  
 
Table 7.  Kinetic and IC50 determinations for M1G, 6-oxo-M1G and M1dG in rat 
liver cytosol. aIC50 determined based on inhibition of M1G consumption. bIC50 
determined based on inhibition of 2,6-dioxo-M1G production with M1G as a substrate. 
cValues taken from Otteneder et al. (157). 
 
 
 
 
 
 
 
M1G, 6-oxo-M1G, and M1dG all appear to undergo oxidative metabolism by 
similar enzymes; namely XOR and AO.  In rat liver cytosol, approximately 75% of the 
M1G metabolism (and all of the 6-oxo-M1G metabolism) can be attributed to XOR, as 
gauged by allopurinol inhibition.  It should be noted that the relative amount of AO to 
XOR activity in Sprague Dawley rat liver cytosol is low.  Other species, such as guinea 
pig and rabbit, often contain higher ratios of AO to XOR (252).  Therefore, the total 
contribution of AO towards the metabolism of M1G, 6-oxo-M1G, and M1dG may be 
underestimated in these studies. 
The metabolism of each substrate is inhibited by co-incubation with allopurinol in 
rat liver cytosol.  Co-incubation of menadione, in the absence of allopurinol, resulted in 
the stimulation of metabolism for each substrate (157).  This phenomenon of XO 
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stimulation by menadione was first observed by Mahler et al. (243), continues to appear 
in the literature (234, 245, 277), and is seen in the metabolism of M1dG (157).  
Stimulation by menadione was mitigated when saturating concentrations of allopurinol 
were used.  Thus, this effect can be attributed to the stimulation of XO metabolism.  
When saturating concentrations of allopurinol were co-incubated with increasing 
concentrations of menadione, the ability of rat liver cytosol to metabolize M1G was 
abolished (IC50 = 5 µM). 
  Under physiological conditions, XOR is believed to exist as a dehydrogenase 
(XD) (239).  Ex-vivo manipulations of the enzyme leads to irreversible proteolytic 
cleavage, or reversible oxidation (formation of disulfides), generating the oxidase form 
(240, 241).  Both forms of the enzyme are catalytically competent and capable of using 
molecular oxygen as a terminal electron acceptor; although, XO is more efficient that XD 
at utilizing O2 (242). XD can use NAD+, which increases the efficiency of catalysis, and 
has no effect on XO (242).  Preliminary evaluation of rat liver cytosol did not reveal 
enhanced metabolism in the presence of NAD+, suggesting the oxidase form is 
responsible for the oxidation of M1dG, M1G, and 6-oxo-M1G in the liver cytosols 
evaluated. 
The enzymatic conversion of M1G to two separate, oxidized metabolites is unique 
to the free base, and not observed in metabolism studies with the deoxynucleoside, 
M1dG.  Furthermore, the sites of metabolism on M1G are similar to the sites of oxidation 
on hypoxanthine, which is converted to xanthine, which is then oxidized to uric acid by 
XOR.  Hypoxanthine oxidation occurs first at the 2-position on the pyrimidine ring 
(analogous to the 6-position on the pyrimido ring of M1G) and subsequently on the 8-
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position of the imidazole ring (analogous to the 2-position on the imidazole ring of M1G).   
Further metabolism of 6-oxo-M1dG on the imidazole ring is likely prevented by the steric 
hindrance from the deoxyribose moiety. 
When exogenously administered to male Sprague Dawley rats (5 mg/kg), M1G 
was oxidized in vivo, and the principal metabolite (based on relative ionization) appeared 
to be 6-oxo-M1G with 2,6-dioxo-M1G less abundant.  These results were in agreement 
with the in vitro data, which suggested that at high concentrations M1G could out-
compete 6-oxo-M1G, thus minimizing the amount of 2,6-dioxo-M1G produced.  One may 
expect the ratio of 2,6-dioxo-M1G to 6-oxo-M1G to increase in vivo when lower 
concentrations of M1G are present.  However, the sensitivity at later time-points during 
this analysis was too low to reliably address this hypothesis.  When low concentrations of 
M1G were incubated with rat liver cytosol, a near complete conversion of M1G to 2,6-
dioxo-M1G was observed (Figure 57), which would suggest that upon physiological 
generation of M1G in vivo, 2,6-dioxo-M1G may be the main species observed. 
The main route for repair of M1dG residues in genomic DNA appears to be the 
NER pathway.  Despite the fact that the base excision repair and DNA glycosylase 
enzymes have never been definitively associated with M1dG repair in vitro, one cannot 
rule out the involvement of these repair pathways in vivo.  Considering the high degree of 
structural similarity between M1dG and the etheno adducts, it seems likely that a DNA 
glycosylase may catalyze the removal of M1G from DNA. 
The concept that repaired DNA adducts may undergo metabolism prior to urinary 
excretion has been previously investigated (266). Wang and Hecht evaluated the in vivo 
stability of the N-nitrosopyrrolidine (NPYR) guanine adduct, 2-amino-6,7,8,9-tetrahydro-
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9-hydroxypyrido[2,1-f]purin-4(3H)-one (N7,C8-NPYR-Gua), by ip administration of 
[14C]-labeled N7,C8-NPYR-Gua to male F-344 rats.  Results from this study 
demonstrated that approximately 52% of the dose was recovered in the urine following 
48 h of collection.  HPLC with radioflow analysis revealed than 90% of the urinary 
radioactivity was recovered as the parent molecule (N7,C8-NPYR-Gua), while the other 
10% was distributed across several minor peaks – suggestive of metabolism. Neither the 
fate of the remaining 48% of the administered radioactivity, nor the identity of the peaks 
in the urine profile was commented on by the investigators.  It seems likely that N7,C8-
NPYR-Gua was eliminated in the feces and that N7,C8-NPYR-Gua underwent significant 
biliary uptake into the bile (as either the parent molecule or as a metabolite(s)).  These 
data demonstrate that exogenously administered adducts are subject to metabolism in 
vivo, with elimination presumably proceeding through multiple pathways. 
These studies demonstrate that in addition to deoxynucleoside adducts, purine 
base adducts are subject to metabolism following repair in vivo (157, 266).  In the case of 
M1G, the base is a better substrate for enzymatic oxidation than the deoxynucleoside 
(M1dG).  Endogenous lesions are subject to multiple repair pathways.  Following repair, 
these adducts are exposed to membrane-bound and cytosolic enzymes.  Structural analogs 
of M1G and M1dG, and other exocyclic ring adducts are likely candidates to undergo 
metabolism in vitro and in vivo.  Therefore, a yet undiscovered population of biomarkers 
may exist to assess exposure to oxidative damage in vivo. 
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Figure 57.  Metabolic processing of M1dG. BER, base excision repair; RLC, rat liver 
cytosol. 
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CHAPTER VI 
 
METABOLISM OF ETHENO AND PROPANO ADDUCTS IN VITRO 
 
Summary 
Non-invasive strategies for the analysis of endogenous DNA damage are of 
interest for the purpose of monitoring in vivo exposure to biologically produced 
chemicals.  We have focused our research on the peroxidation-derived pyrimidopurinone 
dG adduct, M1dG, and factors that may effect its appearance in urine.  Recent studies 
have demonstrated that both M1dG and its free base M1G are subject to oxidative 
metabolism in vitro and in vivo.   In fact, the base is a better substrate for in vitro 
metabolism than the deoxynucleoside (~ 5-fold).  This observation suggests structurally 
similar exocyclic base adducts maybe good candidates for oxidative metabolism.  We 
investigated several endogenously occurring etheno adducts (1,N2-ε-Gua, 1,N6-ε-Ade, 
3,N4-ε-Cyd, heptanone-1,N2-ε-Gua) and their corresponding deoxynucleosides for 
metabolism in vitro.  Both 1,N2-ε-Gua and heptanone-1,N2-ε-Gua underwent oxidative 
metabolism in vitro in incubations with rat liver cytosol.  Heteronuclear NMR 
experiments revealed oxidation occurred on the imidazole ring for each substrate.  
Additional experiments with structural analogs of M1G (5,6-dihydro-M1G and PGua) 
suggested the aromatic nature of the exocyclic ring effects oxidation.  Our analysis 
revealed tertiary heterocyclic imine carbons are targeted for oxidation.  Additionally, the 
deoxynucleoside adducts 1,N2-ε-dG and 1,N6-ε-dA are subject to phosphorolysis by 
purine nucleoside phosphorylase (PNP) in rat liver.  Together these data suggest that 
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multiple exocyclic adducts undergo metabolism in vitro in rat liver cytosol to oxidized 
and phosphorolyzed products—in some instances in succession.  The multiple pathways 
of biotransformation produce an array of products from exocyclic DNA adducts.  Thus, 
our data suggests the metabolic processing of exocyclic adducts should be considered as 
part of development projects designed to non-invasively quantify their in vivo levels. 
 
Introduction 
 The endogenous DNA lesion, M1dG, is derived from reactions of the lipid 
peroxidation product, MDA, or the DNA peroxidation product, base propenal (42, 58, 96-
98, 106, 107, 257). M1dG, is miscoding in bacteria and humans producing mainly M1dG 
→ T transversions and  M1dG → A transitions (88, 119-121, 258).  When site-
specifically incorporated into a reiterated repeat sequence (5´-CGr-3´) M1dG induces 
frameshift mutations (121).  Genetic and biochemical evidence suggests that M1dG is 
released from by NER (120, 122), which results in the formation of the free 
deoxynucleoside, M1dG, following repair.  The free base, M1G, is a putative product of 
base excision repair by glycosylase action.  However, no evidence suggests the role of 
base excision repair in the release of M1G from DNA, which is surprising since several 
structurally similar etheno adducts (1,N2-ε-Gua, N2,3-ε-Gua, 1,N6-ε-Ade, 3,N4-ε-Cyd) are 
reported substrates for DNA glycosylases (217-223). 
Our laboratory has recently described the metabolic processing of M1dG and M1G 
(157, 261, 267).  M1dG undergoes a single oxidation on the 6-position of the pyrimido 
ring to 6-oxo-M1dG whereas M1G undergoes successive oxidations: first at the 6-position 
and then on the 2-position of the imidazole ring to produce 6-oxo-M1G and 2,6-dioxo-
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M1G, respectively.  It was interesting to observe oxidation on the imidazole ring with 
M1G, which was not observed with M1dG, indicating the steric bulk of the deoxyribose   
affects the site of oxidation.  Comparing the turnover of M1dG, M1G, and 6-oxo-M1G in 
rat liver cytosol demonstrated that the bases were better substrate for oxidation than the 
deoxynucleoside (~5-fold).  Based on these observations, we hypothesized that other 
exocyclic adducts were likely to undergo oxidation, with the imidazole ring being a likely 
target for oxidation.  Due to the higher apparent turnover of the M1G bases, we targeted 
our investigation to base adducts that are released from DNA by glycosylase action.  
Furthermore, we undertook a structure activity relationship with several analogs of M1dG 
to determine structural requirements for the oxidation of exocyclic adducts.  
 
Experimental Procedures 
 
Chemicals and Reagents 
All chemicals were obtained from commercial sources and used as received.  
Solvents were of HPLC grade purity or higher.  M1dG, 6-oxo-M1dG, 5,6-dihydro-M1dG 
and PdG were synthesized as previously described (116, 259).  1,N2-ε-Gua (183), 1,N6-ε-
Ade (184), and 3,N4-ε-Cyd (182, 279) were synthesized by established methods.  Liver 
cytosols were prepared by established methods (231).  Bovine XO from buttermilk was 
obtained from CalBiochem (La Jolla, CA). PNP was purchased from Sigma (St. Louis, 
MO).  HPLC separations were performed on a Waters 2695 autosampler and binary 
pump with a Waters 2487 dual wavelength UV detector.  LC-MS/MS and LC-MSn 
spectra were obtained on either ThermoElectron Quantum or LTQ instruments. 
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Liver cytosol incubations and analysis 
1,N2-ε-Gua.  All sample preparation was performed on ice at 4 °C.  The final 
incubation conditions for the kinetic determinations contained 5 mg/mL rat liver cytosol, 
varied concentrations of 1,N2-ε-Gua (10, 25, 50, 75, 100, 150, 250, 500, 750 µM) 
dissolved in 0.1 N NaOH, and 0.4% DMSO in 0.8 M potassium phosphate (pH 7.6).  IC50 
determinations were carried out in 0.8 M potassium phosphate (pH 7.6) and 5 mg/mL rat 
liver cytosol at the calculated Km for 1,N2-ε-Gua (85 µM) with varied concentrations of 
allopurinol (320, 160, 50, 16, 5, 1.6, 0.5, 0.016, 0.005, 0.0016, 0.0 µM).  The inhibitor 
was diluted in DMSO (0.4% total reaction volume).  Reagents were equilibrated to 37 °C 
for 5 min and the reaction was initiated by the addition of substrate.  Reactions were 
terminated after 30 min by adding 0.5 mL ice cold ethanol, vortexed, and extracted twice 
with 2x volume chloroform.  The extracts were evaporated under nitrogen, and 
reconstituted in 0.1 N NaOH for the kinetic determinations and H2O for the IC50 
determinations.  The extraction of 1,N2-ε-Gua from rat liver cytosol in 
ethanol/chloroform resulted in a 70 to 80% recovery from rat liver cytosol incubations.  
Samples were separated on a Phenomenex Luna C18(2) column (4.6 x 250 nm, 5µ) 
equilibrated with 95% solvent A (0.5% formic acid in H2O) and 5% solvent B (0.5% 
formic acid in methanol) at a flow rate of 1 mL/min.  The solvent was programmed as 
follows:  a linear gradient from the starting solvent to 30% B in 15 min, increasing to 
80% B in 0.1 min, holding for 5 min, decreasing to 5% B in 0.1 min, and re-equilibrating 
at initial conditions for 5 min.  Eluting compounds were detected by UV absorbance at 
285 nm.  Samples from the kinetic determinations were quantified in reference to a 
standard curve prepared by spiking known concentrations of 1,N2-ε-Gua (2.5, 5, 50, 100, 
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250, 500, 750 µM) into 5 mg/mL rat liver cytosol solutions, followed immediately by 
termination, extraction, and analysis as outlined above.  All incubations and standards 
were performed in triplicate.  The IC50 values ere calculated on the basis of the inhibition 
of 1,N2-ε-Gua consumption in reference to the vehicle (DMSO) control.  Vmax/Km and 
IC50 values were calculated with Prism software (Version 4.0c) using nonlinear 
regression one-site binding and one-site competition models, respectively. 
1,N2-ε-dG, 3,N4-ε-dC, and 3,N4-ε-Cyd. All sample preparation was performed on 
ice at 4 °C.  The final incubation conditions contained 5 mg/mL rat liver cytosol, 100 µM 
of either 1,N2-ε-dG, 3,N4-ε-dC, or 3,N4-ε-Cyd dissolved in 0.1 M potassium phosphate 
(pH 7.4).  Inhibitors (allopurinol, menadione) were dissolved in DMSO with final 
incubation concentration of 160 µM (0.4% DMSO in the reaction). Reagents were 
equilibrated to 37 °C for 5 min and the reaction was initiated by addition of substrate.  
Reactions were terminated at intervals (0, 15, 30, and 60 min) by adding 0.5 mL ice cold 
ethanol, vortexed, and extracted twice with 2x volume chloroform.  The extracts were 
evaporated under nitrogen and reconstituted in 0.1 M potassium phosphate, pH 7.4, for 
HPLC-UV and -MS/MS analysis. 1,N2-ε-dG samples were separated as described above 
for 1,N2-ε-Gua. 3,N4-ε-dC, or 3,N4-ε-Cyd were separated on a Phenomenex Luna Phenyl-
Hexyl column (4.6 x 250 nm, 5µ) equilibrated with 90% solvent A (20 mM ammonium 
acetate, pH 7.0, in H2O) and 10% solvent B (20 mM ammonium acetate, pH 7.0, in 
methanol) at a flow rate of 1.0 mL/min.  The solvent was programmed as follows:  a 
linear gradient from the starting solvent to 50% B in 10 min, decreasing to 10% B in 0.1 
min and holding at initial conditions for 5 min. Eluting compounds were detected by UV 
absorbance at 254 and 285 nm.  All incubations were prepared in triplicate. 
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1,N6-ε-Ade and 1,N6-ε-dA. All sample preparation was performed on ice at 4 °C.  
The final incubation conditions contained 5 mg/mL rat liver cytosol, 40 µM 1,N2-ε-dA or 
1,N2-ε-Ade dissolved in 0.1 M potassium phosphate, pH 7.4, or 0.1 M Tris-HCl, pH 7.4 
buffers.  Reagents were equilibrated to 37 °C for 5 min and the reaction initiated by the 
addition of substrate.  Reactions were terminated at intervals (0, 5, 15, 30, and 60 min) by 
adding 0.5 mL ice cold ethanol, vortexed, and extracted twice with 2x volume 
chloroform.  The extracts were evaporated under nitrogen and reconstituted in 0.1 M 
potassium phosphate, pH 7.4, for HPLC-UV and -MS/MS analysis.  The extraction of 
1,N2-ε-dA  and 1,N2-ε-Ade from rat liver cytosol into ethanol/chloroform resulted in a 
70-80% recovery.  Samples were separated on a Phenomenex Synergi POLAR-RP 
column (2.0 x 150 nm, 4µ) equilibrated with 98% solvent A (0.5% formic acid in H2O) 
and 2% solvent B (0.5% formic acid in methanol) at a flow rate of 0.3 mL/min.  The 
solvent was programmed as follows:  a linear gradient from the starting solvent to 40% B 
in 10 min, holding at 40% B for three min, decreasing to 2% B in 0.1 min and holding at 
initial conditions for 7 min. Eluting compounds were detected by UV absorbance at 254 
and 275 nm.  All incubations were prepared in triplicate. 
Heptanone-1,N2-ε-Gua and heptanone-1,N2-ε-dG. All sample preparation was 
performed at room temperature.  The final incubation conditions for reactions contained 5 
mg/mL rat liver cytosol, and 50 µM of either heptanone-1,N2-ε-Gua or heptanone-1,N2-ε-
dG in 0.2 M potassium phosphate (pH 7.8).  Inhibitors (allopurinol, menadione, 
raloxifene) were dissolved in DMSO to a final incubation concentration of 160 µM (0.4% 
DMSO in the reaction).  Reagents were equilibrated to 37 °C for 5 min and the reaction 
was initiated by addition of substrate.  Reactions were terminated at intervals (0, 15, 30, 
  158 
and 60 min) by adding 0.5 mL ice-cold ethanol, vortexed, and put on ice.  The samples 
were extracted twice with 2x volume chloroform.  The organic layer was evaporated 
under nitrogen and reconstituted in methanol for HPLC-UV and -MS/MS analysis. 
Extraction of heptanone-1,N2-ε-Gua and heptanone-1,N2-ε-Gua metabolite from rat liver 
cytosol into ethanol/chloroform resulted in a >90% recovery.  Samples were separated on 
a Phenomenex Luna C18(2) column (4.6 x 250 nm, 5µ) equilibrated with 70% solvent A 
(0.5% formic acid in H2O) and 30% solvent B (0.5% formic acid in methanol) at a flow 
rate of 1 mL/min.  The solvent was programmed as follows:  a linear gradient from the 
starting solvent to 70% B in 20 min, increasing to 90% B in 0.1 min, holding for 5 min, 
decreasing to 30% B in 0.1 min, and re-equilibrating at initial conditions for 5 min.  
Eluting compounds were detected by UV absorbance at 300 nm. All incubations and 
standards were performed in triplicate. 
  5,6-Dihydro-M1dG, 5,6-dihydro-M1G, PdG, PGua, γ-OH-PdG, and α-OH-PdG. 
All sample preparation was performed on ice at 4 °C.  The final incubation conditions 
contained 5 mg/mL rat liver cytosol and 200 µM substrate dissolved in 0.1 M potassium 
phosphate (pH 7.4).  Reagents were equilibrated to 37 °C for 5 min and the reaction 
initiated by the addition of substrate.  Reactions were terminated at intervals (0, 20, 40, 
and 60 min) by adding 0.1 mL ice cold methanol, vortexed, and centrifuged at 200,000 g 
for 30 min.  Supernatants were removed and analyzed directly by HPLC-UV analysis. 
Samples were separated on a Phenomenex Luna C18(2) column (4.6 x 250 nm, 5µ) 
equilibrated with 90% solvent A (0.5% formic acid in H2O) and 10% solvent B (0.5% 
formic acid in methanol) at a flow rate of 1.0 mL/min.  The solvent was programmed as 
follows:  a linear gradient from the starting solvent to 20% B in 10 min, holding at 20% B 
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for 10 min, increasing to 85% B in 0.1 min, holding at 85% B for 5 min, decreasing to 
10% B in 0.1 min, and holding at initial conditions for 5 min. Eluting compounds were 
detected by UV absorbance at 254 nm.  All incubations were prepared in triplicate. 
 
Incubations of 1,N2-ε-Gua with purified XO 
All sample preparation was performed on ice at 4 °C.  The final incubation 
conditions for the kinetic determinations contained 0.10 units XO/mL (CalBiochem, La 
Jolla, CA), varied concentrations of 1,N2-ε-Gua (10, 25, 50, 75, 100, 150, 250, 500, 750 
µM), and 0.4% DMSO in 0.8 M potassium phosphate (pH 7.6).  Reagents were 
equilibrated to 37 °C for 5 min and the reaction was initiated by the addition of the 
substrate.  Reactions were terminated after 15 min by adding 0.5 mL ice cold ethanol, 
vortexed, and extracted twice with 2x volume chloroform.  The extracts were evaporated 
under nitrogen, and reconstituted in 0.1 N NaOH.  Samples were separated on a 
Phenomenex Luna C18(2) column (4.6 x 250 nm, 5µ) equilibrated with 95% solvent A 
(0.5% formic acid in H2O) and 5% solvent B (0.5% formic acid in methanol) at a flow 
rate of 1 mL/min.  The solvent was programmed as follows:  a linear gradient from the 
starting solvent to 30% B in 15 min, increasing to 80% B in 0.1 min, holding for 5 min, 
decreasing to 5% B in 0.1 min, and re-equilibrating at initial conditions for 5 min.  
Eluting compounds were detected by UV absorbance at 285 nm.  Samples from the 
kinetic determinations were quantified in reference to a standard curve prepared by 
spiking known concentrations of 1,N2-ε-Gua (2.5, 5, 50, 100, 250, 500, 750 µM) into 
0.10 units/mL XO solutions, followed immediately by termination, extraction, and 
analysis as outlined above.  All incubations and standards were performed in triplicate.  
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Vmax/Km values were calculated with Prism software (Version 4.0c) using nonlinear 
regression one-site binding and one-site competition models, respectively. 
 
Incubations of 1,N6-ε-dA with purified human PNP 
All sample preparation was performed on ice at 4 °C.  The final incubation 
conditions contained 100 µM 1,N6-ε-dA dissolved in 0.1 M potassium phosphate (pH 
7.4) buffer and varied amounts of PNP (0.05, 0.1, 0.25 and 0.75 Units/mL).  The specific 
activity of PNP was 18 U/mg.  Reagents were equilibrated to 37 °C for 5 min and the  
reaction was initiated by the addition of substrate.  Reactions were terminated at intervals 
(0, 5, 15, and 30 min) by adding 0.5 mL ice cold ethanol, vortexed, and extracted twice 
with 2x volume chloroform.  The extracts were evaporated under nitrogen and 
reconstituted in 0.1 M potassium phosphate, pH 7.4, for HPLC-UV analysis.  Samples 
were separated on a Phenomenex Synergi POLAR-RP column (2.0 x 150 nm, 4µ) 
equilibrated with 98% solvent A (0.5% formic acid in H2O) and 2% solvent B (0.5% 
formic acid in methanol) at a flow rate of 0.3 mL/min.  The solvent was programmed as 
follows:  a linear gradient from the starting solvent to 40% B in 10 min, holding at 40% B 
for 3 min, decreasing to 2% B in 0.1 min and holding at initial conditions for 7 min. 
Eluting compounds were detected by UV absorbance at 254 and 275 nm.  All incubations 
were prepared in duplicate. 
 
LC-MS/MS analysis 
Following sample work-up as noted above, selected samples were analyzed by 
LC-MS/MS analysis.  The previously described gradients (see above) were adapted to 
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lower flow rates (0.3 mL/min) for sample analysis.  Eluting compounds were analyzed on 
either ThermoElectron LTQ or Quantum instruments.  Positive ion ESI LC-MS/MS or 
LC-MSn were performed with the following general parameters:  spray voltage = 4.2 eV; 
capillary temperature = 275 °C; sheath gas = 60 psi; source CID off; with varied collision 
energies. 
 
Biochemical synthesis of metabolites 
 1,N2-ε-Gua metabolite.  1,N2-ε-Gua (2 mg) was incubated with 5 mL of 
concentrated rat liver cytosol (13.6 mg/mL) and allowed to proceed to completion.  The 
reaction mix was centrifuged at 10,000 g for 15 min to pellet protein and the supernatant 
was injected directly onto the HPLC.  Fractions corresponding to the 1,N2-ε-Gua 
metabolite were pooled, evaporated under reduced pressure and dissolved in DMSO-d6 
for NMR analysis. 
Heptanone-1,N2-ε-Gua metabolite. Heptanone-1,N2-ε-Gua (1 mg) was reacted in 
30 mL of concentrated gerbil liver cytosol and allowed to proceed to completion.  15 mL 
of ethanol was added to the reaction mix and centrifuged at 10,000 g for 15 min to 
precipitate protein.  An additional 15 mL of ethanol was added to the supernatant and the 
mixture was extracted twice with 50 mL chloroform.  The organic layers were pooled and 
evaporated under reduce pressure.  The remaining residue was re-dissolved in methanol 
and directly injected onto the HPLC.  Fractions corresponding to the heptanone-1,N2-ε-
Gua metabolite were collected, evaporated under reduced pressure and dissolved in d6-
DMSO for NMR analysis. 
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NMR analysis of 1,N2-ε-Gua and heptanone-1,N2-ε-Gua metabolites 
 NMR experiments were acquired using a 14.0 T Bruker magnet equipped with a 
Bruker AV-II console operating at 600.13 MHz.  All spectra were acquired in 2.5 mm 
NMR tubes using a Bruker 5 mm TCI cryogenically cooled NMR probe. Chemical shifts 
were referenced internally to acetone (7.1 ppm), which also served as the 2H lock solvent.   
For 1D 1H NMR, typical experimental conditions included 32K data points, 13 ppm 
sweep width, a recycle delay of 1.5 s, and 32-256 scans depending on sample 
concentration.  For 2D 1H-1H COSY, experimental conditions included 2048 x 512 data 
matrix, 13 ppm sweep width, recycle delay of 1.5 s and 4 scans per increment.  The data 
was processed using squared sinebell window function, symmetrized, and displayed in 
magnitude mode.  Multiplicity-edited heteronuclear single quantum coherence (HSQC) 
experiments were acquired using a 1024 x 256 data matrix, a J(C-H) value of 145 Hz 
which resulted in a multiplicity selection delay of 34 ms, a recycle delay of 1.5 s and 16 
scans per increment along with GARP decoupling on 13C during the acquisition time (150 
ms). The data was processed using a π/2 shifted squared sine window function and 
displayed with CH/CH3 signals phased positive and CH2 signals phased negative.  J1(C-
H) filtered HMBC experiments were acquired using a 2048 x 256 data matrix, a J(C-H) 
value of 9 Hz for detection of long range couplings resulting in an evolution delay of 
55ms,  J1(C-H) filter delay of 145 Hz (34 ms) for the suppression of one-bond couplings, 
a recycle delay of 1.5 s, and 128 scans per increment. The HMBC data was processed 
using a π/2 shifted squared sine window function and displayed in magnitude mode. 
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Results 
 
Metabolism of 1,N2-ε-Gua in rat liver cytosol 
 1,N2-ε-Gua is released from DNA by the alkylpurine-DNA-N-glycosylase in 
mammalian cells (217, 219).  The base adduct 1,N2-ε-Gua is structurally very similar to 
the pyrimidopurinone adduct, M1G, which is oxidatively metabolized in vitro and in vivo. 
1,N2-ε-Gua and M1G differ only by one carbon in the exocyclic ring (Figure 58).  To 
investigate whether 1,N2-ε-Gua was also a substrate for oxidative metabolism we 
performed in vitro experiments in rat liver cytosol. Profiling the reaction extracts by 
HPLC with UV detection demonstrated a time-dependent decrease of 1,N2-ε-Gua and the 
appearance of a new peak eluting shortly after 1,N2-ε-Gua.  Positive ion ESI LC-MS 
analysis of the later eluting peak revealed a m/z of 192.1, which suggested the 
incorporation of an oxygen atom.  No additional products were observed in the MS- or 
UV-spectra.  MSn experiments were carried out on the putative metabolite, which 
displayed similar fragmentation patterns to 1,N2-ε-Gua, except for the addition of 16 
amu, which was apparent with the base peak and with some fragments. 1,N2-ε-Gua 
metabolite production was inhibited by allopurinol, an inhibitor of XOR, and not by 
menadione or raloxifene, inhibitors of AO, which suggested the involvement of XOR in 
the oxidation of 1,N2-ε-Gua.  
Further investigation into the turnover of 1,N2-ε-Gua revealed a Km of 84 µM and 
a Vmax of 105 pmol min-1 mg-1 (Km/Vmax =  0.005 min-1 mg-1) (Figure 59).  These 
calculated values are very close to what was observed with M1G metabolism in rat liver 
cytosol (Km = 105 µM, Vmax/Km = 0.005 min-1 mg-1 (261)). IC50 determinations of 
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Figure 58.  Structures of endogenous exocyclic DNA adducts and structural analogs 
of M1dG. 
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1,N2-ε-Gua metabolism with allopurinol revealed complete inhibition of metabolite 
production at saturating concentrations of allopurinol in rat liver cytosol (IC50 of 1.4 µM) 
(Figure 60). 
 
Metabolism of 1,N2-ε-Gua with purified XO 
 The complete inhibition of 1,N2-ε-Gua metabolism by allopurinol suggested XOR 
was the only enzyme involved in the metabolism of 1,N2-ε-Gua.  To verify this 
observation, in vitro metabolism of 1,N2-ε-Gua was performed using by purified bovine 
XO.  XO efficiently metabolized 1,N2-ε-Gua demonstrating a Km of 108 µM and Vmax of 
10.1 µmol min-1 mg XO-1 (Figure 61). 
 
 
 
 
 
Figure 59. Concentration dependence of 1,N2-ε-Gua oxidation in rat liver cytosol.  
(A) 1,N2-ε-Gua consumption. (B) 1,N2-ε-Gua metabolite formation. 1,N2-ε-Gua 
consumption was calculated by reference to a standard curve (Km = 84 µM and Vmax = 
105 pmol min-1 mg-1) whereas product formation was based on the peak area production 
of the 1,N2-ε-Gua metabolite (Km = 156 µM). 
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Figure 60.  IC50 determination in rat liver cytosol with allopurinol using 1,N2-ε-Gua 
as a substrate.  Using 1,N2-ε-Gua (84 µM) as a substrate, IC50 values were determined 
based on 1,N2-ε-Gua metabolite inhibition with increasing concentrations of allopurinol 
in rat liver cytosol (IC50 = 1.4 µM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 61. Concentration dependence of 1,N2-ε-Gua oxidation in purified XO. 1,N2-
ε-Gua consumption was calculated by reference to a standard curve (Km = 108 µM and 
Vmax = 10.1 µmol min-1 mg XO-1). 
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Biochemical synthesis of 1,N2-ε-Gua metabolite 
 To identify the product of 1,N2-ε-Gua metabolism in rat liver cytosol we 
biochemically synthesized the metabolite with concentrated rat liver cytosol and purified 
the product by fraction collection from an HPLC.  The product was concentrated and 
dissolved in d6-DMSO for NMR analysis.  Comparison of the 1H-NMR spectra for 1,N2-
ε-Gua and the metabolite revealed an absence of the singlet corresponding to H2 (7.8 
ppm) from the imidazole ring, while two correlated doublets remained from the etheno 
ring for H7 (d, 1H, 7.6 ppm) and H6 (d, 1H, 7.4 ppm) (210).  This was confirmed by the 
HSQC spectrum, which demonstrated the metabolite only contained CH protons.  If 
oxidation had occurred on the etheno ring, the adjacent carbon to the site of oxidation 
would have been reduced to CH2.  HMBC analysis revealed three-bond couplings for H7 
and H6 to C4a (145 ppm) confirming oxidation had not occurred on the etheno ring, but on 
the imidazole ring yielding 2-oxo-ε-Gua (Figure 62). 
 
Metabolism of 1,N2-ε-dG in rat liver cytosol 
 The observed metabolism of 1,N2-ε-Gua in rat liver cytosol led us to investigate  
the metabolism of the deoxynucleoside, 1,N2-ε-dG.  We were curious to know if 
oxidation would occur on the imidazole ring of the etheno adduct containing 
deoxyribose.  Identical incubation conditions to 1,N2-ε-Gua metabolism studies were 
carried out using 1,N2-ε-dG in rat liver cytosol.  The deoxynucleoside adduct did not 
undergo oxidation.  However, LC-UV and LC-MS analysis of the reaction mixture 
indicated 1,N2-ε-dG was consumed over time, producing a new chromatographic peak 
eluting with an identical retention time and mass spectrum for the base, 1,N2-ε-Gua.   
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Furthermore, the newly produced 1,N2-ε-Gua was converted to the oxidized product, 2-
oxo-ε-Gua.  There was no evidence to support direct oxidation of the deoxynucleoside.  
These data suggested 1,N2-ε-dG was subject to depurination in rat liver cytosol, and the 
product of this conversion was then subject to oxidation (Figure 63). 
 
 
 
 
Figure 62. HMBC spectrum of the 1,N2-ε-Gua metabolite from rat liver cytosol. 
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Depurination was not observed with M1dG metabolism in vitro in rat liver cytosol 
or in vivo in the rat (157, 267).  Results with 1,N2-ε-dG suggest the involvement of an 
additional pathway for exocyclic adduct metabolism.  PNP is an enzyme involved in the 
purine salvage pathway, which carries out the phosphorolysis of 6-oxo-purine 
nucleosides and deoxynucleosides (guanosine, inosine, dG and deoxyinosine) to their 
corresponding bases (Gua and xanthine).  The enzyme uses inorganic phosphate (H2PO4-) 
as a co-substrate and produces (deoxy)ribose-1-phosphate in addition to the base.  PNP is 
expressed in rat liver (280, 281).  The observed cleavage of 1,N2-ε-dG to 1,N2-ε-Gua 
suggests the involvement of PNP in rat liver cytosol metabolism. 
 
 
 
 
 
 
Figure 63. Conversion of 1,N2-ε-dG to 2-oxo-ε-Gua in rat liver cytosol. 
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Metabolism of heptanone-1,N2-ε-Gua in rat liver cytosol 
 Two exocyclic base adducts (M1G and 1,N2-ε-Gua) have been characterized to 
undergo oxidation on the imidazole ring.  Presence of the deoxyribose moiety on the 
imidazole portion of the base prohibits this oxidation.  As a corollary, we were curios to 
know what effects etheno ring substituents would have on imidazole oxidation.  To 
address this question we investigated the endogenously produced heptanone-1,N2-ε-dG, 
which contains a heptanone sidechain extending off of C7 on the etheno ring (Figure 58) 
(199).  We performed in vitro metabolism experiments in rat liver cytosol with 
heptanone-1,N2-ε-dG and its corresponding base, heptanone-1,N2-ε-Gua.  The 
deoxynucleoside was stable in rat liver cytosol, and was neither a substrate for oxidation 
nor phosphorolysis.  However, the base adduct heptanone-1,N2-ε-Gua was subject to 
metabolism.  Profiling the reaction mixtures by LC-MS/MS revealed a new peak eluting 
shortly after heptanone-1,N2-ε-Gua, which contained an addition of 16 amu to the parent 
mass.  The use of chemical inhibitors suggested the involvement of XOR because co-
incubation with allopurinol inhibited metabolism, but co-incubation with menadione and 
raloxifene did not. Limitations in analyte solubility precluded concentration-dependent 
kinetic determinations in rat liver cytosol. 
 
Biochemical synthesis of the heptanone-1,N2-ε-Gua metabolite 
 Heptanone-1,N2-ε-Gua was reacted to completion in concentrated gerbil liver 
cytosol, extracted, and purified by reverse phase HPLC.  HPLC fractions containing the 
metabolite were pooled, evaporated to dryness, dissolved in d6-DMSO, and analyzed by 
NMR.  The HSQC and HMBC experiments enabled identification of the metabolite as 2-
  171 
oxo-heptanone-ε-Gua (Figures 64 & 65).  H6 (s, 1H, 7.1 ppm, C6 at 116 ppm) was 
evident in the HSQC spectrum and showed a 2-bond correlation to C7 (119 ppm) and a 3-
bond correlation to C4a (146 ppm) in the HMBC spectrum.  H1´ (s, 2H, 4.1 ppm, C1´ at 39 
ppm) was evident in the HSQC spectrum and exhibited two-bond correlations to C7 (119 
ppm) and C2´ (206 ppm) and a three-bond coupling to C6 (116 ppm) in the HMBC.  The 
3-bond coupling from H6 to C1´ was not observed, however.  Direct comparison of the 
metabolite spectra to the heptanone-1,N2-ε-Gua spectra was inconclusive.  Several 
additional chemical shifts were observed in the starting material, which were an artifact 
of the sample work-up, and attributed to the equilibrium between heptanone-1,N2-ε-Gua 
and the hemiacetal (Figure 22) (199). 
 
 
 
Figure 64. Overlay of the HSQC and HMBC spectra of the heptanone-1,N2-ε-Gua 
metabolite from rat liver cytosol.  HMBC (Green), HSQC-CH (red), HSQC-CH2 
(blue). 
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Figure 65. Conversion of heptanone-1,N2-ε-Gua to 2-oxo-heptanone-ε-Gua in rat 
and gerbil liver cytosol 
 
Investigation of 3,N4-ε-dC, 3,N4-ε-Cyd, 1,N6-ε-dA, and 1,N6-ε-Ade metabolism 
 Several exocyclic adducts of dG have been characterized to undergo oxidation in 
rat liver cytosol.  One of these adducts, 1,N2-ε-dG, is also a substrate for phosphorolysis.  
3,N4-ε-dC and 1,N6-ε-dA are etheno adducts of dC and dA (Figure 58), respectively, 
with proposed routes of endogenous formation (196, 197).  Each of these adducts are 
released from DNA by glycosylase action as the corresponding base adducts, 3,N4-ε-Cyd 
(221-223) and 1,N6-ε-Ade (217, 218).  The exocyclic etheno ring for these molecules is 
structurally similar and contains a heterocyclic imine extending from a quaternary carbon 
on the base, which is a pyrimidine in the case of 3,N4-ε-Cyd and purine for 1,N6-ε-Ade.  
Each base adduct was investigated for metabolism in rat liver cytosol and neither was 
found to be metabolized. 
 The corresponding deoxynucleoside adducts 3,N4-ε-dC and 1,N6-ε-dA were also 
investigated for their stability in rat liver cytosol.  The reaction mixtures were profiled by 
positive ion ESI LC-MS/MS and neither of these adduct was found to be oxidized in 
vitro.  However, 1,N6-ε-dA underwent a time-dependent decrease in total peak area, with 
a corresponding increase of an early eluting peak, which displayed a m/z of 162.1. The 
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appearance of m/z 162.1 was not detected in control incubations.  The early eluting peak 
corresponded to the protonated molecular ion for the base (1,N6-ε-Ade) suggesting that 
1,N6-ε-dA underwent phosphorolysis.  The product of 1,N6-ε-dA metabolism 
demonstrated an identical retention time to a 1,N6-ε-Ade standard and co-
chromatographed when the incubation extract was spiked with 1,N6-ε-Ade.  Identical 
observations were made using 1,N6-ε-adenosine in incubations with rat liver cytosol. 
 PNP uses H2PO4- as a co-substrate.  To investigate the role of PNP in the 
metabolism of 1,N6-ε-dA we performed incubations using either potassium phosphate or 
Tris-HCl buffers.  In the absence of phosphate, the production of 1,N6-ε-Ade was 
diminished (Figure 66).  1,N6-ε-dA was also incubated in reactions with purified PNP 
(from human) using potassium phosphate buffer.  Phosphorolysis of 1,N6-ε-dA was 
dependent on protein and time (Figure 67), providing evidence that 1,N6-ε-dA is a 
substrate for human PNP (Figure 68). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66. Conversion of 1,N6-ε-dA to 1,N6-ε-Ade in rat liver cytosol in potassium 
phosphate or Tris-HCl buffers. 
 
  174 
 
 
 
 
 
Figure 67. Phosphorolysis of 1,N6-ε-dA to 1,N6-ε-Ade with purified PNP from 
human blood. 
 
 
 
 
 
 
 
 
Figure 68. Conversion of 1,N6-ε-dA to 1,N6-ε-Ade with rat liver cytosol and PNP. 
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Metabolism of M1dG analogs in rat liver cytosol 
 To lend further insight into the structural requirements for the metabolic 
processing of exocyclic adducts in rat liver cytosol, we investigated the metabolic 
stability of several pyrimidopurinone-dG analogs of M1dG and M1G (Figure 58).  The 
partially reduced pyrimido analogs 5,6-dihydro-M1dG and 5,6-dihydro-M1G, and fully 
reduced analogs PdG and PGua have previously been used to mimic the biological 
activity of M1dG in several genetic and biochemical investigations (116, 122, 282, 283). 
γ-OH-PdG and α-OH-PdG are endogenous adducts produced from reactions of acrolein 
with dG (163, 164).  These dG modifications impart different electronic and structural 
effects on the exocyclic ring. For example, the pyrimido ring is planar and aromatic, 
while the propano ring is puckered and un-conjugated. This series of dG adducts are 
approximately the same size as the pyrimidopurinone adducts, so the exocyclic propano 
ring should not preclude access to the active sites of XOR, AO, or PNP. 
 All investigations on the metabolism of the deoxynucleoside structural analogs 
revealed no indication of either oxidative metabolism or phosphorolysis.  To our surprise 
none of the base adducts were oxidized.  It appears that planar and electron-rich 
exocyclic ring structures, in part, are a structural requirement for oxidation and 
phosphorolysis in rat liver cytosol in vitro. 
 
Discussion 
 Non-invasive analysis of endogenously occurring DNA damage is of interest for 
use in clinical and animal studies.  Our findings on the metabolism and elimination of 
M1dG suggests that the metabolic processing of exocyclic DNA adducts may impact the 
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ability to detect deoxynucleoside and base adducts in biological matrixes (157, 261, 267).  
We propose that it is important to consider the possibility of metabolism prior to the 
development of analytical methods designed to evaluate endogenous levels of adducts.  
Our recent study was designed to determine structural features of exocyclic adducts that 
led to metabolism.  We based our investigation on small changes in the pyrimido ring of 
dG that imparted alterations to size and conjugation as well as the addition of 
substituents. 
 In total, our findings demonstrate that oxidative metabolism can occur on either 
the exocyclic ring, as seen with M1dG and M1G, or the imidazole ring, as seen with M1G, 
1,N2-ε-Gua and heptanone-1,N2-ε-Gua.  Both deoxynucleosides and bases are subject to 
oxidation, with the base adducts being better substrates.  When conjugated to the base, 
deoxyribose appears to prohibit oxidation on the imidazole ring.  Additionally, the 
metabolic processing is not limited to oxidation, as deoxynucleosides and nucleosides 
may also be phosphorolyzed to the corresponding base adducts.  We did not observe 
oxidative metabolism with dA, Ade, dC, or Cyd etheno adducts, but this does not 
preclude others derivatives of dA, Ade, dC, or Cyd from metabolic processing. 
 There are multiple reports on the structural determinants of XOR and AO 
substrate specificity and inhibition (284-293).  In general, substrates are nitrogen-
containing heterocycles, and the enzyme-mediated oxidation is targeted to electropositive 
carbons, which lie adjacent to ring nitrogens (293).  Our observations with exocyclic 
adducts are consistent with these observations. 
 In series of chemical and biochemical experiments, Leonard et al. demonstrated 
XOR-mediated metabolism with several modified purine structures that are structurally 
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similar to the pyrimido and etheno adducts of dG (Gua) and dA (Ade) (Figure 69) (287, 
288).  Inserting a benzene ring in between the imidazole and pyrimidine rings of and 6-
oxo-purine (hypoxanthine) yielded several “stretched-out” purine analogs.  lin-
Benzoxanthine is similar to M1G; however, for M1G the benzene ring is attached to the 
pyrimidine opposite the imidazole ring.  Using bovine XO, Leonard et al. demonstrated 
successive oxidations of lin-benzohypoxanthine to uric acid-like molecules.  This is 
analogous to what was observed with M1G (261).  Interestingly, Leonard et al. also 
observed successive oxidations with the ribonucleoside, lin-benzoinosine.  In our 
investigations, oxidation on the imidazole ring did not occur with either M1dG, 1,N2-ε-
dG, or any of the propano analogs. 
 Thus far, all characterized oxidation products of exocyclic adducts occur on 
tertiary imine carbons on either the exocyclic or imidazole ring.  Reduction of the 5,6-
double bond on the pyrimido ring of M1dG (M1G) yields a secondary carbon at the 6-
position, which did not undergo oxidation.  Krenitsky et al. demonstrated that purine is 
oxidized by XOR first at the 6-position, and then successively at the 2- and 8 positions.  
However, AO oxidized purine only at the 8-positition on the imidazole carbon (284).  
The analogous position on the M1G analogs is the 2-position, which was not a target for 
oxidation. This would imply that either the non-planar character of the reduced pyrimido 
ring or its reduced electron density impacts oxidation on the imidazole ring.  AO oxidizes 
hypoxanthine only at the 2-position (284), which implies the 9(10)-oxo group of the 
exocyclic dG adducts, may also impact substrate orientation in the AO active site. 
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Figure 69.  Structures of “stretched-out” 6-oxo-purine analogs synthesized by 
Leonard et al. (287) and their conversion to oxidized products by XOR. 
 
  179 
 The effect of substitutions on the exocyclic ring of propano and etheno dG 
adducts was investigated.  PdG adducts with hydroxyl substituents on the exocyclic ring 
did not undergo metabolic processing; although, the base adducts were not investigated.  
The addition of an alkyl substituent on the exocyclic ring of heptanone-1,N2-ε-Gua did 
influence metabolism, however.  Heptanone-1,N2-ε-Gua underwent oxidation on the 2-
position of imidazole ring, but the deoxynucleoside was unmodified; although, 
heptanone-1,N2-ε-dG did not undergo phosphorolysis as seen with the unsubstituted 1,N2-
ε-dG.  Several recent reports from the Blair Laboratory suggest substituted etheno 
adducts of dA, dC and dG are a major class of endogenous adducts derived from products 
of lipid peroxidation (49, 50, 198-200, 202, 216, 294).  The repair products of these 
unsubstituted adducts are unknown.  Purine-based therapeutics (aciclovir, penciclovir, 
zaleplon) and other substituted purine molecules are substrates for oxidation by AO and 
XOR (252, 284, 290, 295-297).  Thus, it will be interesting to elucidate the metabolic 
processing of substituted etheno adducts. 
 Since endogenously formed exocyclic adducts are all modifications of purine and 
pyrimidine structures, we targeted our investigation to the cytosolic components of rat 
liver where XOR and AO are located.  It is possible that other enzymes may catalyze 
metabolism of exocyclic adducts.  CYPs and UDP-glucuronosyl transferases 
(components of the microsomal fraction of rat liver) may have a role in metabolism.  Our 
results with the propano analogs suggest they are stable in vitro in cytosol. Propano 
adducts derived from crotonaldehyde and 4-hydroxy-2-nonenal also have alkyl 
substituents extended from the exocyclic ring, which may be targeted by different 
enzymes and alternate routes of metabolic processing. 
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 1,N2-ε-dG and 1,N6-ε-dA were phosphorolyzed to the base adducts 1,N2-ε-Gua 
and 1,N6-ε-Ade, respectively, in rat liver cytosol by PNP.  Both of these base adducts 
have been detected in urine from humans and rats (212, 298, 299).  The elimination of 
these adducts in urine has generally been attributed to their removal from DNA as base 
adducts.  Interestingly, 1,N6-ε-dA has also been detected in rat urine (211).  Based on our 
metabolism results, 1,N6-ε-Ade maybe the best target for quantitation in urine samples. 
 Understanding the in vitro routes of metabolic processing should help guide 
analytical methodologies for the detection of endogenous adducts.  Several exocyclic 
adducts have been characterized as good substrates for oxidative metabolism in vitro.  
The end products of metabolic processing may therefore be a reliable target for assessing 
the formation of endogenous adducts from biological matrixes in vivo. 
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CHAPTER VII 
 
SUMMARY 
 
Since the discovery of DNA as the heritable genetic material by Avery, and the 
determination of its structure by Watson and Crick, scientists have been investigating the 
coding properties of DNA.  Chemical agents can modify DNA bases to produce DNA 
adducts that may alter the choice of incoming nucleotides during replication.  In the 
absence of repair, miscoding leads to permanent changes in the genetic code.  Therefore, 
assessing exposure of DNA bases to genotoxic chemicals may be a diagnostic marker to 
determine the rate of mutation in human populations. 
Correlations between exposure to chemical agents and DNA mutations are well-
documented in humans and animals for exogenous chemicals such as B[a]P and 
aflatoxin.  Once an exogenous genotoxic chemical has been identified and its 
environmental sources characterized, a person’s risk for mutation is generally related 
their exposure to these sources. Identifying genomic exposure to endogenously produced 
chemical agents is complicated by the absence of a universal source of their production.  
Further complicating this process is the difficulty of detecting specific biologically 
produced chemicals in vivo.  Both oxygen radicals and lipid peroxidation products are 
highly reactive and short-lived, and their direct detection is not feasible.  To assess their 
production in vivo, end-products of their reactions can be monitored.  Thus, to assess 
genomic exposure to endogenously produced chemicals DNA adduct formation can be 
monitored. 
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Two approaches for the detection of DNA adducts are commonly employed: 
analysis of adducts in genomic DNA or as repair-products in biological matrixes.  
Detection of adducts from DNA offers a direct method of analysis, which assesses the 
amount of DNA damage in a defined tissue.  However, this procedure is typically 
considered invasive because it requires cells or tissue from which to isolate DNA.  
Analysis of DNA adducts in urine (a biological elimination product) is considered a non-
invasive strategy for the analysis of DNA adducts.  Urinary analysis is an indirect method 
since the initial sites of adduct formation and removal is unknown.  However, urinary 
analysis may represent a measure of the total systemic exposure to chemical agents.  
Furthermore, a non-invasive strategy for the routine analysis of DNA adducts is desirable 
to minimize cost and labor of sample collection, which offers greater applicability to 
population-based studies. 
The endogenously formed exocyclic adduct M1dG is derived from reactions of dG 
with either the lipid peroxidation product, MDA (also a product of prostaglandin 
synthesis), or the DNA peroxidation product base, propenal.  M1dG is found in genomic 
DNA of humans and rodents at levels of 1-90 adducts per 108 bases.  Genetic and 
biochemical evidence implicates NER in the removal of M1dG from DNA, which 
accounts for its appearance in urine as the deoxynucleoside.  Analysis of urine collected 
from healthy humans revealed that M1dG was eliminated at an average rate of 12 fmol 
kg-1 24 h-1.  The levels of M1dG in DNA are similar to other endogenously formed DNA 
adducts such as: 8-oxo-dG, 1,N6-ε-dA, 1,N2-ε-dG, and heptanone-1,N2-ε-dG (155, 189, 
215, 216). However, M1dG is eliminated in urine at a much lower level than seen for 8-
oxo-dG, 8-oxo-Gua, and 1,N6-ε-Ade (155, 156, 211).  (The urinary levels of 1,N2-ε-dG 
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and heptanone-1,N2-ε-dG have not been detected or reported, respectively).   Based on 
this discrepancy, we hypothesized that biological factors (e.g., metabolism, routes of 
elimination) may limit the direct detection of M1dG in urine. 
 
Oxidative Metabolism of M1dG 
To test the hypothesis that enzymatic metabolism may limit the direct detection of 
M1dG in urine, we devised a series of experiments to investigate the metabolic stability 
of M1dG in vitro and in vivo. M1dG was found to undergo oxidation in vitro in rat liver 
cytosol and in vivo when administered to Sprague Dawley rats.  Metabolism occurred on 
the 6-position of the pyrimido ring to produce 6-oxo-M1dG rats.  Based on experiments 
with chemical inhibitors and with partially purified enzymes from rat liver, both XOR 
and AO were shown to catalyze the oxidation of M1dG.  Human liver cytosol incubations 
with M1dG produced 6-oxo-M1dG in a qualitatively similar manner to rat liver cytosol; 
although, AO appeared to have a greater contribution than XOR in human liver cytosol 
incubations. 
The in vivo contribution of XOR to the metabolism of M1dG was evaluated by 
pretreating Sprague Dawley rats with allopurinol (a specific, tight binding inhibitor of 
XOR), followed by administration of M1dG.  Animals receiving allopurinol pretreatment 
displayed decreased plasma and urinary levels of 6-oxo-M1dG and increased plasma and 
urinary levels of M1dG compared to vehicle control animals.  Total inhibition of M1dG 
metabolism was not observed in this experiment, which suggested either incomplete 
inhibition of XOR or the involvement of AO in the production of 6-oxo-M1dG in the rat.  
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In the rat, XOR appears to play a significant role in the production of 6-oxo-M1dG, while 
AO appears to contribute to a lesser degree. 
 
Metabolism of [14C]M1dG 
The total mass balance and metabolite profile of M1dG was evaluated in vivo by 
stably incorporating a 14C tracer into M1dG. [14C]M1dG was administered to Sprague 
Dawley rats with or without bile catheters.  Urine, feces, and bile were collected 
following administration of [14C]M1dG, and the total [14C]recovery was assessed by 
liquid scintillation counting.  Approximately 50% of the radioactivity was collected in 
urine while the remaining radioactivity was collected in the feces of non-bile-catheterized 
animals and in the bile of bile-catheterized animals.  In urine, approximately 20% of the 
radioactivity was attributed to 6-oxo-M1dG and 70% was attributed to M1dG.  In the bile 
samples, approximately 70% of the radioactivity was attributed to 6-oxo-M1dG and 20% 
corresponded to M1dG.  No other significant metabolites were observed in this study; 
approximately 45% of the administered M1dG was recovered as 6-oxo-M1dG.  When 
[14C]6-oxo-M1dG was administered to Sprague Dawley rats, nearly 70% was recovered 
in the feces of non-bile catheterized rats, while approximately 55% was recovered in the 
bile of bile catheterized rats.  In all biological samples analyzed, [14C]6-oxo-M1dG was 
eliminated unchanged.  Together these results demonstrate that 6-oxo-M1dG is a stable 
metabolite of M1dG that does not undergo additional biotransformation reactions, and 
may represent a significant portion (45%) of the total M1dG levels. 
The amount of M1dG administered in the 14C mass balance study (0.03 mg per 
animal) is likely higher than the anticipated daily clearance in humans and rats.  
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Therefore, we set out to evaluate the in vivo metabolism and elimination of M1dG at 
lower concentrations. AMS analysis was implemented to enhance the limit of detection. 
Sprague Dawley rats were dosed with low levels of [14C]M1dG in separate experiments 
(2.8 ng, 75 pg, and 0.75 pg per animal).  Animals that received 2.8 ng [14C]M1dG 
eliminated 50% of the total 14C in urine and 40% of the 14C eliminated in urine 
corresponded to 6-oxo-M1dG.  A separate cohort of animals received doses of 0.75 pg 
and 75 pg of [14C]M1dG.  Approximately 50% of the 14C was eliminated in urine and 
25% of the urinary radioactivity corresponded to 6-oxo-M1dG.  The 75 pg and 0.75 pg 
studies were performed at the limit of detection by AMS analysis.  Thus, the natural 
abundance of 14C in biological samples prohibited analysis at lower administration levels. 
The direct analysis of 14C in fecal samples was not feasible at low administration levels 
due to the higher carbon background.  It was estimated (based on 14C mass balance study) 
that 50-55% of the [14C]M1dG administered at concentrations below 3 ng per animal was 
converted to 6-oxo-M1dG.  This represents a significant conversion of M1dG to 6-oxo-
M1dG at concentrations that closely approximate the anticipated rate of elimination in 
rats. Although the metabolism of M1dG in human populations has not been investigated, 
the observed conversion of M1dG to 6-oxo-M1dG is only 2-fold.  Therefore, the oxidation 
of M1dG is not likely to limit its detection in urine samples. 
 
Metabolism of M1G 
Based on our observations on the metabolism of M1dG, we were curious to know 
if other structurally related exocyclic DNA adducts may also undergo enzymatic 
oxidation.  The free base of M1dG (M1G, a putative product of base excision repair) was 
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evaluated to investigate the effect of deoxyribose on the metabolism of M1dG.  When 
incubated in rat liver cytosol, M1G underwent successive oxidations.  The first oxidation 
occurred at the 6-position of the pyrimido ring to produce 6-oxo-M1G.  The second 
oxidation occurred on the imidazole ring to produce 2,6-dioxo-M1G.  XOR and AO 
appear to be involved in the production of 6-oxo-M1G, but only XOR is involved in the 
production of 2,6-dioxo-M1G.  Comparing the turnover of M1dG, M1G, and 6-oxo-M1G 
revealed that M1G and 6-oxo-M1G were better substrates (approximately 5-fold) than 
M1dG.  Furthermore, the observed oxidation on the imidazole ring suggested that other 
exocyclic base adducts may undergo oxidation, with the imidazole ring being a likely site 
for oxidation. 
 
Metabolism of Other Exocyclic DNA adducts 
Unsubstituted etheno adducts are released from DNA by DNA glycosylases, and 
the products of repair are base adducts, which display structural similarity to M1G.  In 
particular 1,N2-ε-Gua varies by one carbon in the exocyclic ring from M1G.  When 
incubated in rat liver cytosol 1,N2-ε-Gua underwent oxidation on the imidazole ring to 
produce 2-oxo-ε-Gua.  The deoxynucleoside (1,N2-ε-dG) did not undergo oxidation in rat 
liver cytosol.  However 1,N2-ε-dG was subject to phosphorolysis by PNP to produce 
1,N2-ε-Gua, which was then oxidized to 2-oxo-ε-Gua.  Other unsubstituted etheno base 
adducts (1,N6-ε-Ade, 3,N4-ε-Cyd) were not subject to oxidation in rat liver cytosol.  
Although, 1,N6-ε-dA was subject to phosphorolysis by PNP to yield 1,N6-ε-Ade. 
To investigate the effect of a substituent on the etheno ring the metabolic stability 
of hepatanone-1,N2-ε-Gua was investigated.  Hepatanone-1,N2-ε-Gua underwent 
  187 
oxidation on the imidazole ring to 2-oxo-hepatanone-ε-Gua.  The deoxynucleoside 
(hepatanone-1,N2-ε-dG) was stable in rat liver cytosol and was neither oxidized nor 
phosphorolyzed. 
The metabolic stability of several propano adducts was evaluated.  In all cases 
(both base and deoxynucleoside adducts) the propano adducts did not undergo metabolic 
processing.  These results suggest that the planarity or electron density of the exocyclic 
ring may impact either the oxidation or phosphorolysis of substrates in rat liver cytosol.  
However, molecules with these characteristics may be substrates for other classes of 
enzymes such as CYPs, not found in cytosolic tissue preparations. 
 
Final Summary 
 An increasing body of evidence now exists that demonstrates exocyclic DNA 
adducts are subject to enzymatic oxidation and phosphorolysis reactions (sometimes in 
tandem). Exocyclic base adducts with planar and unsaturated exocyclic rings are the best 
substrates for enzymatic oxidation.  Base adducts containing substitutions such as 
deoxyribose on the imidazole ring of M1dG and a heptanone chain on the etheno ring of 
heptanone-1,N2-ε-Gua do not prohibit oxidative metabolism. The enzymes of purine 
catabolism (XOR, AO, and PNP) are involved in the metabolic processing of exocyclic 
adducts. Based on in vivo metabolism studies at near-physiological concentrations of 
exogenously administered M1dG, the metabolic processing of exocyclic adducts is likely 
to occur at their physiological rate of production in animals and humans. In total, these 
results demonstrate that exocyclic adducts are subject to metabolic processing (oxidation 
and phosphorolysis).  Furthermore, metabolites of endogenously produced DNA adducts 
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are likely to be produced in vivo, and may provide a new class of biomarkers to assess 
exposure to endogenous sources DNA damage. 
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